Pr ot oc ol I 5 T- M C- A A C H ( b) 
D o na ne ma b F oll o w- O n St u d y: Safet y, T olera bilit y, A n d Efficac y i n S y m pt o matic Alz hei mer's Disease 
Wit h Vali dati o n of Re m ote Ne ur o ps yc h ol o gical Assess me nts
N C T 0 4 6 4 0 0 7 7
A p pr o val Date: 1 1- O C T- 2 0 2 1
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1Title P a ge
C o nfi d e nti al I nf or m ati o n
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of cli ni c al i n v e sti g at or s . It i s t h e pr o p ert y of 
Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al 
i n v e sti g ati o n of d o n a n e m a b ( L Y 3 0 0 2 8 1 3) , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt wit h Eli Lill y a n d 
C o m p a n y or it s s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s : T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n 
e x e m pt fr o m p u bli c di s cl o s ur e . Eli Lill y a n d C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r e l e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. 
I n t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or 
ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .
Pr ot oc ol Title: D o na ne ma b F o ll ow- O n St u d y : Safet y, T olera bilit y, A n d Ef ficac y i n 
S y m pt o m atic Alz hei mer’s Disease w ith Vali dat i on o f Re m ot e 
Ne ur o ps yc h ol o gical Assess me nts
Pr ot oc ol N u m ber : I 5 T-M C -A A C H
A me n d me nt N u m ber: b
C o m p o u n d : D o na ne ma b ( L Y 3 0 0 2 8 1 3)
St u d y P h ase : P hase 2
S h ort Title: D o na ne ma b F o ll ow- O n St u d y , w it h Vali dat i on o f Re m ot e S c al e Assess me nt
Acr o n y m : T R AI L B L A Z E R -E X T
S p o ns or N a me : El i Lill y  a n d C o mpa n y
Le g al Re gistere d A d dress : I n dia na p olis, I n dia na, U S A 4 6 2 8 5
Re g ul at or y A ge nc y I de ntifier N u m ber
I N D: 1 0 9 1 5 7
A p pr o v al D ate: Pr ot oc ol A me n d me nt ( b) El ectr o nicall y Si g ne d a n d A p pr o ve d b y Lill y o n date 
pr o vi de d bel o w.
A p pr o v al D at e: [ADDRESS_391687]- 2 0 2 1 G M T
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2Me dic al M o nit or N a me a n d C o nt act I nf or m ati o n will be pr o vi de d se p ar atel y .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
3Pr ot oc ol A me n d me nt S u m m ar y of C h a n ges T a ble
D O C U M E N T HI S T O R Y
D oc u me nt D ate
A m e n d m e nt a 2 7 -J a n -2 0 2 1
Ori gi n al Pr ot o c ol 0 1 -S e p -2 0 2 0
A me n d me nt b
O ver all R ati o n ale f or t he A me n d me nt:
T his a me n d me nt all o w s f or better c haracterizati o n of t he i nci de nce a n d se verity of  A RI A at a n 
earlier ti me p oi nt.
Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale
1. 3. Sc he d ule of 
Act i vitiesA d de d M RI at V [ADDRESS_391688] a n d f o urt h 
i nf usi ons .T o all o w f or better c haracterizat i on of t he 
i nci de nce a n d se verity of  ARI A at a n earlier 
ti me p oi nt.
C ha n ge d V 2 i nter val t olera nce
fr om “± 7” da ys t o “  7 t o + 1 0” 
da ys.T o pr o vi de a d di tio nal ti m e t o perf or m a n d 
re vie w M RI pri or t o i nf usi on.
6. 5. 1. Sta n dar d of 
Care f or 
Alz hei mer’s DiseaseA d de d “ W he n me dicall y 
i n dicate d, i nitiati on, i ncrease , or 
di sc o nti n uati on of s y m pt o mat ic 
treat me nts f or A D is per mitte d.”Cl arificat i on.
7. 1. Disc o nt i n uati on 
of  St u d y 
I nter ve nti o nA d de d cr oss -r efere nce t o t he 
Ma n ual o f O perati o ns re gar di n g 
i nf or mat i on a b o ut per ma ne nt 
di sc o nti n uati on g ui da nce.T o pr o vi d e f urt her g ui da nce.
7. 1. 1. 1. D ue t o 
A RI AA d de d cr oss -r efere nces t o t he 
Ma n ual o f O perati o ns re gar di n g 
i nf or mat i on a b o ut te m p orar y a n d 
p er m a ne nt disc o nt i n uati on 
g ui da nce.T o pr o vi d e f urt her g ui da nce.
M o difie d te xt re gar di n g 
c o nsi deri n g rei nit iati n g I P.Rec o m me n dat i on of D M C .
8. 2. 5. Ma g net ic 
Res o na nce I m a gi n gA d de d te xt , “U nsc he d ule d M RIs 
ma y be perf or me d at t he 
di scretio n of  in vest i gat or.”Cl arificat i on.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale
8. 3. 6. 2. D osi n g 
Rec halle n ge a n d 
Pr e m e dicat i on f or 
I nf usi onsA d de d d osi n g rec halle n ge details. Cl arificat i on/ pr o vi di n g i nf or mati o n.
8. 3. 7. A m yl o i d-
Relate d I m a gi n g 
A b n or m alities 
( A RI A-E a n d 
A RI A- H)A d de d te xt “W hile m ost cases of 
A RI A- E are as y m pt o m at ic, 
serio us cases ha ve bee n re p orte d. 
A vaila ble data s u g gest seri o us 
cases are m ost li kel y t o occ ur 
earl y in d osi n g, after t he first, 
sec o n d, or t hir d i nf usi o n. ”Pr o vi de d a d di tio nal  inf or m atio n.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
5T a ble of C o nte nts
1. Pr ot oc ol S u m m ar y ......................................................................................................[ADDRESS_391689] i vities ( S o A) ......................................................................................[ADDRESS_391690] u d y  Ratio nale ..........................................................................................................2 5
2. 2. Bac k gr o u n d ................................................................................................................2 5
2. 2. 1. Di sease State ..............................................................................................................2 5
2. 2. 2. Vi de o Assess me nt ......................................................................................................2 6
2. 2. 3. D o na ne ma b ................................................................................................................2 7
2. 3. Be nefit/ Ris k Assess me nt ............................................................................................[ADDRESS_391691] u d y Desi g n .............................................................................................................3 2
4. 1. O verall Desi g n ............................................................................................................3 2
4. 1. 1. Scree ni n g ....................................................................................................................3 3
4. 1. 2. Part A: Vi de o Assess me nt ...........................................................................................3 3
4. 1. 3. Part B: O pe n -La bel D o na ne ma b .................................................................................3 3
4. 1. 4. Part C: I ma gi n g a n d C o g nit i ve/ F u ncti o nal Meas ures...................................................[ADDRESS_391692] u d y  I nter ve nti on(s) A d m i nistere d ............................................................................4 1
6. 2. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y .............................................................4 2
6. 3. Meas ures t o Mi ni mize Bias: Ra n d o mizat i on a n d Bli n di n g ..........................................[ADDRESS_391693] u d y  I nter ve nti on C o m plia nce ...................................................................................4 2
6. 5. C o nc o mita nt T hera p y ................................................................................................. 4 3
6. 5. 1. Sta n dar d of Care f or Alz hei mer’s Disease ...................................................................[ADDRESS_391694] u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al ....................................................................................[ADDRESS_391695] u d y I nter ve nti on ........................................................................4 5
7. 1. 1. T e m p orar y  Disc o nti n uati on ........................................................................................4 7
7. 2. P arti cipa nt Disc o nti n uati o n/ Wit h dra wal fr o m t he St u d y .............................................4 7
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
67. 2. 1. Di sc o nti n uatio n of  I na d verte ntl y Enr olle d Partici pa nts ...............................................[ADDRESS_391696] i n g A E a n d S A E 
I nf or mat i on .................................................................................................................5 8
8. 3. 2.  Met h o d of Detecti n g A Es a n d S A Es ...........................................................................5 9
8. 3. 3. F o ll ow- U p of A Es a n d S A Es ......................................................................................5 9
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es............................................................5 9
8. 3. 5. Pre g na nc y ...................................................................................................................5 9
8. 3. 6. H y perse nsi tivi t y, I ncl u di n g I nf usi on- Relate d Reacti o ns ..............................................6 0
8. 3. 7. A m yl o i d-Relate d I m a gi n g A b n or malities ( A RI A-E a n d A RI A -H) ..............................[ADDRESS_391697] atistic al C o nsi der ati o ns .........................................................................................6 5
9. 1. Stati stical H y p ot heses................................................................................................. 6 5
9. 2. S a m ple Si ze Deter mi nat i on .........................................................................................6 5
9. 3. P o p ul at i ons f or A nal yses ............................................................................................6 6
9. 4. Stati stical A nal yses .....................................................................................................6 6
9. 4. 1. Ge neral C o nsi derati o ns ...............................................................................................6 6
9. 4. 2. Pri mar y E n d p o i nt(s) ...................................................................................................6 7
9. 4. 3. Sec o n dar y  E n d p oi nt(s)................................................................................................6 8
9. 4. 4. Terti ar y/ E x pl orat or y E n d p oi nt(s) ................................................................................6 8
9. 4. 5. Ot her Safet y A nal yse(s) ..............................................................................................6 9
9. 4. 6. Ot her A nal yse(s) .........................................................................................................6 9
9. 5. I nteri m A nal yses.........................................................................................................6 9
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
79. 6. Data M o nit ori n g C o m mittee ( D M C) ...........................................................................7 0
1 0. S u p p orti n g D oc u me nt ati o n a n d O per ati o n al C o nsi der ati o ns ................................7 1
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y O versi g ht 
C o nsi derati o ns ............................................................................................................[ADDRESS_391698] u d y  a n d Site Start a n d Clos ure .................................................................................7 4
1 0. 1. 9. P u blicat i on P olic y .......................................................................................................7 5
1 0. 1. 1 0. I n vesti gat or I nf or mati on .............................................................................................7 5
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests........................................................................7 6
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi nit i ons a n d Pr oce d ures f or 
Rec or di n g, E val uat i n g, F oll o w-U p, a n d Re p orti n g ......................................................7 9
1 0. 3. 1. Defi nit i on o f A E .........................................................................................................7 9
1 0. 3. 2. Defi nit i on o f S A E .......................................................................................................8 0
1 0. 3. 3. Rec or di n g a n d F o ll ow- U p of A E a n d/ or S A E .............................................................8 1
1 0. 3. 4. Re p orti n g of  S A Es......................................................................................................8 3
1 0. 4. A p pe n di x 4: Li ver Safet y:  S u g geste d Acti o ns a n d F oll o w-U p 
Assess me nts ...............................................................................................................8 4
1 0. 5. A p pe n di x 5: Fl or beta pir F 1 8 A m yl o i d P E T I ma gi n g ..................................................8 6
1 0. 6. A p pe n di x 6: Fl orta uci pir F 1 8 Ta u P E T I ma gi n g ........................................................8 9
1 0. 7. A p pe n di x 7: A b bre viat i ons .........................................................................................9 0
1 0. 8. A p pe n di x 8: Pr o visi o ns f or C ha n ges i n St u d y  C o n d uct D uri n g 
E xce pt i onal Ci rc u msta nces.........................................................................................9 4
1 0. 9. A p pe n di x 9: Pr ot oc ol A me n d me nt Hist or y ................................................................. 9 8
1 1. Refere nces .................................................................................................................9 9
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
81. Pr ot oc ol S u m m ar y
1. 1. S y n o psis
Pr ot oc ol Title: D o na ne ma b F o ll ow- O n St u d y : Safet y, T olera bilit y, A n d Efficac y  i n 
S y m pt o m atic Alz hei mer’s Disease w ith Vali dat i on o f Re m ot e 
Ne ur o ps yc h ol o gical Assess me nts
S h ort Title: D o na ne ma b F o ll ow- O n St u d y , wit h Vali dati on of Re m ote Scale Assess me nt
R ati o n ale :
P art A
Re m ote assess me nts of i n di vi d uals wit h A D via tele m e dici ne ha ve t he p ote ntial t o re d uce 
b ur de ns ass ociate d wit h cli nical care a n d researc h partici pat i on. Researc h c o m pari n g cli nical 
i nter vie wi n g c o n d ucte d t hr o u g h vi de o c o nfere nci n g a n d tra dit i onal o n -sit e c o n ditio n s has 
s u g geste d ge nerall y g o o d a gree me nt i n a variet y of c o n di tio ns, i ncl u di n g de m e nt ia a n d c o g niti ve 
i m pair me nt of vari o us ca uses. H o we ver, li mite d data is a vaila ble o n t he vali dit y of re m ote 
we b -base d assess me nt of c o g nit i ve a n d f u ncti onal meas u res t ypi[INVESTIGATOR_1306] y i m ple me nte d i n A D 
researc h st u dies. T heref ore, t he aim of  St u d y I 5 T-M C -A A C H ( A A C H ) Part A i s t o e valuate t he 
vali dit y of  r e mote (at -h o me) vi de o assess me nts of c o g nit i ve a n d f u ncti onal meas ures.
St u d y  A A C H Part A is a mul tice nter, ra n d o mize d, m ult i ple cr oss o ver st u d y t o vali date re m ote 
assess me nt of c o g nit i ve a n d f u ncti onal scales. Partici pa nts will be assesse d re m otel y (t hr o u g h 
vi de oc o nfere nci n g) as well as o n- sit e.
P art B
Part B i s a mul tice nter, o pe n -label st u d y of d o na ne ma b treat me nt f or partici pa nts wit h 
s y m pt o mat ic A D a n d naï ve t o d o na ne ma b.
St u d y  A A C H Part B will pr o vi de a d dit i onal safet y a n d cli nical inf or m atio n as a n o pe n -la bel 
st u d y. P arti ci pa nts fr o m a s p o ns or -a p pr o ve d ori gi nati n g d o na ne ma b st u d y w h o were assi g ne d 
pl ace b o will recei ve d o na ne ma b i n t he si n gle o pe n -label ar m . 
P art C
T h ose w h o recei ve d d o na ne ma b i n a n ori gi nati n g st u d y  ma y part ici pate i n a si n gle i ma gi n g a n d 
c o g nitive/f u nct i onal assess me nt visit . 
St u d y  A A C H Part C will assess t he l o n g -t er m effect of d o na ne ma b o n P E T i ma gi n g bio m ar kers, 
c o g nitio n , a n d f u nct i oni n g i n partici pa nts w h o ha ve n ot recei ve d I P f or at least 5 2 wee ks.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9O bjecti ves a n d E n d p oi nt s
O bject i ves E n d p oi nts
Pri mar y
P art A
T o e val uate t he relia bilit y of  V T C c o mpare d 
wi t h o n-site a d mi nistere d c o g niti ve a n d 
f u ncti onal meas uresT he i ntraclass c orrelat i on bet wee n V T C a n d 
o n -site assess me nt f or P AI R 1 f or 
 A D A S -C o g 1 3
 A D C S -A D L
 M M S E
 C D R -S B
P art B
T o e val uate safet y  a n d t olera bility of  
d o na ne ma bSta n dar d safet y assess me nts i n Part B : 
 S p o nta ne o usl y re p orte d A Es
 Cli nical la b orat or y  t ests
 Vi t al si g n a n d b o d y wei g ht 
meas ure me nts
 1 2- lea d E C Gs
 P h ysical a n d ne ur ol o gical 
e xa mi nat i ons
M RI ( A RI A a n d e mer ge nt ra di o l ogi cal 
fi n di n gs)
I nf usi on -r elate d reactio ns
C- S S R S
Sec o n dar y
T o assess t he effect of d o na ne ma b o n cli nical 
pr o gressi o n i n part ici pa nts wit h s y m pt o matic 
A D C ha n ge fr o m baseli ne u p t o Wee k 7 2 as 
meas ure d i n Part B b y : 
 M M S E sc ore
 A D A S -C o g 1 3sc ore
 i A D R S sc ore
 A D C S -i A D L sc ore
 C D R -S B
T o assess t he effect of d o na ne ma b o n brai n 
a m yl o i d de p ositio n C ha n ge i n brai n a m yl o i d pla q ue de p ositio n 
fr om baseli ne at Wee k 3 6 of Part B as 
meas ure d b y fl or beta pir F 1 8 P E T sca n
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391699] d o na ne ma b i n Part B i ncl u di n g 
 treat me nt -e mer ge nt A D As 
 ne utralizi n g a nt i b o dies
A b bre viati o ns: A D = Alz hei mer’s disease; A D A = a n ti dr u g a nti b o d y; A D A S -C o g 1 3= Alz hei mer’s Disease 
Assess me nt Scale – C o g niti ve s u bscale ; A D C S -A D L = Alz hei mer’s Disease C o o perati ve St u d y – Acti vities of 
Dail y  Li vi n g I n ve nt or y; A D C S -i A D L = Alz hei mer’s Disease C o o perati ve St u d y – i nstr u me ntal Acti vities of
Dail y  Li vi n g; A E = a d verse e ve nt; A RI A = a m y l oi d-relate d i ma gi n g a b n or mality ; C D R-S B = Cli nical De me ntia 
Rati n g Scale – S u m of B o xes; C -S S R S = C ol u m bia S uici de Se verit y Rati n g Scale; E C G = electr ocar di o gra m;
i A D R S = i nte grate d Alz hei mer’s Disease Rati n g Scale; M M S E = Mi ni Me ntal State E xa mi nati o n; 
M RI = ma g netic res o na nce i ma gi n g; P E T = p ositr o n e missi o n t o m o gra p h y; P K = p har mac o ki netics;
V T C = vi de o telec o nfere nce.
O ver all Desi g n
P art A:
T he vi de o vali dat i on peri o d is a m ul tiple cr oss o ver desi g n wi t h partici pa nts alter nati n g bet wee n 
i n-cli nic assess me nt s a n d at -h o me assess me nt s of  c o g nitive a n d f u nct i onal scales o ver a 
mi ni m u m o f 1 a n d a ma xi m u m o f 3 cr oss o vers . T otal ti me i n Part A ca n var y fr o m a mi ni m u m o f 
4 wee ks ( 1 cr oss o ver [ 1 P AI R]) t o a ma xi m u m o f 2 4 wee ks ( 3 cr oss o vers [ 3 P AI R S]). 
P arti cipa nts d o n ot recei ve st u d y  I P d urin g t he vi de o vali dat i on peri o d . Partici pa nts are 
ra n d omize d 1: [ADDRESS_391700] assess me nt, eit her:
 Gr o u p 1: C o g nit i ve/f u ncti o nal scale assess me nt at t he st u d y sit e (o n -sit e), foll o we d b y  a n 
at -h o me assess me nt ( V T C) , or
 Gr o u p 2: C o g nit i ve/f u ncti o nal scale assess me nt at h ome ( V T C), f oll o we d b y assess me nt 
o n -sit e. 
P art B:
Part B i s a mul tice nter, o pe n-label, f o ll ow- o n st u d y  of d o na ne ma b i n partici pa nts wit h 
s y m pt o mat ic A D . Partici pa nts w h o recei ve d place b o i n t he ori gi nat i n g trial recei ve d o na ne ma b 
7 0 0 m g I V Q 4 W f or 3 d oses, t he n 1 4 0 0 m g i nt ra ve n o usl y e ver y 4 wee ks f or u p to 3 6 wee ks, (u p 
t o 4 8 wee ks t otal d uratio n i n Part B).
P arti cipa nts ma y  recei ve d o na ne ma b t hr o u g h Wee k 3 6 or Wee k 4 8 . Criteria f or sc he d ule d d ose 
di sc o nti n uati on at 3 6 wee ks are defi ne d b y t he s p o ns or a n d ma y be base d o n res ults of t he 
parti ci pa nt’s fl or be t a pir F [ADDRESS_391701] u d y  
A A C G .
P art C:
P arti cipa nts w h o recei ve d d o na ne ma b i n t he ori gi nati n g trial ma y  p artici pate i n a n i ma gi n g a n d 
c o g nitive/f u nct i onal assess me nt visit ( V isit 2 0 1). V isit [ADDRESS_391702] 5 2 wee ks 
fr om t he partici pa nt’s last d o u ble -bli n d visit i n t he ori gi nati n g st u d y . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391703] ate me nt : 
T his is a si n gle-ar m tr e at me nt st u d y wit h 1 ar m t hat is n ot bli n de d.
N u m ber of P artici p a nt s:
A p pr o xi matel y  [ADDRESS_391704] u d y .
I nter ve nti o n Gr o u ps a n d D ur ati o n :
Part A: T he vi de o vali dat i on peri o d i s a mul tiple cr oss o ver desi g n wit h partici pa nts alter nat i n g 
bet wee n i n- cli nic assess me nt a n d at -h o me assess me nt of c o g nitive a n d f u nct i onal scales o ver a 
mi ni m u m o f 1 a n d a ma xi m u m o f 3 cr oss o vers . T otal ti me i n Part A ca n var y fr o m a mi ni m u m o f 
4 wee ks ( 1 cr oss o ver [1 P AI R ]) t o a ma xi m u m of 2 4 wee ks ( 3 cr oss o vers [3 P AI R S ]). 
P arti cipa nts d o n ot recei ve st u d y  I P d urin g t he vide o vali dat i on peri o d . Partici pa nts are 
ra n d omize d 1: [ADDRESS_391705] assess me nt, eit her:
 Gr o u p 1: C o g nit i ve/f u ncti o nal scale assess me nt at t he st u d y sit e ( o n-sit e), foll o we d b y  a n 
at -h o me assess me nt ( V T C; vi de o telec o nfere nce) or
 Gr o u p 2: C o g nit i ve/f u ncti o nal scale assess me nt at h ome ( V T C), f oll o we d b y assess me nt 
o n -sit e. 
Part B : Partici pa nts w h o recei ve d place b o i n t he ori gi nat i n g trial recei ve d o na ne ma b 7 0 0 m g I V 
Q 4 W f or 3 d oses, t he n 1 4 0 0 m g I V e ver y 4 wee ks f or u p t o 3 6 wee ks (u p t o 4 8 wee ks t otal 
d urati o n i n Part B). 
Part C: Partici pa nts w h o recei ve d d o na ne ma b i n t he ori gi nat i n g trial ma y p artici pat e i n a n 
i ma gi n g a n d c o g nitive/f u nct i onal assess me nt visit ( Visit 2 0 1). V isit [ADDRESS_391706] 
5 2 wee ks fr o m t he partici pa nt’s last d o u ble -bli n d visit i n t he ori gi nat i n g st u d y.
T he m a xi m u m t ot al d uratio n of  st u d y partici pati on f or eac h partici pa nt, i ncl u di n g scree ni n g a n d 
t he p osttreat me nt f o ll ow- u p peri o ds, i s u p t o 1 2 4 wee ks:
 Scree ni n g : u p t o 3 0 da ys pri or t o V isit 6 0 2
 Part A, Vi de o assess me nt: u p t o 2 4 wee ks
 Part B, O pe n -lab el d o na ne ma b : u p t o 7 2 wee ks (treat me nt recei ve d f or 3 6 or 4 8 wee ks)
 Part B, F oll o w - u p: u p t o 2 4 wee ks
N ote: Part C is n ot a d de d t o t he ma xi m u m t ot al d uratio n of  st u d y p artici pat i on beca use Part C is 
a si n gle visit , a n d Part B partici pa nts d o n ot partici pate i n Part C.
D at a M o nit ori n g C o m mittee: N o
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 21. 2. Sc he m a
A b bre viati o ns: I P = i n vesti gati o nal pr o d uct; I V = i ntra ve n o us; L Y = d o na ne ma b; P B O = place b o; Q 4 W = e ver y 
4 wee ks; S o A = Sc he d ule of Acti vities; V = visit .
* Partici pa nt s h o ul d partici pate i n P AI R [ADDRESS_391707] visit of 
Part B or Part C is ≥ 4 wee ks.
♦ I P is a d mi nistere d u p t o V [ADDRESS_391708] u d y as 
i n dicate d i n t he S o A. 
● I ma gi n g a n d c o g niti ve & f u ncti o nal mea s ures visit occ urs a n y ti me ≥ 5 2 wee ks after t he partici pa nt’s last d o u ble -
bli n d visit i n t he ori gi nati n g st u d y. See V 2 0 1 i n t he S o A f or pr oce d ures.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 31. 3. Sc he d ule of Acti vities ( S o A)
Scree ni n g a n d Part A
Scree ni n g Part A: Vi de o Vali dati o n C o m me nts
Visit N u m ber 6 0 1 6 0 2- 6 0 7
Wee ks R elati ve t o B aseli ne ( V 1) See f o ot n ote a.
Visit Int e r val T olera nce ( da ys) – ± 4 ± 4
E ntr y a n d A d mi nistr ati ve
F ull inf or me d c o nse nt (p artici pa nt a n d st u d y 
p art ner)X
I ncl usi o n a n d e xcl usi o n criteria, re vie w a n d 
c o nfir mX
I nter val me dical hist or y, i ncl u di n g rele va nt 
c ha n ges si nce last visit of ori gi nati n g st u d yX
S u bsta nce use (alc o h ol, caffei ne, t o bacc o 
use) X
C o nc o mita nt me dicati o ns X X X
A Es X X X
Cli nic al Assess me nts
P h y sical/ ne ur ol o gical e xa mi nati o n XC o m plete p h ysical a n d ne ur ol o gical 
e xa m, as descri be d i n Secti o n 8. 2. 1 .
A n y  cli nicall y si g nifica nt c ha n ges 
fr o m baseli ne o n 
p h y sical/ ne ur ol o gical e xa mi nati o ns 
s h o ul d be n ote d o n t he A E C R F.  
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 4Scree ni n g Part A: Vi de o Vali dati o n C o m me nts
Visit N u m ber 6 0 1 6 0 2- 6 0 7
Wee ks R elati ve t o B aseli ne ( V 1) See f o ot n ote a.
Visit Int e r val T olera nce ( da ys) – ± 4 ± 4
Cli nici a n- A d mi nistere d Assess me nts ( Electr o nic)
A D A S -C o g 1 3 X XA d mi nister t he A D A S -C o g 1 3, 
A D C S -A D L, C D R -S B, a n d M M S E 
pri or t o me dical pr oce d ures t hat 
c o ul d be stressf ul t o t he partici pa nt 
( bl o o d dra ws, etc.; Secti o n 8. 1. 2 ). 
T hese tests i ncl u de t he a u di o v oice 
rec or di n g of t he rater’s q uesti o ns a n d 
t he partici pa nt a n d st u d y part ner 
res p o nses t o assess me nt q uesti o ns.A D C S -A D L X X
C D R -S B X X
M M S E X X
R a n d o miz ati o n 
Ra n d o mizati o n X
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 5Part B
Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7
E ntr y a n d A d mi nistr ati ve
Re vie w M RI, 
cli nical la bs, a n d 
cli nical stat usXC o nfir m partici pa nt d oes 
n ot meet disc o nti n uati o n 
criteria ( Secti o n 7. 2 ).
C o nc o mita nt 
me dicati o nsX  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X
A Es X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X
Cli nic al Assess me nts
Hei g ht X
Wei g ht X X X X X  X X  X  X
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 6Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7
Vital si g ns X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  XSitti n g B P, p ulse, a n d 
te m perat ure ( wit h sitti n g 
vitals) will be meas ure d at 
all visits. 
Sitti n g B P a n d p ulse will 
be meas ure d after 
a p pr o xi matel y 5 mi n utes i n 
t he sitti n g p ositi o n o nl y. 
I n a d diti o n, ort h ostatic B P 
a n d p ulse will be meas ure d 
at V1, V 4, V 7 , V 10 , V 1 3 , 
V 1 4 , E D, a n d U Vs . 
P h y sical/ ne ur ol o gi
cal e xa mi nati o nX X X X X  X X  X  XI ncl u des n e ur ol o gical 
e xa mi nati o n
V 6 0 1 is a brief p h ysical 
a n d ne ur ol o gical e xa m, as 
descri be d i n Secti o n 8. 2. 1 .
A n y  cli nicall y si g nifica nt 
c ha n ges fr o m baseli ne o n 
p h y sical/ ne ur ol o gical 
e xa mi nati o ns s h o ul d be 
n ote d o n t he A E C R F .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 7Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7
1 2 -lea d E C G 
(ce ntral or l ocal)X X X X X  X XPerf or m pri or t o 
a d mi nistrati o n of I P, w he n 
a p pr o priate.
E C G at V 14 n ot re q uire d 
f or partici pa nts w h o 
c o m plete d d osi n g at V 1 0. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 8Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± [ADDRESS_391709] u d y occ urre d 
> [ADDRESS_391710], 
sec o n d, or t hir d d ose, a n 
M RI is t o be perf or me d 
a n d re vie we d pri or t o t he 
f o urt h i nf usi o n.
M RI at V 4 is t o be 
perf or me d a n d re vie we d 
pri or t o V 4 i nf usi o n.
M RI at V 4 m a y  occ ur 
1 4 da ys bef ore t he 
sc he d ule d visit date 
wit h o ut pr ot oc ol de viati o n.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 9Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7
Fl or beta pir F 1 8
P E T sca nX XeFl or beta pir F 1 8 P E T sca n 
m a y  occ ur ± 1 4 da ys fr o m 
sc he d ule d visit date 
wit h o ut pr ot oc ol de viati o n.
Cli nici a n- A d mi nistere d Assess me nts ( Electr o nic)
A D A S -C o g 1 3 X X X X X  X  X  X  X  XA d mi nister t he A D A S -
C o g 1 3, A D C S-A D L, C D R -
S B, a n d M M S E pri or t o 
me dical pr oce d ures t hat 
c o ul d be stressf ul t o t he 
partici pa nt ( bl o o d dra ws, 
etc. ; Secti o n 8. 1. 2 ). T hese 
tests i ncl u de t he a u di o 
v oice rec or di n g of t he 
rater’s q uesti o ns a n d t he 
partici pa nt a n d st u d y 
part ner res p o nses t o 
assess me nt questi o ns.A D C S -A D L X X X X X  X  X  X  X  X
C D R -S B ( Gl o bal 
S u m of B o xes -
C D R)X X X X X  X  X  X  X  X
M M S E X X X X X  X  X  X  X  X
Cli nici a n- A d mi nistere d Assess me nts ( P a per)
C- S S R S 
Scree ni n g/ Baseli neX
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 0Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± [ADDRESS_391711] u d y were 
c ollecte d > 6 m o nt hs bef ore 
V 1.Cli nical C he mistr y X  X  X  X  X X X X  X X
P- t a u X X X X X  X  X  X  X  X
Nf L X X X X X  X  X  X  X  X
A X X X X X  X  X  X  X  X
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 1Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7
P K sa m ple 
( pr ed ose)X X  X  X X XD o n ot c ollect if t he last I P 
i nf usi o n was > 6 m o nt hs 
pri or t o t he sc he d ule d visit.
Pre d ose c ollecti o ns ma y be 
c ollecte d fr o m t he I V site 
pri or t o t he i nf usi o n.
Ra n d o m P K sa m ple 
c ollecte d f or partici pa nts 
w h o d o n ot recei ve d ose at 
V 1 3.
P K sa m ple 
( post d ose)X X XD o n ot c ollect if t he last I P 
i nf usi o n was > [ADDRESS_391712] fr o m t he ar m t hat 
I P was n ot a d mi nistere d 
t hr o u g h.
P K sa m ple 
(ra n d o m)X  X  X  X  XD o n ot c ollect if t he last I P 
i nf usi o n was > 6 m o nt hs 
pri or t o t he sc he d ule d visit.
I m m u n o ge nicit y 
( A D A) sa m plesX  X  X  X  X X X  X  X  X  X  X
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 2Part B: O pe n -La belPart B: F oll o w - Up, U V , 
E DC o m me nts
Visit N u m ber U Pb1 2 3 4 5 6 7 8 9 1 0 1 1c1 2c1 3c1 4c1 5 8 0 1d8 0 2dU V E DE D o nl y if partici pa nt has 
c o m plete d V 1 a n d recei ve d I P 
i n Part B.
Wee ks R elati ve t o 
B aseli ne ( V 1)0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 6 0 7 2 8 4 9 6 9 9 7Pr oce d ures f or s o me visits 
m a y  ta ke m ore t ha n 1 da y.
Visit Int e r val 
T olera nce ( da ys)–-7 t o 
+ 1 0± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± 7 ± [ADDRESS_391713] u d y site. 
T he partici pa nt s h o ul d be 
o bser ve d f or a mi ni m u m of 
6 0 mi n utes f oll o wi n g t he 
e n d of eac h i nf usi o n.
O nl y a d mi nister I P at V 1 1, 
V 1 2, a n d V 1 3 f or 
partici pa nts recei vi n g I P 
f or 4 8 wee ks.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 3Part C
Part C C o m me nts
Visit N u m ber 2 0 1
Ti mi n g A n y  ti me ≥ 5 2 wee ks after 
partici pa nt’s last d o u ble -bli n d 
visit i n t he or i gi nati n g st u d y.Pr oce d ures ma y ta ke m ore t ha n 
1 da y .
P E T Sc a ns
Fl orta uci pir F 1 8 P E T sca n Xg
Fl or beta pir F 1 8 P E T sca n Xg
Cli nici a n A d mi nistere d Assess me nts ( Electr o nic)
A D A S -C o g 1 3 X If a P E T sca n is d o ne o n t he sa me 
da y , ad mi nister t he A D A S -C o g 1 3, 
A D C S -A D L, C D R -S B, a n d 
M M S E pri or t o P E T sca n . T hese 
tests i ncl u de t he a u di o v oice 
rec or di n g of t he rater’s q uesti o ns 
a n d t he partici pa nt a n d st u d y 
part ner res p o nses t o assess me nt 
q uesti o ns.A D C S -A D L X
C D R -S B ( Gl o bal S u m of 
B o xes - C D R)X
M M S E X
P- t a u X
Nf L X
A X
E x pl o rat or y bi o mar ker sa m ples XC ollect u nless n ot all o we d or 
u nfeasi ble d ue t o l ocal re g ulati o ns.
A E s X
C o nc o mita nt me dicati o ns X
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 4A b bre viati o ns : A β = a m y l oi d beta; A D A = a nti dr u g a nti b o d y; A D A S -C o g 1 3= Alz hei mer’s Disease Assess me nt Scale – C o g niti ve s u bscale ; A D C S -
A D L = Alz hei mer’s Disease C o o perati ve St u d y – Acti vities of Dail y Li vi n g I n ve nt or y; A E = a d verse e ve nt; B P = bl o o d press ure; C D R -S B = Cli nical 
De me ntia Rati n g Scale – S u m of B o xes; C -S S R S = C ol u m bia S uici de Se verit y Rati n g Scale; C R F = case re p ort f or m; E C G = electr ocar di o gra m; E D = earl y 
disc o nti n uat i o n; I P = i n vesti gati o nal pr o d uct; I V = i ntra ve n o us; I W R S = i nteracti ve we b-res p o nse s yste m; M M S E = Mi ni Me ntal State E xa mi nati o n; 
M RI = ma g netic res o na nce i ma gi n g; Nf L = ne ur ofila me nt li g ht c hai n ; P E T = p ositr o n e missi o n t o m o gra p h y; P K = p har mac o ki netics; P- ta u = p h os p h or ylate d 
ta u; U P = u nsc he d ule d pr oce d ure; U V = u nsc he d ule d visit; V = visit .
a V 6 0 1 occ urs u p t o 3 0 da ys pri or t o V 6 0 2 . V 6 0 2 ca n n ot occ ur < 3 0 da ys fr o m t he partici pa nt’s last d o u ble -bli n d visit of t he ori gi nati n g st u d y. V 6 0 2 t hr o u g h 
V 6 0 7 ea c h  occ ur 4 wee ks a part. Part A visits ma y occ ur u p t o 2 4 wee ks pri or t o Part B ( V 1 ), f or eli gi ble partici pa nts. T he e xact wee k relati ve t o V [ADDRESS_391714] visit of Part B or Part C is 
≥ [ADDRESS_391715] at t he start of Part B ( pri or t o V 1), a n d is o nl y c o n d ucte d if : partici pa nt’s last M RI fr o m t he ori gi nati n g st u d y is > [ADDRESS_391716] u d y were c ollecte d > 6 m o nt hs fr o m V 1. T he i n vesti gat or c o nfir ms c o nti n ue d eli gi bilit y as descri be d i n Secti o n 7. 2 .
c V 1 1 a n d V 1 2 d o n ot occ ur f or partici pa nts wit h a fi nal d ose at or bef ore V 1 0. Partici pa nts res u me t he visit sc he d ule wit h V 1 3 ( Wee k 4 8) . V [ADDRESS_391717] la bs pri or t o a d mi nistrati o n of I P, u nless ot her wise n ote d. 
g Perf or m t he fl orta uci pir F 1 8 a n d fl or beta pir F 1 8 P E T sca ns ≥ 1 6 h o urs a part fr o m eac h ot her . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391718] u d y I 5 T-M C -A A C H ( A A C H ) Part A i s t o e valuate t he 
vali dit y of  r e mot e ( at -h o me ) vi de o assess me nts of c o g nit i ve a n d f u ncti onal meas ures .
St u d y  A A C H P art A is a m ult ice nter, ra n d o mize d, m ulti ple cr oss o ver st u d y t o vali date re m ote 
assess me nt of c o g nit i ve a n d f u ncti onal scales. Partici pa nts will be assesse d r e mot e l y (t hr o u g h 
vi de oc o nfere nci n g) as well as o n -sit e.
P art B
Part B is a m ult ice nter, o pe n -label , st u d y of d o na ne ma b tr e at me nt f or partici pa nts wit h 
s y m pt o mat ic A D a n d naï ve t o d o na ne ma b.
St u d y  A A C H Part B will pr o vi de a d dit i onal safet y a n d cli nical i nf or mati o n as a n o pe n-la bel 
st u d y. P arti ci pa nts fr o m a s p o ns or-a p pr o ve d ori gi nati n g d o na ne m a b st u d y w h o were assi g ne d 
pl ace b o will recei v e d o na ne ma b i n t he si n gle o pe n -label ar m . 
P art C
T h ose w h o recei ve d d o na ne ma b i n a n ori gi nati n g st u d y ma y part ici pate i n a si n gle i ma gi n g a n d 
c o g nitive/f u nct i onal assess me nt visit . 
St u d y  A A C H Part C will assess t he lo n g- t er m effect of d o na ne ma b o n P E T i m a gi n g bio m ar kers, 
c o g nitio n , a n d f u nct i oni n g i n partici pa nts w h o ha ve n ot recei ve d I P f or at least [ADDRESS_391719] ome . A n ot her hall mar k ne ur o pat h ol o gical lesio n  of AD is c o m prise d of i ntra ne ur o nal, 
ne ur ofi brillar y  ta n gles c o nsisti n g of ta u pr otei ns, w hic h s prea d t hr o u g h t he brai n a n d mar k 
di sease pr o gressio n ( Braa k a n d Braa k 1 9 9 6) . T he relat i ons hi p bet wee n t hese [ADDRESS_391720] ill 
u nclear, alt h o u g h t he prese nce of b ot h is necessar y f or t he dia g n osis of defi nite A D.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
2 6C o n ver gi n g e vi de nce fr o m b ot h ge net ic at-ris k a n d a ge at-ris k c o h orts s u g gests t hat t he 
pat h o p h ysi o l ogi c al pr ocess of A D be gi ns well m ore t ha n a deca de bef ore t he cli nical sta ge n o w 
rec o g nize d as A D de me nt ia, a n d t hat ne ur o de ge nerati o n is alrea d y a p pare nt o n M RI b y t he sta ge 
of  M CI. Li ke ma n y  dis or ders, A D occ urs o n a c o nti n u u m fr o m as y m pt o matic ( precli nical) t o 
M CI, a n d t he n t o de me nt ia i n mil d, m o derate, a n d se vere sta ges . Rece nt cli nical tri al r es ults i n 
mil d -t o-m o derate A D de me nt ia, as well as e vi de nce fr om tra ns ge nic a ni mal e x peri me nts, s u g gest 
t hat treati n g A D d uri n g t he earlier sta ges c o ul d ha ve t he greatest p ote ntial be nefit o n t he disease 
a n d i n hi bit i n g pr o gressi o n, partic ularl y w he n c onsi deri n g t hera pi[INVESTIGATOR_318304] d at A β re d ucti o n 
( D o o d y et al. 2 0 1 4; Fleis her et al. 2 0 1 5; Sie mers et al. 2 0 1 6).
2. 2. 2. Vi de o Assess me nt
V T C i n healt hcare setti n gs is c o m m o n a n d is use d t o carr y  o ut c o g nitive assess me nts, t o c o n d uct 
ps yc hiatric i nter vie ws a n d c o ns ult at i ons, a n d t o hel p wit h t he ma na ge me nt of c hr o nic c o n ditio n s
(C ull u m et al. 2 0 1 4 ; I g nat o wicz et al. 2 0 1 9). Researc h c o m pari n g cli nical i nter vie wi n g 
c o n d ucte d t hr o u g h vi de o c o nfere nci n g a n d tra dit i onal o n -site c o n ditio ns i n dicates ge nerall y g o o d 
a gree me nt i n a variety of  c o n ditio ns, i ncl u di n g de me nt ia a n d c o g niti ve i m pair me nt of vari o us 
ca uses (Casta n h o et al . 2 0 1 7). 
A rece nt s y st e mat ic re vie w a n d meta-a nal ysis assesse d t he effect of V T C a d mi nistrati o n o n a d ult 
c o g nitive tests a n d i n vesti gate d w het her t he sc ores ac q uire d d uri n g a V T C a d mi nistrati o n were 
differe nt fr o m t hose ac q ui re d d uri n g o n-site a d mi nistratio n ( Brearl y  2 0 1 7). T he re vie w 
c o nclu de d t hat st u dies i ncl u di n g partici pa nts wit h a mea n a ge of [ADDRESS_391721] i on, i n dicate d c o nsiste nt perf or ma nce acr oss V T C a n d 
o n -site c o n ditio ns (st u di es wit h slo wer c o n nect i ons were m ore varia ble). F urt her m or e, s u b gr o u p 
a nal yses i n dicate d t hat V T C sc ores f or u nti me d tas ks a n d t h ose all o wi n g f or re petiti o n fell 1/ [ADDRESS_391722] i gate d b y se veral a ut h ors 
(Ci e mi ns et al. 2 0 0 9; C ull u m et al. 2 0 1 4; Casta n h o et al 2 0 1 7 ) a n d n o differe nces were re p orte d 
bet wee n vi de o a n d o n -site a d mi nistratio ns. 
V T C of  t he A D A S-C o g [ADDRESS_391723] u dies s h o w n o differe nce i n baseli ne a n d f o ll ow- u p sc ores of t he A D A S -C o g 1 3bet wee n 
o n -sit e a n d V T C testi n g (Car ote n ut o et al. 2 0 1 8; Y os hi d a et al . 2 0 2 0). O ne of t hese st u dies 
re p orte d t hat i n patient s wit h more pr o n o u nce d c o g nit i ve deficits ( M M S E < 1 7), t he assess me nt 
via V T C o veresti mate d t he c o g niti ve i m pair me nt (Car ote n ut o et al. 2 0 1 8 ).
T here are a c o u ple n ota ble li mitati ons of t hese st u dies: t he re mote assess me nt di d n ot ta ke place 
at t he partici pa nt ’s h o me or ot her desi g nate d e xter nal e n vir o n me nt, b ut rat her, o n -sit e, wit h t he 
parti ci pa nt bei n g l ocate d i n a differe nt r o o m fr o m t he test a d mi nistrat or. Als o , in m o st st u dies
descri be d a b o ve, a tec h nicia n was a vaila b le t o set u p t he a u dio vis ual  a n d V T C har d ware . As 
s uc h, re m ote a d mi nistrati o n i n a real-w orl d ( at -h o me ) setti n g nee ds t o be f urt her i n vest i gate d. 
F urt her, t est sc ores are relia ble if t he scale is a d mi nistere d i n acc or da nce wit h h o w t hat scale has 
bee n vali date d. A n y m o dificat i on t o a n assess me nt -vali date d versi o n ca n i n vali date test sc ores. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391724] u d y  part ner a n d rater f or its a d mi nistrati o n. H o w t hese 
m o dificati o ns ha ve bee n o perati o nalize d (a n d t h us, t o w hat e xte nt vali dity has bee n esta blis he d) 
is n ot clear.
T heref ore, t his st u d y ai ms t o e val uate t he relia bilit y of  r e mot e a d mi nistrati o n, c o mpare d t o
o n -sit e a d mi nistrati o n, of  t he s pecific c o g nitive a n d f u nct i onal meas ures descri be d .
2. 2. 3. D o n a ne m a b
D o na ne ma b is a n a nt i b o d y directe d at t he p yr o glut a m at e mo dificati o n of  t he t hir d a mi n o aci d of 
A β ( N 3 p G A β) e pit o pe t hat is prese nt o nl y in brai n a m y l oi d pla q ues. It is bei n g st u die d f or t he 
treat me nt of A D . T he m ec ha nis m of actio n of  d o na ne ma b a nti b o d y is t o tar get a n d re m o ve 
de p osi te d a m yl oi d pla q ue, a ke y pat h olo gi cal hall mar k of A D, via micr o glial-me diate d 
cleara nce. 
2. 2. 3. 1. D o n a ne m a b Cli nic al St u dies
T he first h u ma n d ose st u d y  of d o na ne ma b w as St u d y I 5 T-M C -A A C C ( A A C C) . St u d y A A C C 
was a P hase 1, d o u bl e- bli n d, ra n d o mize d wit hi n c o h ort, place b o -c o ntr olle d, parallel-gr o u p, 
si n gle-d os e f ol l owe d b y m ult i ple-d ose, d ose -escalati o n st u d y in patie nts wit h M CI d u e t o A D or 
mil d -t o-m o derate A D t o assess t he safet y,  t olera bilit y, P D, a n d P K of si n gle a n d m ulti ple I V 
d oses of d o na ne ma b . After si n gle -d ose a d mi nistrati o n fr om 0. 1 m g/ k g t o 3. 0 m g/ k g, t he m ea n 
ter mi nal eli mi nati on half -life was a p pr o xi matel y 4 da ys, i ncreasi n g t o a p pr o xi matel y 1 0 da ys 
( 2 4 3 h o urs) at t he 1 0-m g/ k g d ose le vel . T he P K of a si n gle d ose of 1. 0 m g/ k g I V of d o na ne ma b
i n y o u n g, heal t hy s u bjects was i n disti n g uis ha ble fr o m t he P K i n A D patie nts at t he sa me d ose 
le vel.
I n St u d y  A A C C, fl or beta pir F [ADDRESS_391725] d ose, 1 0 m g/ k g ( p <. 0 0 0 2). T he a nal ysis 
s h o we d c o nsiste nt re d ucti o n i n c ortical a m yl o i d a m on g t he patie nts w h o recei ve d 3 t o 5 d oses of 
1 0 m g/ k g of d o na ne ma b . T he mea n o bser ve d re d ucti o n i n fl or beta pir F 1 8 P E T si g nal  
c orres p o n ds t o a mea n 5 0 % re d ucti o n i n t otal brai n fi brillar a m yl o i d. Mea ni n gf ul tar get 
e n ga ge me nt (a m yl o i d re d ucti o n) was li kel y n ot ac hie ve d at d oses s maller t ha n or e q ual t o 
3 m g/ k g I V Q [ADDRESS_391726] u d y  I 5 T-M C -A A C D ( A A C D) is a P hase [ADDRESS_391727] u d y has n ot c o m plete d data base l oc k . It is e val uati n g 6 1 patie nts i n 
7 treat me nt gr o u ps recei vi n g si n gle- d ose, Q 2 W or Q 4 W d osi n g of eit her 1 0 m g/ k g, 2 0 m g/ k g, or 
4 0 m g/ k g of d o na ne ma b . Treat m e nt d uratio ns bei n g assesse d i ncl u de si n gle -d ose, [ADDRESS_391728] u d y are use d t o i nf or m furt her de vel o p me nt of d o na ne ma b . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391729] u d y  I 5 T-M C -A A C G ( A A C G) is a n o n g oi n g P hase 2, d o u ble -bli n d, place b o -c o ntr olle d st u d y t o 
e val uate t he safet y a n d efficac y of d o na ne ma b i n patie nts wit h earl y s y m pt o mat ic A D . 
St u d y A A C G is e val uati n g a p pr o xi matel y  27 2 pat ie nts ra n d omize d t o d o na ne ma b ( 7 0 0 m g Q 4 W 
f or 3 d oses, t he n 1 4 0 0 m g Q 4 W) or place b o . 
St u d y  I 5 T-M C -A A CI ( A A CI) is a n o n g o i n g P hase 2, d o u ble-bli n d, pl ace b o -c o ntr olle d st u d y t o 
e val uate t he safety a n d efficac y of d o na ne ma b i n patie nts wit h earl y s y m pt o mat ic A D . 
St u d y A A CI i s e val uati n g a p pr o xi matel y 5 0 0 patie nts ra n d omize d t o d o na ne ma b ( 7 0 0 m g I V 
Q 4 W f or 3 d oses, t he n 1 4 0 0 m g I V Q 4 W) or pl ace b o.
See t he I B f or detaile d n o ncli nical, safety, a n d P K i nf or mat i on re gar di n g d o na ne ma b .
2. 3. Be nefit/ Ris k Assess me nt
M ore detaile d i nf or mat i on a b o ut t he k n o w n a n d e x pecte d be nefits a n d ris ks a n d reas o na bl y 
e x pecte d A Es of  d o na ne ma b ma y b e f o u n d i n t he I B.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391730] he i ntraclass c orrelat i on bet wee n V T C a n d 
o n -sit e assess me nt f or P AI R 1 f or 
 A D A S -C o g 1 3
 A D C S -A D L
 M M S E
 C D R -S B
P art B
T o e val uate safet y a n d t olera bility of  
d o na ne ma bSta n dar d safet y assess me nts i n Part B : 
 S p o nta ne o usl y re p orte d A Es
 Cli nical la b orat or y  t ests
 Vi t al si g n a n d b o d y wei g ht 
meas ure me nts
 1 2- lea d E C Gs
 P h ysical a n d ne ur ol o gical 
e xa mi nat i ons
M RI ( A RI A a n d e mer ge nt ra di o l ogi cal 
fi n di n gs)
I nf usi on -r elate d reactio ns
C- S S R S
Sec o n dar y
T o assess t he effect of d o na ne ma b o n cli nical 
pr o gressi o n i n part ici pa nts wit h s y m pt o matic 
A DC ha n ge fr o m baseli ne u p t o Wee k 7 2 as 
meas ure d i n Part B b y : 
 M M S E sc ore
 A D A S -C o g 1 3sc ore
 i A D R S sc ore
 A D C S -i A D L sc ore
 C D R -S B
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391731] d o na ne ma b i n Part B i ncl u di n g 
 treat me nt -e mer ge nt A D As 
 ne utralizi n g a nt i b o dies
Terti ar y/ E x pl orat or y
T o assess l o n g -t er m effect of d o na ne ma b o n 
brai n a m yl o i d de p ositio n, brai n ta u 
de p osi tio n, bl o o d -base d bi o mar kers, a n d 
cli nical pr o gressi o n of A D i n partici pa nts w h o 
recei ve d d o na ne ma b i n t he ori gi nat i n g st u d yC ha n ge i n t he f o ll owi n g e n d p o i nts fr o m 
baseli ne i n t he ori gi n at i n g st u d y t hr o u g h 
≥ 5 2 wee ks after t he partici pa nt’s last 
d o u bl e- bli n d visit i n t he ori gi nat i n g stu d y, 
usi n g Part C assess me nts: 
 A m yl o i d pla q ue de p ositio n as 
meas ure d b y fl or beta pir F 1 8 P E T 
sca n
 Ta u de p osi tio n as m eas ure d b y 
flort a u ci pir F 1 8 P E T sca n
 Nf L
 P- t a u
 A 
 M M S E sc ore
 A D A S -C o g 1 3sc ore
 i A D R S sc ore
 A D C S -i A D L sc ore
 C D R -S B
T o assess t he effect of d o na ne ma b o n 
bl o o d -base d bi o mar kersC ha n ge fr o m baseli ne t o Wee k 7 2 i n t he 
f oll owi n g bl o o d -base d bi o mar kers i n Part B:
 Nf L
 P- t a u
 A 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391732] he i ntraclass c orrelat i on bet wee n V T C a n d 
o n -sit e assess me nt f or P AI R 2 a n d P AI R 3 
c o mpare d wi t h int raclass c orrelat i on of 
P AI R 1 f or 
 A D A S -C o g 1 3
 A D C S -A D L
 M M S E
 C D R -S B
T o assess cli nical pr o gressi o n as me as ure d b y 
V T C vers us F 2 F -a d mi nistere d c o g nitive a n d 
f u ncti onal meas uresC ha n ge fr o m V 6 0 2 t o V 6 0 8 as meas ure d b y  
 A D A S -C o g 1 3
 A D C S -A D L
 M M S E
 C D R -S B
A b bre viati o ns: A β = a m y l oi d beta; A D = Alz hei mer’s disease; A D A = a nti dr u g a nti b o d y; 
A D A S -C o g 1 3= Alz hei mer’ s Disease Assess me nt Scale – C o g niti ve s u bscale ; A D C S -A D L = Alz hei mer’s 
Disease C o o perati ve St u d y – Acti vities of Dail y Li vi n g I n ve nt or y; A D C S -i A D L = Alz hei mer’s Disease 
C o o perati ve St u d y – i nstr u me ntal Acti vities of Dail y Li vi n g; A E = a d verse e ve nt; A RI A = a m y l oi d-relate d 
i ma gi n g a b n or malit y; C D R-S B = Cli nical De me ntia Rati n g Scale – S u m of B o xes; C -S S R S = C ol u m bia S uici de 
Se verit y  Rati n g Scale; E C G = electr ocar di o gra m; F 2 F = face t o face; i A D R S = i nte grate d Alz hei mer’s Disease 
Rati n g Scale; M M S E = Mi n i Me ntal State E xa mi nati o n; M RI = ma g netic res o na nce i ma gi n g; Nf L = 
ne ur ofila me nt li g ht c hai n; P E T = p ositr o n e missi o n t o m o gra p h y; P K = p har mac o ki netics; P -ta u = p h os p h or ylate d 
ta u; V = visit; V T C = vi de o telec o nfere nce.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391733] u d y Desi g n
4. 1. O ver all Desi g n
P art A:
T he vi de o vali dat i on peri o d is a m ul tiple cr oss o ver desi g n wi t h p artici pa nts alter nati n g bet wee n 
i n-cli nic assess me nt s a n d at -h o me assess me nt s of  c o g nitive a n d f u nct i onal scales o ver a 
mi ni m u m o f 1 a n d a ma xi m u m o f 3 cr oss o vers. T otal ti me i n Part A ca n va r y fr o m a mi ni m u m of 
4 wee ks ( 1 cr oss o ver [ 1 P AI R]) t o a ma xi m u m of 2 4 wee ks ( 3 cr oss o vers [ 3 P AI R S]).
P arti cipa nts d o n ot recei ve st u d y  I P d uri n g t he vi de o vali dat i on peri o d . Partici pa nts are 
ra n d omize d 1: [ADDRESS_391734] assess me nt , eit her :
 Gr o u p 1: C o g nit i ve/f u ncti o nal scale assess me nt at t he st u d y sit e (o n -sit e), foll o we d b y  a n 
at -h o me assess me nt ( V T C; vi de o telec o nfere nce), or
 Gr o u p 2: C o g nit i ve/f u ncti o nal scale assess me nt at h ome ( V T C ), foll o we d b y assess me nt
o n -sit e. 
P art B:
Part B is a m ult ice nter, o pe n-label, f oll ow- o n st u d y of d o na ne ma b i n part ici pa nts wit h 
s y m pt o mat ic A D . Partici pa nts w h o recei ve d place b o i n t he ori gi nat i n g trial recei ve:
 d o na ne ma b 7 0 0 m g I V Q 4 W f or 3 d oses, t he n
 d o na ne ma b 1 4 0 0 m g I V Q 4 W f or u p t o 3 6 wee ks i n Part B.
P arti cipa nts ma y  recei ve d o na ne ma b t hr o u g h Wee k 3 6 or Wee k 4 8. Criteria f or sc he d ule d d ose 
di sc o nti n uati on at 3 6 wee ks are defi ne d b y t he s p o ns or a n d ma y be base d o n res ults of t he 
parti ci pa nt’s fl or beta pir F [ADDRESS_391735] u d y  
A A C G .
P art C:
P arti cipa nts w h o recei ve d d o na ne ma b i n t he ori gi nati n g trial ma y p artici pate i n a n i ma gi n g a n d 
c o g nitive/f u nct i onal assess me nt visit ( Visit 2 0 1). V isit [ADDRESS_391736] 5 2 wee k s 
fr om t he partici pa nt’s last d o u ble -bli n d visit i n t he ori gi nati n g st u d y. 
O ver all St u d y:
T he m a xi m u m t ot al d uratio n of  st u d y partici pati on f or eac h partici pa nt, i ncl u di n g scree ni n g a n d 
t he p osttreat me nt f o ll ow- u p peri o ds, i s u p t o 1 2 4 wee ks:
 Scree ni n g : u p t o 3 0 da y s prior t o V isit 6 0 2
 Part A, Vi de o assess me nt: u p t o 2 4 wee ks
 Part B, O pe n -lab el  d o na ne ma b : u p t o 7 2 wee ks (treat me nt recei ve d f or 3 6 or 4 8 wee ks)
 Part B, F oll o w - u p: u p t o 2 4 wee ks
N ote: Part C is n ot a d de d t o t he ma xi m u m t ot al d uratio n of  st u d y p artici pat i on beca use Part C i s 
a si n gle visit , a n d Part B partici pa nts d o n ot partici pate i n Part C .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
3 34. 1. 1. Scree ni n g
At  or bef ore Visit 6 0 1 (ra n d o mizati o n f or Part A), t he st u d y  will be e x plai ne d t o t he partici pa nt 
(a n d his or her le gal re prese ntative, if a p plica ble) a n d st u d y  part ner. I nf or me d c o nse nt m ust be 
o btai ne d bef ore a n y st u d y  pr oce d ures are c o n d ucte d. T he scree ni n g peri o d c o nsists of t he visit 
wi n d o w of V isit [ADDRESS_391737] m eet scree ni n g eli gi bilit y crit eria of 
 Part A 
a n d eit her 
 Part B (if partici pa nt recei ve d place b o i n t he ori gi nati n g st u d y ) or 
 Part C (if partici pa nt recei ve d d o na ne ma b i n t he ori gi nati n g st u d y a n d c o nse nts t o 
parti ci pate i n t his visit). 
C urre nt or pla n ne d use of c o nc o mit a nt me dicat i ons, t he effects of vacat i ons or a bse nces o n 
pr ot oc ol  c o mplia nce, a n d ge neral c o m plia nce wit h t he pr ot oc ol will be disc u sse d at Visit [ADDRESS_391738] u d y  assess me nts are s h o w n i n t he So A ( Secti o n 1. 3 ). 
4. 1. 2. P art A: V i de o Assess me nt
P art A is a m ult ice nter, ra n d omize d, m ulti p le cr oss o ver st u d y t o vali date re m ote assess me nt of 
c o g nitive a n d f u nct i onal scales. Part A be gi n s at Visit 6 0 1 (ra n d o mizat i on), after scree ni n g is 
c o mplete . Parti ci pa nts are ra n d o mize d t o o ne of 2 gr o u ps, as descri be d i n t he Sc he ma a n d 
O verall Desi g n ( Secti o ns 1. 2 a n d 4. 1 , res pecti vel y) t o be assesse d b ot h r e motel y  (t hr o u g h V T C) 
as well as o n -sit e. 
Part A c o nsists of  6 assess me nts or 3 pairs: 
 P ai r 1 c o mprises V isits 6 0 2 a n d 6 0 3
 P ai r 2 c o mprises V isits 6 0 4 a n d 6 0 5
 P ai r [ADDRESS_391739] t o pr ocee d t o Part B ( Visit 1) at a n y ti me after parti ci pat i n g i n Part A 
P ai r 1. 
4. 1. 3. P art B: O pe n -L a bel D o n a ne m a b
Part B i s a n o pe n-labe l d o na ne ma b p hase be gi n ni n g at V isit 1 . Partici pa nts s h o ul d parti ci pate i n,
at a mi ni m u m, P ai r 1 of Part A bef ore starti n g Part B. 
At  Visit 1, a p p oi nt me nt s s h o ul d be ma de f or all re mai ni n g visits a n d s h o ul d be sc he d ule d as 
close as p ossi ble t o t he tar get date, relat i ve t o Visit 1. 
Assess me nts a n d pr oce d ures will be perf or me d as i n dicate d i n t he S o A ( Secti o n 1. 3 ). Pr oce d ures 
f or s o me visits m a y t a k e m o re t ha n 1 da y.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391740] u d y t o i ncrease o bjecti vity of  c o g nitive assess me nts . 
P arti cipa nt s w h o meet e ntr y criteria f or Part B will be e nr o lle d t o recei ve u p t o 4 8 wee ks of 
treat me nt wit h d o na ne ma b I V Q 4 W. 
4. 1. 4. P art C: I m a gi n g a n d C o g niti ve /F u ncti o n al Me as ures
P arti cipa nts w h o pre vi o usl y recei ve d d o na ne ma b i n a n ori gi nat i n g st u d y will be gi ve n t he o ptio n 
of  p artici pat i n g i n Visi t [ADDRESS_391741] 5 2 wee ks after t he 
parti ci pa nt’s last d o u ble- bli n d visit i n t he ori gi nat i n g st u d y.
T he st u d y  in vesti gat or a n d site cli nical st u d y  t e a m will not ha ve access t o fl or beta pir F [ADDRESS_391742] u d y Desi g n
O verall, S t u d y A A C H is c o m prise d of 3 parts: A, B , a n d C (as i n dicate d i n Sect i on 4. 1 ).
T he o bj ect i ve of P art A is t o a d dress t he scie ntific nee d f or vali dati n g re m ote cli nical o utc o me 
assess me nts, as a met h o dol o g y  t hat re d uces site b ur de n. T he st u d y d esig n al ter nates bet wee n i n 
pers o n, o n -site cli nic assess me nts wit h h o me V T C assess me nts. 
P art B i n v ol ves treat me nt wit h d o na ne ma b a n d is desi g ne d t o c ollect data o n t he safety,  
t olera bilit y, a n d ot her cli nical o utc o m e effects of d o na ne ma b f or u p t o [ADDRESS_391743] u d y  (rat her t ha n d o na ne ma b), a n d n o w ha ve o p p ort u nity f or access t o d o na ne ma b 
treat me nt. As a n o pe n -lab el  st u d y, t here will be n o place b o gr o u p. T he p ote ntia l d urat i on of dr u g 
e x p os ure of [ADDRESS_391744] i on 
of A E re p orti n g (incl u di n g i nf usi o n- r elate d reactio ns) , la b orat or y assess me nts, M RI assess me nts, 
vit al si g ns a n d weig h t, E C G, p h ysical e xa mi nati ons, ne ur ol o gical e xa mi nat i ons, a n d assess me nts 
of  s uici dal i deati on a n d be ha vi or t o facilitate a c o m pre he nsi ve safet y e val uat i on.
I mm u n o ge nicit y testi n g will be perf or m e d. I n a d diti o n t o cli nical o utc o mes, i ma gi n g bi omar kers 
(fl or beta pir a n d v o l umetric M RI ) will als o be meas ure d . Fl or beta pi r F [ADDRESS_391745] of 
d o na ne ma b o n brai n a m yl o i d de p ositi on, brai n ta u de p ositi o n, a n d cli nical pr o gressi o n of A D i n 
parti ci pa nts o ver t he int er val peri o d w he n t he y no l o n ger recei ve d o na ne ma b.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
3 54. 3. J u stific ati o n f or D ose
T he d o na ne ma b tar get d ose of  1 4 0 0 mg a d mi nistere d I V o nce Q 4 W was selecte d base d o n 
c urre nt precli nical p har mac ol o g y a n d t o xic olo g y  data a n d cli nical P K, P D, a n d safety data . Pri or 
a n d o n g o i n g e x p os ures i ncl u de 0. 1 m g/ k g, 0. 3 m g/ k g, 1 m g/ k g, 3 m g/ k g, 1 0 m g/ k g, 2 0 m g/ k g, 
a n d 4 0 m g/ k g i n si n gle - a n d/ or mul ti- d ose d osi n g sc he d ules. Data fr o m St u d ies A A C C a n d 
A A C D s u g geste d t hat P K of d o na ne ma b was li near w he n t he d ose was ≥ 1 0 m g/ k g . Mea n half -
life was a b o ut 8 t o 1 0 da ys w he n t he d ose was ≥ 1 0 m g/ k g, s o mi ni mal acc u m ulat i on i n plas ma 
P K was pre dicte d f or 1 4 0 0 m g Q 4 W I V d osi n g . Hi g h le vels of fl or beta pir F 1 8 P E T si g nal  
re d uctio ns were see n wit h a si n gle d ose of 2 0 m g/ k g, a n d were c o m para ble t o fl or bet a pir F 1 8
P E T re d ucti o ns see n wit h a 1 0 m g/ k g Q 2 wee k d osi n g sc he d ule at 3 m o nt hs (see Sect i on 2 a n d 
t he I B f or details). 
Base d o n t his as well as decrease d patie nt b ur de n wit h a Q 4 W d osi n g sc he d ule c o m pare d wit h a 
Q 2 W d osi n g sc he d ule a n d c o m para ble safet y (see Secti o n 2 ), [ADDRESS_391746] i ncl u di n g A RI A- E; A RI A- H 
a n d h y perse nsit i vity react i ons ; a n d t he o verall fre q ue nc y, se verit y,  a n d serio us ness of A Es at t hi s 
d ose l e vel. 
Pr ot oc ol  a me n d me nt (a) inc or p orates a titrati o n sc he d ule of [ADDRESS_391747] u d y if he/s he has c o m p lete d all re q uire d 
p hases of t he p arts (as descri be d i n Secti o n 4. 1 ) of  t he st u d y t he partici pa nt e nr olle d i n, i ncl u di n g 
t he last visit or t he last sc he d ule d pr oce d ure s h o w n i n t he S o A.
T he e n d o f t he st u d y is defi ne d as t he date of last sc he d ule d assess me nt s h o w n i n t he S o A f or t he
last partici pa nt i n t he trial.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391748] u d y P o p ul ati o n
Pr os pecti ve a p pr o val o f pr ot oc ol  de viatio ns t o recr ui t me nt a n d e nr o ll me nt criteria, als o k n o w n as 
pr ot oc ol  wai vers or e xe m pti ons, is n ot per mitte d.
5. 1. I ncl usi o n Criteri a
P art A:
1. Ha ve part ici pate d i n a d o u ble-bli n d treat me nt peri o d of  a s p o ns or-a p pr o ve d ori gi nati n g
d o na ne ma b trial .
2. Ha ve a st u d y  part ner w h o will pr o vi de writte n i nf or me d c o nse nt t o partici pate, is i n 
fre q ue nt c o ntact wit h t he partici pa nt ( defi ne d as at least 1 0 h o urs per wee k), a n d will 
acc o m pa n y t he partici pa nt t o st u d y visits or be a vailable b y  vi de o/tele p h o ne at desig nate d 
ti mes. 
A sec o n d st u d y  part ner ma y ser ve as bac k u p.
3. T he st u d y  part ner(s) is/are re q uire d t o acc o mpa n y  t he parti ci pa nt f or sig ni n g c o nse nt . 
O ne st u d y  part ner is re q ueste d t o be prese nt o n all da ys t he C-S S R S/ Self -H ar m  
S u p pl e me nt F or m is a d mi nistere d a n d m ust be prese nt o n all da ys t he c o g nit i ve a n d 
f u ncti onal scales are a d mi nistere d. If a parti ci pa nt has a sec o n d st u d y  part ner, it is 
preferre d t hat [ADDRESS_391749] u d y  
part ner a vaila ble b y tele p h o ne if n ot acc o m pa n yi n g partici pa nt at a visit for t he f oll o wi n g 
assess me nts: 
 A Es a n d c o nc o mit a nt me dicat i ons
 Rele va nt p orti o ns of t he C -S S R S/ Self -H ar m  S u p pl e m e nt F or ms
If a st u d y part ner must wi t hdra w fr o m  st u d y p artici pat i on, a re place me nt ma y be all o we d 
at t he i n vesti gat or’s discret i on . T he re pl ace me nt will nee d t o si g n a se parate i nf or me d 
c o nse nt o n t he first visit t hat he or s he acc o m pa nies t he parti ci pa nt . 
4. Ha ve a de q uate literac y, visi o n, a n d heari n g f or ne ur o ps y c h o l ogi cal testi n g i n t he o pi [INVESTIGATOR_318305]  t he i n vesti gat or at  t he ti me of scree ni n g.
5. Are relia ble a n d willi n g t o ma ke t he msel ves a vaila ble f or t he d urati o n of t he st u d y  a n d 
are willi n g t o f o ll ow s t u d y pr oce d ures.
6. Sta bl e s y m pt o mat ic A D me dicat i ons a n d ot her me dicat i on t hat m a y i m pact c o g nit i on f or 
at least 3 0 da ys pri or t o ra n d o mizat i on i nto Part A ( d oes n ot a p pl y t o as nee de d or 
di sc o nti n ue d me dicati ons).
7. Ca pa ble of gi vi n g si g ne d i nf or me d c o nse nt a s descri be d i n Secti on [ADDRESS_391750] i ons liste d i n t he I C F a n d i n t his pr ot oc ol.
P art B:
If t he parti ci pa nt’s treat me nt assig n me nt is k n o w n at t he ti me of scree ni n g, o nl y e val uate Part B 
i ncl usi on crit eria if t he partici pa nt recei ve d place b o i n t he ori gi nat i n g st u d y. 
8. Males a n d fe males of  n o nc hil d beari n g p ote ntial will  be eli gi ble f or Part B .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391751] u dies.
Male parti ci pa nts:
i. Me n, re gar dless of t heir fertilit y stat us, wit h n o n-pre g na nt W O C B P part ners
m ust a gree t o eit her re mai n a bst i ne nt (if t his is t heir preferre d a n d us ual 
lifestyle) or use c o n d o ms as well as 1 a d dit i onal hi g hl y  effecti ve (less t ha n 
1 % fail ure rate) met h o d of c o ntrace pti o n (s uc h as c o m bi nati on oral  
c o ntrace pti ves, i m pla nte d c o ntrace pt i ves, or i ntra uteri ne de vices) or effecti ve 
met h o d of c o ntrace pti o n (s uc h as dia p hra g ms wit h s per mici de or cer vical 
s p o n ges) f or t he d urati o n of st u d y Part B a n d u ntil t heir plas ma c o nce ntrati o ns 
are bel o w t he le vel t hat c o ul d res ult i n a rele va nt p ote nt ial e x p os ure t o a 
p ossi ble fet us, pre dicte d t o be [ADDRESS_391752] i ne nce (e. g., cale n dar, o v ulati on, s y m pt ot her mal, 
p ost -o v ul at i on met h o ds), decl aratio n of  a bsti ne nce j ust f or t he d urati o n 
of  a trial, a n d wit hdra wal  are n ot acce pta ble met h o ds of c o ntrace pti o n.
ii. Me n wi t h pre g na nt part ners s h o ul d use c o n d o ms d uri n g i nterc o urse f or t he 
d urati o n of  t he st u d y a n d u ntil t he e n d of esti mate d rele va nt p ote ntial e x p os ure 
i n W O C B P ( 9 0 da y s).
iii. Me n s h o ul d refrai n fr o m s per m d o nati on f or t he d uratio n of  t he st u d y a n d 
u nt il t heir plas ma c o nce ntratio ns are bel o w t he le vel t hat c o ul d res ult i n a 
r ele va nt p ote ntial e x p os ure t o a p ossi ble fet us, pre dicte d t o be [ADDRESS_391753] d ose of I P.
i v. Me n w h o are i n e xcl usi vel y sa me se x relat i ons hi ps (as t heir preferre d a n d 
us ual lifest yle) are n ot re q uire d t o use c o ntrace pti o n.
Fe male partici pa nts:
i. W o me n n ot of c hil d beari n g p ote ntial ma y partici pate a n d i ncl u de t h ose w h o 
are:
A. i nfertile d ue t o s ur gical sterilizati on ( h ysterect o m y, bilateral 
o o p h orect o m y , or t u bal li gati on), c o n ge nital a n o mal y s uc h a s 
M ulleria n a ge nesis; or
B. p ost m e n o pa usal – defi ne d as eit her
a. A w o ma n at l east [ADDRESS_391754] 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
3 81 year wit h o ut a n alter nat i ve me d ical ca use, A N D a 
f ollicle-sti m ulati n g h or m o ne > 4 0 mI U/ m L; or
b. A w o ma n [ADDRESS_391755] 1 2 mo nt hs of s p o nta ne o us a me n orr hea; or
c. A w o ma n at l east [ADDRESS_391756] me nt t hera p y.
5. 2. E xcl usi o n Criteri a
P art A:
9. C urre nt seri o us or u nsta ble ill nesses i ncl u di n g car di o vasc ular, he pat ic, re nal, 
gastr oe nter ol o gic, res pi[INVESTIGATOR_1305] y , e n d ocri n ol ogi c, n e ur olo gic ( ot her t ha n A D), ps y c hi atric, 
i m m u n ol ogic, or he mat ol o gic disease a n d ot her c o n dit i ons t hat, i n t he i n vest i gat or’s 
o pi [INVESTIGATOR_9384] o n, c o ul d i nterfere wi t h o ut c o m e assess me nts or t he a nal yses i n t his st u d y.
[ADDRESS_391757] u d y  a n d/ or t heir i m me diate 
fa milies. I mme diate fa mil y is defi ne d as a s p o use, pare nt, c hil d, or si bli n g, w het her 
bi o l ogical  or le gall y a d o pte d.
[ADDRESS_391758] o yees.
P art B:
If t he partici pa nt’s treat me nt assi g n me nt is k n o w n at t he ti me of scree ni n g, o nl y e val uate Part B 
e xcl usi o n criteria if t he partici pa nt recei ve d place b o i n t he ori gi nati n g st u d y. 
1 2. Life e x pecta nc y  < 2 4 mo n t hs per t he i n vesti gat or’s j u d g me nt.
[ADDRESS_391759] i gat or, acti vel y s uici dal, a n d t heref ore , dee me d t o be at 
sig nifica nt ris k f or s ui ci de.
1 5. P o or ve n o us access.
1 6. Ha ve a n y c o ntrai n dicati o ns f or M RI, i ncl u di n g cla ustr o p h o bia or t he prese nce of 
c o ntrai n dicate d metal (ferr o ma g net ic) i m pla nts/car diac pace ma ker.
[ADDRESS_391760] u d y. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391761] t he partici pa nt ’s a bility t o s afel y 
parti ci pate i n t he st u d y.
[ADDRESS_391762] 3 0 da ys ( [ADDRESS_391763] u dies c o n d ucte d i n Ja pa n; 
[ADDRESS_391764] u dies c o n d ucte d i n t he U nite d Ki n g d o m), i n a cli nica l trial in v o l vi n g a n 
I P. If t he pre vi o us I P is scie ntificall y or me dicall y i nc om pat i ble wit h t his st u d y a n d has a 
l on g half -life, 3 m o nt hs or 5 half-li ves ( w hic he ver is l on ger) s h o ul d ha ve passe d pri or t o 
scree ni n g ( partici pati o n i n o bser vati o nal st u dies ma y be per mitte d u p o n re vie w of t he 
o bser vat i onal st u d y  pr ot oc ol a n d a p pr o val b y t he s p o ns or).
P art C
If t he partici pa nt’s treat me nt assi g n me nt is k n o w n at t he ti me of scree ni n g, o nl y e val uate Part C 
e xcl usi o n if t he partici pa nt recei ve d d o na ne ma b i n t he ori gi nati n g st u d y a n d pla ns t o partici pate 
i n Part C. 
2 4. F or parti ci pat i on i n P E T assess me nt: P rese nt or pla n ne d e x p os ure t o i o nizi n g ra diati on 
t hat, i n c o m bi nat i on wi t h t he pla n ne d a d mi nistrati o n of st u d y P E T li ga n ds, w o ul d res ult 
i n a c u mulat i ve e x p os ure t hat e xcee ds l ocal rec o m me n de d e x p os ure li mit s, or ot her 
c o ntrai n dicat i on t o P E T i ma gi n g.
a. F or parti ci pat i on i n fl or bet a pir P E T i ma gi n g: Ha ve se nsit i vity t o fl or beta pir F 1 8.
b. F or parti ci pat i on i n fl ort a u cipi r P E T i ma gi n g: Ha ve se nsit i vity t o fl orta uci pir 
F [ADDRESS_391765] u d y e n ds. 
E xcessi ve alc o h o l c o ns u m pti o n is defi ne d f or me n as c o ns u mi n g a n a vera ge of m ore t ha n 
3 dri n ks per da y, or m ore t ha n 2 1 dri n ks per wee k. F or w o me n, e xcessi ve use of alc o h o l is 
defi ne d as c o ns u mi n g a n a vera ge of m ore t ha n 2 dri n ks per da y , or more t ha n 1 4 dri n ks per 
wee k.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391766] be c o ntacte d f or 
ot her e xce pt i onal reas o ns f or rescree ni n g.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391767] u d y  i nter ve nt i on is defi ne d as a ny i n vesti gati onal i nter ve nt i on (s), mar kete d pr o d uct(s), 
pl ace b o , or m e dical de vice(s) i nte n de d t o be a d mi nistere d t o / use d b y a st u d y p artici pa nt 
acc or di n g t o t he st u d y pr ot oc ol . F or t hi s st u d y, I P is use d i nterc ha n gea bl y with st u d y  
i nter ve nt i on.
6. 1. St u d y I nter v e nti o n(s) A d mi nistere d
T he I P use d i n t his st u d y  is:
 D o na ne ma b
I P is a d mi nistere d o nl y d uri n g t he o pe n-lab el  d o na ne ma b p eri o d ( Part B). Parti ci pa nts d o n ot 
recei ve I P d uri n g P art A or Part C . 
T he f o ll owi n g cli nical a n d i ma gi n g assess me nts are t o be perf or m e d prior t o a d mi nistrati o n of I P 
at Part B Visit 1:
 V isit 1 p h ysical a n d ne ur o l ogi cal e xa mi natio n, vi t al si g ns, a n d E C G
 If > [ADDRESS_391768] u d y a n d Visit 1, cli nical la b orat or y  assess me nt ( See S o A ; Secti o n 1. 3 )
 If > [ADDRESS_391769] u d y 
a n d V isit 1, M RI assess me nt ( See S o A ; Secti on 1. 3 )
See Secti o n [ADDRESS_391770] n ot be a d mi nistere d at a d osi n g i nter val o f < [ADDRESS_391771] u d y  
me dicat i on c o ul d t he oreti call y be a d mi nistere d at a 2 -wee k i nter val . H o we ver, a d mi nistrati o n of 
2 d oses wit hi n < [ADDRESS_391772] ha ve res uscitat i on e q ui p me nt a vaila ble. 
P ac k a gi n g a n d L a beli n g
Cli nical trial materials will be la bele d acc or di n g t o t he c o u ntr y ’s re g ulat or y r e q uire me nts. All I Ps 
will be st ore d, i n ve nt orie d, rec o ncile d, a n d destr o ye d acc or di n g t o a p plica ble re g ulat i ons . 
Cli nical trial materials are ma n ufact ure d i n acc or da nce wit h c urre nt G o o d Ma n ufact uri n g 
Practi ces.
I P will be s u p plie d i n a vial. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 26. 2. Pre p ar ati o n/ H a n dli n g/ St or a ge/ Acc o u nt a bilit y
1. T he i n vest i gat or or desi g nee m ust c o nfir m a p pr o priate te m perat ure c on dit i ons ha ve bee n 
mai ntai ne d d uri n g tra nsit f or all I P recei ve d a n d a n y discre pa ncies are re p orte d a n d 
res ol ve d bef ore use of t he I P.
2. O nl y partici pa nts e nr o lle d i n Part B of t he st u d y ma y recei ve I P a n d o nl y a ut h orize d sit e 
staff ma y s u p pl y or a d mi nister I P. All I P m ust be st ore d i n a sec ure, e n vir o n me ntall y 
c o ntr olle d, a n d m o nit ore d ( ma n ual or a ut o mate d) area i n acc or da nce wit h t he la bele d 
st ora ge c o n diti ons wit h access li mite d t o t he i n vesti gat or a n d a ut h orize d site staff.
3. T he i n vest i gat or, i nstit uti o n, or t he hea d of t he me dical i nst ituti o n ( w here a p plica ble) is 
res p o nsi ble f or I P acc o u nta bility, rec o nciliat i on, a n d rec or d mai nte na nce (i.e., recei pt, 
rec o nciliati on, a n d fi nal dis p osit i on rec or ds).
4. F urt her g ui da nce a n d i nf or mati o n f or t he fi nal dis p osit i on of u n use d I Ps are pr o vi de d b y 
t he s p o ns or.
6. 3. Me as ures t o Mi ni mize Bi as: R a n d o miz ati o n a n d Bli n di n g
P art A
F or t he vi de o assess me nt peri o d, partici pa nts will be ra n d o mize d 1: 1 t o eit her
 Gr o u p 1 : C o g nitive/f u ncti o nal scale assess me nt perf or me d o n -sit e, f oll owe d b y  
at -h o me ( V T C ) assess me nt, or
 Gr o u p 2 : C o g niti ve/f u ncti o nal scale assess me nt at h ome ( V T C ), foll o we d b y 
o n -sit e assess me nt . 
T o mi ni mize bias, partici pa nts f o ll ow a cr oss o ver desi g n, alter nati n g bet wee n assess me nt 
l ocat i on s, st artin g wit h t heir ra n d omize d i nit ial l oc atio n . 
P art B
Part B i s a n o pe n-label d o na ne ma b p hase . 
P art C
P arti cipa nts d o n ot recei ve I P i n Part C . Ra n d o mizati o n a n d bli n di n g are n ot a p plica ble.
6. 4. St u d y I nter ve nti o n C o m pli a nce
W he n partici pa nts are d ose d at t he site, t he y  will recei ve I P direct l y fr o m t he i n vesti gat or or 
desi g nee, u n der me dical s u per visi o n . T he date , ti me, a n d v ol ume of  eac h d ose a d mi nistere d i n 
t he cli nic will be rec or de d i n t he s o urce d oc u me nts a n d rec or de d i n t he electr o nic C R F . 
A n y i nf usi o n at w hic h 7 5 % (a p pr o xi matel y 1 0 5 m L) or m ore of t he i nf usi o n s ol ut i on is gi ve n 
will be c o nsi dere d a c o m plete i nf usi o n.
If a p artici pa nt atte n ds a visit b ut d oes n ot recei ve a c o m plete i nf usi o n (e. g., d ue t o tec h nical 
c o mplicat i ons), e ver y eff ort s h o ul d be ma de t o c o m plete t he i nf usi o n wi t hi n 2 4 h o urs if p ossi ble. 
If less t ha n 7 5 % of t he i nf usi on s ol ut i on is gi ve n, t his m ust be rec or de d as a n i nc o m p lete i nf usi on 
o n t he C R F.
Misse d i nf usi o ns s h o ul d be rec or de d o n t he C R F.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 3If at a n y time it is disc o vere d t hat t he partici pa nt has n ot c o m plete d pr o per d osi n g d uri n g t he 
titr atio n p hase, t he s p o ns or s h o ul d be c o ntacte d pri or t o t he s u bs e q ue nt i nf usi o ns t o disc uss t he 
p ossi bilit y of c o m p leti n g a pr o per titrati o n p hase, if nee de d.
6. 5. C o nc o mit a nt T her a p y
A n y me dicat i on or vacci ne (i ncl u di n g o ver -t he- c o u nter or prescri pt i on me dici nes, vita mi ns, 
a n d/ or her bal s u p ple me nts) t hat t he partici pa nt is recei vi n g at t he ti me of e nr oll me nt or recei ves 
d uri n g t he st u d y  must be rec or de d i n t he C R F, al o n g wit h a n y c ha n ges t o d ose. 
T he m e dical mo ni t or s h o uld be c o ntacte d if t here are a n y  q uestio ns re gar di n g c o nc o mita nt or 
pri or t hera p y .
P arti cipa nt s a n d t heir st u d y part ners will be i nstr ucte d t o c o ns ult t he i n vesti gat or or ot her 
a p pr o priate st u d y pers o n nel at t he site bef ore i niti atio n of  a n y ne w me dicat i ons or s u p ple me nts 
a n d bef ore c ha n gi n g d ose of a n y c urre nt c o nc o mit a nt me dicat i ons or s u p ple me nts.
6. 5. 1. St a n d ar d of C are f or Alz hei mer’s Dise ase
T o e ns ure sta n dar d of care f or A D, use of a p pr o ve d s y m pt o mat ic treat me nts f or A D is per mitte d 
i n t his st u d y. T he sect i on bel o w pr o vi des a d dit i onal g ui da nce o n ma na gi n g c o nc o mit a nt 
me dicat i on use.
Use of a p pr o ve d or sta n dar d of  care s y m pt o mat ic treat me nts f or A D is per mitte d d uri n g t he 
st u d y, pr o vide d t hat t he d ose has bee n u nc ha n ge d f or [ADDRESS_391773] i on or as p re me dicati o n f or i nf usi ons s h o ul d be d oc u me nte d.
6. 5. 3. E xcl u de d Me dic ati o ns
I mm u n o gl o b uli n G t hera p y  (als o k n o w n as ga m ma gl o b uli n or I V i m m u n o gl o b uli n [I VI G]) is 
n ot all o we d d uri n g t he st u d y . Ot her disease -m o dif yi n g t hera pe utic a ge nts ma y als o be e xcl u de d 
me dic at i ons (see Secti o n 7. 2 f or a d ditio nal details).
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 46. 6. D ose M o dific ati o n
T he d osi n g g oal  is for t he parti ci pa nt t o be titrate d t o t he tar get d ose of  1 4 0 0 mg . 
F or partici pa nts w h o de vel o p A RI A d uri n g t he titrati o n peri o d ( t hat is, bef ore t he f ourt h i nf usi o n 
of  st u d y dr u g), t he i n vest i gat or ma y deci de t o 
 te m p oraril y s us pe n d d osi n g as descri be d i n Sect i on 7. 1. 1. [ADDRESS_391774] 3 d oses 
or t hr o u g h o ut t he re mai n der of t he treat me nt peri o d ,
 c o nti n ue t he [ADDRESS_391775] 3 d oses or 
t hr o u g h o ut t he re mai n der of t he treat me nt peri o d, or
 c o nti n ue t he d osi n g sc he d ule as o utli ne d i n Sect i on 4. [ADDRESS_391776] u d y
N ot a p plica ble . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391777] u d y I nter ve nti o n a n d P artici p a nt 
Disc o nti n u ati o n/ Wit h dr a w al
7. 1. Disc o nti n u ati o n of St u d y I nter ve nti o n
I P ma y be disc o nt i n u e d for a parti ci pa nt f or t he f oll o wi n g reas o ns ( details gi ve n bel o w) : 
 B y  re q uest of t he partici pa nt or partici pa nt’s desi g nee (f or e xa m ple, le gal g uar dia n) 
 Cli nical j u d g me nt 
 A he pat ic e ve nt or li ver test a b n or mality
 C- S S R S res ults
 A RI A
 S y ste mic h y perse nsiti vity react i on
 Se vere n o nc o m p lia nce 
 T he parti ci pa nt re q uires a n e xcl u de d t hera pe utic a ge nt
 Pl ace me nt of de vice i nc o m pat i ble wit h M RI
I n rare i nsta nces, it ma y be necessar y for a parti ci pa nt t o per ma ne nt l y disc o nti n ue ( defi niti ve 
di sc ont i n uati on) I P . If I P is defi niti vel y disc o nti n ue d, t he partici pa nt will re mai n i n t he st u d y 
(f oll owi n g t he S o A, e xce pt as n ote d bel o w) t o be e val uate d f or safety a n d efficac y. 
If I P i nf usi on is per ma ne ntl y disc o nti n ue d a n d t he parti ci pa nt re mai ns i n t he st u d y, [ADDRESS_391778] sc he d ule d visit re gar dless if P K c o llecti on is o n t he S o A at t hat 
visit . D osi n g dates a n d ti mes s h o ul d be c ollecte d . S u bse q ue nt P K sa m ple c o llecti on s h o ul d 
f oll ow t he pr ot oc ol S o A u nless t he sc he d ule d visit e xcee ds 6 m o nt hs si nce disc o nti n uati o n o f 
i nf usi ons . N o a d di tio nal  P K  c o llecti on is re q uire d o nce t he partici pa nt e xcee ds 6 m o nt hs si nce 
di sc o nti n uati on of d o na ne ma b i nf usi o ns.
Cli nical J u d g me nt
A E or cli nicall y si g nifica nt la b orat or y  val ue, E C G res ult, p h ysical e xa mi nati on fi n di n g, M RI 
fi n di n g (s uc h as s y m pt o matic isc he mic str o ke), C-S S R S res ult, or vital si g n meas ure me nt of s uc h 
se verity t hat, i n t he o pi [INVESTIGATOR_9384] o n o f t he i n vest i gat or or Lill y-desi g nate d me dical m o nit or, c o nti n ue d 
treat me nt is n ot i n t he best i nterest of t he parti ci pa nt .
He pati c E ve nt or Li ver Test A b n or malit y
P arti cipa nts w h o are di sc o nti n ue d fr om I P d ue t o a he patic e ve nt or li ver test a b n or mality s h o uld 
ha ve a d dit i onal he patic safet y  data c ollecte d via t he C R F .
Di sc o nti n uatio n of  t he I P f or a b n or mal li ver tests s h o ul d be c o nsi dere d b y t he i n vest i gat or w he n 
a partici pa nt meets 1 of t he f o ll owi n g c o n di tio ns after c o ns ultat i on wi t h t he s p o ns or-desi g nate d 
me dical m o nit or : 
 A L T or A S T > 8 X U L N
 A L T or A S T > 5 X U L N f or m ore t ha n 2 wee ks
 A L T or A S T > 3 X U L N a n d T B L > 2 X U L N or I N R > 1. 5
 A L T or A S T > 3 X U L N wit h t he a p peara nce of fat i g ue, na usea, v omit i n g, ri g ht 
u p per -q ua dra nt pai n or te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia ( > 5 %)
 A L P > 3 X U L N
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 6 A L P > 2. 5 X U L N a n d T B L > 2 X U L N
 A L P > 2. 5 X U L N wit h t he a p peara nce of fati g ue, na usea, v o mit i n g, ri g ht q ua dra nt pai n or 
te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia ( > 5 %)
C- S S R S 
I n a d diti on, I P m a y be disc o nti n ue d if partici pa nts:
 A ns wer “ yes” t o Q uesti o n 4 or Q uesti o n 5 o n t he “ S uici dal I deat i on” p orti o n of t he 
C- S S R S, or
 A ns wer “ yes” t o a n y  of t he s uici de-r elate d be ha vi o rs o n t he S uici dal Be ha vi or p orti o n of 
t he C-S S R S.
A ps yc hiatrist or a p pr o priatel y trai ne d pr ofessi o nal ma y  assist i n t he decisi o n t o disc o nt i n ue t he 
parti ci pa nt . 
E C G
If a cli nicall y si g nifica nt fi n di n g is i de ntifie d (i ncl u di n g, b ut n ot li mite d t o, c ha n ges fr o m 
baseli ne i n Q T i nter val c orrecte d usi n g Q Tc F) after e nr oll me nt, t he i n vesti gat or or q ualifie d 
desi g nee will deter mi ne if t he parti ci pa nt ca n c o nti n ue i n t he st u d y a n d if a n y c ha n ge i n 
parti ci pa nt ma na ge me nt is nee de d. T hi s re vie w of t he E C G pri nte d at t he ti me of c ollect i on m u st 
be d oc u m e nte d. A n y ne w cli nicall y rele va nt fi n di n g s h o ul d be re p orte d as a n A E.
A RI A
Treat me nt wit h I P ma y be per ma ne ntl y disc o nt i n ue d i n parti ci pa nt s wit h T E A RI A -E a n d/ or 
A RI A- H at t he discret i on of t he PI [INVESTIGATOR_318306] n di n g o n se verit y of  cli nical a n d ra diol o gi c fi n di n gs (see 
Ma n ual o f O perati o ns f or p er m a ne nt disc o nt i n uati o n g ui da nce). F or te m p orar y  disc o nti n uat i on 
f or A RI A-relate d reas o ns, see Secti o n 7. 1. 1. [ADDRESS_391779] i gat or, ma y be reas o n f or disc o nt i n ui n g I P.
E xcl u de d T hera pe ut ic A ge nt
T he parti ci pa nt , for a n y  reas o n, re q uires a treat me nt wit h a n e xcl u de d t hera pe utic a ge nt
( Sectio n 6. 5. 3 ) a n d te m p orar y disc o nt i n uati on cri t eria ca n n ot be met (see Secti o n 7. 1. 1. 2 ).
Pl ace me nt of De vice I nc om pat i ble wit h M RI
P arti cipa nts w h o re q ui r e a ferr o ma g net ic i m pla nt or i nserti o n of a car diac pace ma ker t hat is n ot 
M RI -c o mpat i ble will be per ma ne ntl y disc o nti n ue d fr om I P a n d s h o ul d ha ve n o M RIs. If t he 
parti ci pa nt disc o nt i n ues fr om t he st ud y, wit h t he e xce pt i on of a n M RI, t he partici pa nt s h o ul d 
ha ve e n d -of -t hera p y a nd/ or e n d -of -st u d y pr oce d ures perf or me d as s h o w n i n t he S o A.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 77. 1. 1. Te m p or ar y Disc o nti n u ati o n
7. 1. 1. 1. D ue t o A RI A
T he de vel o p me nt of A RI A -E a n d/ or A RI A -H ( micr o he m orr ha ges a n d/ or c ortical s u per ficial 
sid er osi s) are e x pecte d e ve nts f or s o me partici pa nt s d ue t o t he treat me nt wit h d o na ne ma b. T he 
sit e PI [INVESTIGATOR_21039] y t e mp oraril y  disc o nti n ue I P if t he parti ci pa nt de vel o ps T E A RI A -H or A RI A -E t o a n 
e xte nt dee me d cli nicall y sig nifica nt b y  t he sit e PI (see Ma n ual of O perati ons f or t e mp or ar y
di sc o nti n uati on g ui da nce) . Rei nitiati n g I P ca n be c o nsi dere d after res ol uti on of A RI A -E a n d 
sta bilizati o n of A RI A- H i ma gi n g fi n di n gs a n d t he res ol ut i on of a n y  ass ociate d s y m pt o ms. B ot h 
di sc o nti n uati on a n d re -i nitiatio n decisi o n s ma y be di sc usse d wit h t he s p o ns or. D o se m o dificati o n 
c o nsi derati o ns are descri be d i n Secti on 6. 6 .
I n t he e ve nt of a fi n di n g of A RI A-E o n M RI, t he i n vesti gat or is t o c o m plete t he C R F re gar di n g 
t he prese nce or a bse nce of s y m pt o ms relate d t o t he A RI A -E.
I n cases of ne w A RI A- E or A RI A -H, gi ve n t he c o nte xt of t he se verit y of  t he i ma gi n g fi n di n gs 
a n d s y m pt o ms, t he site PI, at his/ her cli nical discr etio n, ca n elect t o rec o m me n d disc o nt i n ui n g I P 
a n d t he n f o ll ow t he parti ci pa nt wit h serial M RIs e ver y  4 t o 6 wee ks (fl ui d atte n uatio n i n versi o n 
rec o ver y [F L AI R ] a n d T 2 * gra die nt -recall ec h o) a n d m o nit or s y m pt o ms, t o mo ni t or sta bilizati o n 
or res ol ut i on . U p o n res ol ut i on of A RI A -E a n d sta bilizati on of  ARI A -H a n d t he res ol ut i on of  a n y 
ass ociate d s y m pt o ms, t he parti ci pa nt ca n be c o nsi dere d f or re -i nitiati n g I P. T here is n o defi ne d 
ti me d urati o n f or t his m onit ori n g peri o d w hile off I P a n d will be base d o n cli n ical j u d g me nt. See 
t he Ma n ual of O perat i ons f or t e mp orar y  a n d per ma ne nt disc o nt i n uati on g ui da nce.
7. 1. 1. 2. D ue t o Re as o ns Ot her t h a n A RI A
T e m p orar y  disc o nti n uati on fr om I P treat me nt is all o we d if a s h ort-t er m treat me nt wit h a n 
e xcl u de d me dicat i on is necessar y, sec on dar y  t o h os pi[INVESTIGATOR_5186] n, pers o nal  circ u msta nces or t o 
e val uate t he I P i m pact o n a n u ncertai n A E. 
I P ma y be restarte d at t he ne xt sc he d ule d visit, at t he i n vest i gat or’s discreti o n. 
If te mp orar y  disc o nti n uati on is d ue t o a n A E, it s h o ul d be re p orte d t o t he Lill y m e dical m o ni t or. 
T e m p orar y  treat me nt disc o nti n uati on a n d restarti n g s h o ul d be d oc u me nte d . Restarti n g treat me nt 
after a disc o nti n uati on peri o d t hat is greater t ha n 1 2 wee ks s h o ul d be disc usse d bet wee n t he 
i n vesti gat or a n d Lill y m e dical m o ni t or.
7. 2. P art ici p a nt Disc o nti n u ati o n/Wit h dr a w al fr o m t he St u d y
A partici pa nt ma y wit h dra w fr o m t he st u d y: 
 at a n y ti me at his/ her o w n re q uest 
 at t he re q uest of his/ her desi g nee (f or e xa m ple, pare nts or le gal g uar dia n)
 at t he discreti o n of t he i n vest i gat or f or safety,  be ha vi or al , c o mplia nce, or a d mi nistrati ve 
reas o ns
 if t he partici pa nt bec ome s pre g na nt d uri n g t he st u d y 
 if t he partici pa nt e nr olls i n a n y ot her cli nical st u d y i n v ol vi n g a n i n vesti gati onal 
me dici nal pr o d uct or e nr oll me nt i n a n y  ot her t yp e of  me dical researc h j u d ge d n ot t o be 
scie ntificall y or me dicall y c om pati ble wit h t his st u d y
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
4 8 if t he partici pa nt, f or a n y reas o n, re q uires treat me nt wit h a n ot her disease-m o dif yi n g 
t hera pe utic a ge nt t hat has bee n de m o nstrate d t o be effect i ve f or treat me nt of t he st u d y 
in dicat i on, di sc o nti n uati on fr om t he st u d y occ urs prior t o i ntr o d ucti o n of  t he ne w a ge nt
 parti ci pat i on i n t he st u d y nee ds t o be st o p pe d f or me dical, safety,  re g ulat or y, or ot her 
reas o ns c o nsiste nt wit h a p plica ble la ws, re g ulati o ns, a n d G C P
o i ncl u des fi n di n gs of  e xcl us or y M RI, he mat olo g y , or cli nical c he mistr y at a n 
u nsc he d ule d p r oce d ure pri or t o t he partici pa nt starti n g Part B. 
N O T E: If a cli nicall y i m p orta nt a b n or mality, as deter mi ne d b y t he i n vest i gat or, i n 
p h ysical or ne ur ol o gical e xa mi nat i on, vital si g n, E C G, or cli nical la b orat or y  test res ults 
c o uld be detri me ntal  t o t he partici pa nt or c o ul d c o m pr o mise t he st u d y , t he n t he 
parti ci pa nt s h o uld n ot recei ve I P i n Part B.
P arti cipa nts m ust n ot e nter Part B if t he fi nal ce ntrall y  rea d M RI fr o m t he origi nat i n g 
st u d y or u nsc he d ule d M RI perf or me d i n St u d y  A A C H pri or t o Part B de m o nstrat e
prese nce of A RI A -E, > [ADDRESS_391780] t he partici pa nt ’s a bility t o s afel y p artici pate i n t he 
st u d y.
At  t he ti me of disc o nti n ui n g fr o m t he st u d y, if p ossi ble, a n earl y disc o nti n uati on visit s h o ul d be 
c o n d ucte d if partici pa nt c o m plete d Visit 1 a n d recei ve d I P ( Part B o nl y), as s h o w n i n t he S o A. 
See S o A f or data t o be c ollecte d at t he ti me of st u d y  disc o nti n uati on a n d f o ll ow- u p a n d f or a n y  
f urt her e val uati ons t hat nee d t o be c o m plete d . T h e partici pa nt will be per ma ne nt l y disc o nti n ue d 
b ot h fr o m t he I P a n d fr o m t he st u d y at t hat ti me.
If t he partici pa nt wit h dra ws c o nse nt f or discl os ure of f ut ure i nf or mati on, t he s p o ns or ma y  retai n 
a n d c o nt i n ue t o use a n y data c ollecte d bef ore s uc h a wit h dra wal of c o nse nt. If a partici pa nt 
wi t hdra ws fr o m t he st u d y, he/s he ma y re q uest destr uctio n of  a n y sa mples ta ke n a n d n ot teste d, 
a n d t he i n vest i gat or m ust d oc u me nt t his i n t he site st u d y rec or ds.
7. 2. 1. Disc o nti n u ati o n of I n a d verte ntl y E nr olle d P artici p a nts
If t he sp o ns or or i n vest i gat or i de ntif y a partici pa nt w h o di d n ot meet e nr oll me nt criteria a n d was 
i na d verte ntl y e nr olle d, disc ussi on s h o ul d occ ur bet wee n t he s p o ns or a n d i n vest i gat or. If t he 
i n vesti gat or a n d t he Lill y m e dical mo ni t or a gree it is me dicall y a p pr o pr iate t o c o nti n ue, t he 
i n vesti gat or m ust o btai n d oc u me nte d a p pr o val fr o m t he Lill y m e dical m o ni t or t o all o w t he 
i na d verte ntl y e nr olle d partici pa nt t o c o nti n ue i n t he st u d y wit h or wit h o ut treat me nt wit h I P. 
S af et y f oll ow- u p i s as o utli ne d i n Secti on 1. 3 ( S o A), Secti o n 8. 2 ( Safet y Assess me nts), a n d 
Secti o n 8. 3 ( A Es a n d S A Es) of t he pr ot oc ol.
7. 3. L ost t o F oll o w - U p
A partici pa nt will be c o nsi dere d l ost t o f oll o w -u p if  he or s he re peate dl y fails t o ret ur n f or 
sc he d ule d visits a n d is u na ble t o be c o ntacte d b y t he st u d y sit e. Si te pers o n nel are e x pecte d t o 
ma ke dili ge nt atte m pts t o c o ntact partici pa nts w h o fail t o ret ur n f or a sc he d ule d visit or were 
ot her wi se u na ble t o be f oll owe d u p b y t he site.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391781] u d y as a w h ole are ha n dle d as part of re g ulat or y, 
et hical, a n d trial o versi g ht c o nsi derat i ons i n Secti on 1 0. 1. 8 .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391782] u d y: 
 A D A S -C o g 1 3
 A D C S -A D L
 M M S E
 C D R -S B
T hese meas ures are utilize d i n P arts A , B, a n d C . F o r differe nces i n a d mi nistrati o n of t he 
meas ures, see Secti o n 8. 1. 2 . 
8. 1. 1. 1. C D R -S B
T he C D R -S B ( H u g hes et al . 1 9 8 2; M orris 1 9 9 3) is a glo bal assess me nt t o ol t hat ca n be use d t o 
effect i vel y e val uate b ot h c o g niti o n a n d f u ncti on. T he t o ol  was i nitiall y d e v elo p e d t o m eas ure 
d e m e nt ia se verity a n d c o vers 6 cate g ories or “ b o xes”: Me m or y , Orie nt atio n, J u d g m e nt a n d 
Pr o ble m S o l vi n g, C om m u nit y Affairs, H o me a n d H o b bies, a n d Pers o nal Care . 
T he C D R gl o b al  rati n gs, calc ulate d usi n g a n al g orit h m, ra n ge fr o m 0 ( n o de me nt ia) t o 3 (se vere 
d e m e nt ia) w hile C D R-S B sc ores, calc ulate d b y a d di n g t he b o x sc ores, ra n ge fr o m 0 t o 1 8 ( wi t h 
hi g her sc ores i n dicat i ve of m ore i m pair me nt). Sc ori n g is deter mi ne d b y a cli nicia n t hr o u g h a 
se mistr uct ure d a n d i n-de pt h i nter vie w wit h b ot h t he affecte d i n di vi d ual a n d t heir st u d y part ner. 
T he st u d y  part ner a n d parti cipa nt m ust be i nter vie we d se paratel y.
T his scale de m o nstrates acce pta ble ps yc h o met ric c haracterist ics (C ol e y et al. 2 0 1 1; Ce dar ba u m 
et al. 2 0 1 3) a n d has bee n s h o w n t o be se nsiti ve e n o u g h t o detect disease pr o gressi o n, e ve n i n 
p o p ul at i ons wit h less a d va nce d cli nical disease (Willia ms et al. 2 0 1 3; Wessels et al. 2 0 1 5).
8. 1. 1. 2. M M S E
T he M M S E is a brief i nstr u me nt use d t o assess c o g nit i ve f u ncti on i n patient s ( F olstei n et al. 
1 9 7 5) . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
5 1T he i nstr u me nt meas ures orie ntati o n, me m or y , a n d atte ntio n ; t he a bilit y of t he parti ci pa nt t o 
na me o bjects ; f oll ow ver bal a n d writte n c o m ma n ds ; wri te a se nte nce; a n d c o p y fi g ures. T he 
ra n ge f or t he t otal M M S E sc ore is 0 t o 3 0, wit h l o wer sc ores i n dicati n g greater level o f 
i m pair me nt.
8. 1. 1. 3. A D A S -C o g 1 3
T he A D A S -C o g 1 3is a rater- a d mi nistere d i nstr u me nt t hat was desi g ne d t o assess t he se verit y of  
d y sf u ncti on i n t he c o g niti ve a n d n o nc o g niti ve be ha vi ors c haracteristic of pers o ns with A D 
( R ose n et al. 1 9 8 4). 
T he c o g nit i ve s u bscale of t he A D A S, t he A D A S-C o g [ADDRESS_391783] t ypi[INVESTIGATOR_1306] y  i m paire d i n A D: ori e nt atio n, ver bal me m or y , 
la n g ua ge, pra xis, dela ye d free recall, di git ca ncellati o n, a n d maze-c o m p leti o n meas ures ( M o hs et 
al. 1 9 9 7). T he A D A S -C o g 1 3scale ra n ges fr o m 0 t o 8 5, wit h hi g her sc ores i n dicati n g greater 
di sease se verit y.
8. 1. 1. 4. i A D R S
T he i A D R S ( Wessels et al. 2 0 1 5) re prese nts a c o m p osite t hat was de vel o pe d usi n g b ot h a 
t he or y-dri ve n a p pr oac h (i nc or p orati n g meas ures of b ot h c o g nit i on a n d f u ncti o n) a n d a 
data -mi ni n g a p pr oac h (i de nt if yi n g t he m ost se nsiti ve c om bi nat i on of s cales t hr o u g h a nal ysis of 
data fr o m  t he A D Ne ur oi ma gi n g I nit iati ve a n d t he E X P E DI TI O N, E X P E DI TI O N 2, a n d 
E X P E DI TI O N 3 st u dies). 
T he i A D R S is a si m ple li near c o m bi nat i on of sc ores fr o m [ADDRESS_391784] u d y part ner ( Galas k o et al. 1 9 9 7, 2 0 0 4). 
F or eac h of t he s pecific ite ms, t he st u d y  part ner is first as ke d if t he partici pa nt att e mpte d t he 
A D L d uri n g t he past [ADDRESS_391785] u d y part ner is as ke d 
t o rate t he perf or ma nce le vel base d o n a set of perf or ma nce descri pt i ons . Sc ores f or eac h ite m 
a n d t he o verall sc ore f or t he t o ol are calc ulate d . T he ra n ge f or t he t otal A D C S -A D L sc ore is 0 t o 
7 8, wi t h l ower sc ores i n dicati n g greater le vel of i m pair me nt ( Galas k o et al. 1 9 9 7, 2 0 0 4). 
8. 1. 2. Or der of Assess me nts a n d R ater R oles
Assess me nts a d mi nistere d t o t he partici pa nt are t he M M S E, A D A S -C o g 1 3 , C D R, a n d C-S S R S 
( C-S S R S i s i n Part B o nl y) . As sess me nt s a d mi nistere d t o t he st u d y part ner are t he C D R a n d 
A D C S -A D L.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391786] u d y P art ner
1: M M S E
2: A D A S -C o g 1 31: A D C S -A D L 
2: C D Ra
P artici p a nt
4: C -S S R S ( Part B o nl y) 3: C D Ra
A b bre viati o ns: A D A S -C o g 1 3= Alz hei mer’s Disease Assess me nt Scale – C o g niti ve s u bscale ; 
A D C S -A D L = Alz hei mer’s Disease C o o perati ve St u d y – Acti vities of Dail y Li vi n g I n ve nt or y; C D R = Cli nical 
De me ntia Rati n g Scale; C -S S R S = C ol u m bia S uici de Se verit y Rati n g Scale; M M S E = Mi ni Me ntal State 
E xa mi nati o n ; V T C = vi de o telec o nfere nce.
a T he C D R m ust al wa ys be a d mi nistere d t o t he st u d y part ner first a n d t he n t o t he partici pa nt. It is rec o m me n de d 
t hat b ot h secti o ns are a d mi nistere d o n t he sa me da y. F or V T C assess me nt; t he partici pa nt a n d t he st u d y part ner 
ca n n ot be prese nt d uri n g t he ot her part y’s i nter vie w.
N ote t hat , i n Parts B a n d C, t he A D A S-C o g [ADDRESS_391787] i n g s h o ul d be perf or me d bef ore me dical 
pr oce d ures t hat c o ul d be stressf ul f or t he parti ci pa nt (e. g., bl o o d dra ws). N ote t hat s o me 
pr oce d ures ( M RI, fl orta uci pir F 1 8 P E T ta u i ma gi n g, fl or beta pir F 1 8 P E T a m yl o i d i ma gi n g) ca n 
be c o n d ucte d o n ot her da y s wit hi n t he visit wi n d o w. T he C D R rater s h o ul d be bli n de d t o A Es t o 
a v o i d bias i n t he C D R assess me nt . 
C o g ni tive a n d f u nct i onal testi n g will be a d mi nistere d usi n g a n e C O A ta blet . T he a u di o v oice 
rec or di n gs of t he rater’s q uesti o ns a n d t he parti ci pa nt ’s a n d st u d y part ner’s res p o nses will als o be 
c ollecte d via t he e C O A ta blet d uri n g a d mi nistratio n of  t he c o g nitive a n d f u nct i onal testi n g f or 
ce ntral mo ni t orin g of rater scale a d mi nistrati o n . C o g ni tive a n d f u nct i onal test i n g f or eac h 
parti ci pa nt s h o uld be perf or m e d at a p pr o xi matel y t he sa me ti me o n eac h da y, w he ne ver p ossi ble, 
t o re d uce p ote ntial varia bilit y.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391788] u d y are descri be d i n t he res pecti ve secti ons 
bel o w:
 Fl or beta pi r F 1 8 P E T sca n – Secti o n 8. 6. 1
 Fl ort a u ci pir F 1 8 P E T sca n – Secti o n 8. 8
 V ol u metric M RI – Secti o n 8. [ADDRESS_391789] a n ne d ti me p o i nts f or all safety assess me nts are pr o vi de d i n t he S o A.
8. 2. 1. P h ysic al a n d Ne ur ol o gic al E x a mi n ati o ns
C o m plete a n d bri ef p h ysical e xa mi nati ons will be perf or me d as i n dicate d i n t he S o A 
( Sectio n 1. 3 ). 
T he c o m plete p h ysical e xa mi nat i on will i ncl u de assess me nt of t he f o ll owi n g : 
 ge neral a p peara nce; 
 s ki n, hea d, a n d nec k; 
 l y m p h n o des; 
 t h yr oid;
 a b d o me n ( b o wel s o u n ds, li ver a n d s plee n pal pat i on) ; 
 bac k (c ost o verte bral a n gle te n der ness); a n d
 m usc ul os keletal, car di o vasc ular, a n d res pi[INVESTIGATOR_1305] y  s yste ms. 
T he brief p h ysical e xa mi nat i on will  incl u de assess me nts of t he f o ll owi n g:
 s ki n, 
 l u n gs, 
 car dio vasc ular s yste m , a n d 
 a b d o me n ( b o wel s o u n ds, li ver a n d s plee n pal pat i on).
C o m plete ne ur ol o gical  e xa mi nat i ons will be perf or me d as i n dicate d i n t he S o A ( Secti o n 1. 3 ). 
T he e xa mi nat i ons will i ncl u de a t h or o u g h assess me nt of t he f o ll owi n g:
 g ai t, 
 bala nce, 
 c o or di nat i on, 
 cra nial ner ves, 
 se ns or y a n d mot or s yste m s, a n d
 refle xes. 
If necessar y, gi ve n t he tra i ni n g of t he PI, a ne ur ol o gist ma y be c o ns ulte d i n t he e ve nt of 
sig nifica nt ne w fi n di n gs. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391790] u d y , a n a d ditio nal f ull 
ne ur o l ogi cal e xa m s ho ul d be perf or m e d as s o o n as p ossi ble, al o n g wit h a n y o t her me dical 
f oll ow- u p dee m e d necessar y b y t he i n vesti gat or.
8. 2. 2. Vit al Si g ns
Vi t al si g ns, i ncl u di n g te m perat ure, will be meas ure d as i n dicate d i n t he S o A ( Secti o n 1. 3 ). 
Vi t al si g ns s h o uld be ta ke n bef ore a d mi nistrati o n of I P . Vi t al sig ns m a y be re peate d as nee de d . 
8. 2. 2. 1. Bl o o d Press ure
Si tti n g blo o d press ure a n d p ul se will be meas ure d after 5 mi n utes i n t he sitti n g p osit i on at all 
visit s. I n a d diti on, ort h ostatic bl o o d press ure a n d p ulse will be meas ure d s u pi [INVESTIGATOR_050] a n d sta n di n g at 
desi g nate d visits, as detaile d i n t he S o A ( Secti o n 1. 3 ).
F or ort h ostati c bl o o d press ure m o nit ori n g, partici pa nts s h o ul d be s u pi [INVESTIGATOR_050] f or at least [ADDRESS_391791] u d y treat me nt s h o uld be re p orte d t o 
Lill y or i ts desig nee as a n A E via C R F/electr o nic data e ntr y .
8. 2. 2. 2. Hei g ht, Wei g ht, a n d B o d y Te m per at ure
H ei g ht a n d b o d y  wei g ht will be meas ure d . Meas ure m e nts s h o uld be ta ke n, w he n p ossi ble, wit h 
the sa me scale f or all meas ure me nts . B o d y  mass i n de x will be calc ulate d fr o m t he hei g ht a n d 
b o d y  wei g ht. 
T e m perat ure will be rec or de d usi n g a n oral or t y m pa nic ( or ot her acce pta ble r o ute) t her m o meter.
A n y b o d y  w eig ht data e ntere d i nt o t he C R F will be use d f or t he o verall data a nal ysis.
8. 2. 3. Electr oc ar di o gr a ms
1 2- lea d di gital E C Gs will be c ollecte d acc or di n g t o t he S o A ( Secti o n 1. 3 ). Partici pa nt s must be 
s u pi [INVESTIGATOR_050] f or a p pr o xi matel y [ADDRESS_391792] i on.
E C Gs ma y be o btai ne d at a d dit i onal t i mes, w he n dee me d cli nicall y necessar y. C o llecti on of 
m o re E C Gs (re plicates) t ha n e x pecte d at a ti me p oi nt is all o we d w he n nee de d t o e ns ure 
hi g h -q ualit y rec or ds.
E C Gs will i nit iall y be i nter prete d b y a q ualifie d p h ysicia n (t he i n vesti gat or or q ualifie d desi g nee) 
at t he site as s o o n after t he ti me of E C G c ollect i on as p ossi ble, a n d i deall y w hile t he parti ci pa nt
is still prese nt, t o deter mi ne w het her t he s u bject meets e ntr y crit eria at t he rele va nt visit(s) a n d 
f or i m me diate partici pa nt ma na ge me nt, s h o ul d a n y cli nicall y rele va nt  fi n di n gs be i de ntifie d.
After e nr o ll me nt, if a cli nicall y si g nifica nt i ncrease i n t he Q T/ Q Tc i nter val fr om baseli ne or 
ot her cli nicall y si g nifica nt q ua ntitati ve or q ualitat i ve c ha n ge fr om baseli ne is i de ntifie d, t he 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
5 5parti ci pa nt will be assesse d b y t he i n vesti gat or f or s y m pt o ms (e. g., pal pi[INVESTIGATOR_242960] i ons, near s y nc o pe, 
s y nc o pe) a n d t o deter mi ne w het her t he partici pa nt ca n c o nt i n ue i n t he st u d y. T he i n vesti gat or or 
q ualifie d desi g nee is res p o nsi ble f or deter mi ni n g if a n y c ha n ge i n parti ci pa nt ma na ge me nt i s 
nee de d . T he i n vest i gat or or q ualifie d desi g nee m ust d oc u me nt his/ her re vie w of t he E C G pri nte d 
at t he ti me of e val uat i on.
All di gital E C Gs will be electr o nicall y  tra ns mitte d t o a desig nate d ce ntral E C G la b orat or y . A 
car diol o gi st at t he ce ntral E C G la b orat or y will t he n c o n d uct a f ull o verrea d. A re p ort base d o n 
data fr o m  t his o verrea d will be iss ue d t o t he i n vesti gati ve site. T hese data are n ot r o uti nel y 
re p orte d bac k t o t he i n vesti gati ve site. All data fr o m t he o verrea ds will be place d i n t he Lill y  
data base f or a nal yt ical a n d st u d y re p ort p ur p oses.
W he n t here are differe nces i n E C G i nter pretati o n bet wee n t he i n vest i gat or ( or q ualifie d 
desi g nee) a n d t he car di o l ogi st at t he ce ntral E C G la b orat or y, t he i n vesti gat or’s ( or q ualifie d 
desi g nee’s) i nter pretati o n will be u s e d for s t u d y e ntr y a n d i m me diate partici pa nt ma na ge me nt . 
I nter pretati o ns fr o m t he car di ol ogi st at t he ce ntral E C G la b orat or y will be use d f or data a nal ysis 
a n d re p ort writ i n g p ur p oses.
T he i n vest i gat or ( or q ualifie d desi g nee) m ust d oc u me nt his/ her re vie w of  t he E C G pri nte d at t he 
ti me of c ollecti on, t he fi nal o verrea d E C G re p ort iss ue d b y t he ce ntral E C G la b orat or y , a n d a n y 
alert re p orts.
8. 2. 4.  Cli nic al S afet y L a b or at or y Assess me nts
See Secti o n [ADDRESS_391793] be file d wit h t he s o urce d oc u me nts . Cli nicall y si g nifica nt a b n or mal 
la b orat or y fi n di n gs are t h ose w hic h are n ot ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d 
b y t he i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt's c o n dit i on.
All la b orat or y tests wit h val ues c o nsi dere d cli nicall y si g nifica ntl y a b n or mal d uri n g partici pat i on 
i n t he st u d y, or wit hi n t he fol l ow- u p peri o d aft er t he last d ose of I P, s h o ul d be re peate d u ntil t he 
val ues ret ur n t o n or mal, baseli ne, or are n o l o n ger c o nsi dere d cli nicall y si g nifica nt b y  t he 
i n vesti gat or or me dical m onit or.
1. If s uc h val ues d o n ot ret ur n t o n or mal/ baseli ne withi n a perio d of  ti me j u d ge d reas o na ble b y 
t he in vest i gat or, t he eti ol og y  s h o uld b e i de ntifie d a n d t he s p o ns or n otifie d.
2. All pr ot oc ol -re q uire d la b orat or y assess me nts, as defi ne d i n Secti on 1 0. 2 , mus t be c o n d ucte d 
i n acc or da nce wit h t he la b orat or y  ma n ual a n d t he S o A.
3. If la b orat or y val ues fr o m n o n pr ot oc ol -s pecifie d la b orat or y assess me nts perf or me d at t he 
i nstituti o n’s l o c al  la b orat or y r e q uire a c ha n ge i n partici pa nt ma na ge me nt or are c o nsi dere d 
cli nica ll y si g nifica nt b y t he i n vestigat or (f or e xa m pl e, S A E, A E, or d ose m o dificat i on), t he n 
t he res ults must be rec or de d i n t he C R F.
Lill y or i ts desig nee will  pr o vi de t he i n vestig at or wi t h t he res ults of la b orat or y tests a nal yze d b y 
a ce ntral ve n d or, if a ce ntr al ve n d or is use d f or t he cli nical trial. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391794] d ose of I P s h o ul d be re p orte d t o Lill y or its desi g nee 
as a n A E via C R F/electr o ni c data e ntr y.
8. 2. 5. M a g netic Res o n a nce I m a gi n g
M RI of  t he brai n will be perf or me d acc or di n g t o t he S o A ( Secti o n 1. 3 ) a n d as cli nicall y 
i n dicate d. U nsc he d ule d M RIs ma y be perf or me d at t he discreti o n of i n vest i gat or.
T his tec h n o l og y  will be use d t o c hec k f or e vi de nce of A RI A-H or A RI A - E a n d safet y fi n di n gs 
( vol u metri c M RI will als o be use d t o calc ulate brai n v o l umes, as n ote d i n Sect i on 8. 8 ).
T he M RI sca ns will be re vie we d b y  t he i n vesti gat or or q ualifie d desi g nee f or i m me diate 
parti ci pa nt ma na ge me nt . A n y cli nicall y si g nifica nt fi n di n gs n ote d t hat res ult i n a ne w or u p date d 
di a g n osis s h o uld be rec or de d as a n A E . After t he M RI sca n is rea d l ocall y, t he M RI sca ns will be 
se nt f or a nal ysis t o a ce ntralize d M RI ve n d or desi g nate d b y Lill y. T he ce ntralize d M RI ve n d or’s 
i nter pretatio n of  t he partici pa nt’s fi nal M RI fr o m t he ori gi nat i n g st u d y or u nsc he d ule d M RI 
perf or m e d i n St u d y A A C H prior t o Part B will deter mi ne fi nal M RI eli gi bilit y f or Part B.
S pecific a nal yses of t he sca ns, i ncl u di n g assess me nts of A RI A- H a n d A RI A -E a n d calc ulat i ons 
of  brai n v ol umes, will be i nter prete d b y  t he ce ntralize d M RI ve n d or f or data a nal ysis a n d re p ort 
wri ti n g p ur p oses. 
Res ults of ce ntrall y  rea d M RIs re gar di n g parti ci pa nt care/safet y will be re p orte d bac k t o sites.
8. 2. 6. He p atic S afet y M o nit ori n g
Cl ose H e pat ic M o ni t ori n g
La b orat or y  tests ( Sectio n 1 0. 4 ), i ncl u di n g A L T, A S T, A L P, T B L, direct bilir u bi n, G G T, a n d C K, 
s h o uld be re peate d wi t hi n 4 8 t o 7 2 h o urs t o c o nfir m t he a b n or malit y a n d t o deter mi ne if it is 
i ncreasi n g or decreasi n g, if 1 or mor e of  t hese c o n diti ons occ ur:
If a p artici p a nt wit h b aseli ne res ults of ... de vel o ps t he f oll o wi n g ele v ati o ns:
A L T or A S T < 1. 5 x U L N A L T or A S T ≥ 3 x U L N
A L P < 1. 5 x U L N A L P ≥ 2 x U L N
T B L < 1. 5 x U L N T B L ≥ 2 x U L N (e xce pt f or partici pa nt s wit h Gil bert’s s y ndr o me)
A L T or A S T ≥ 1. 5 x U L N A L T or A S T ≥ 2 x baseli ne
A L P ≥ 1. 5 x U L N A L P ≥ 2 x baseli ne
T B L ≥ 1. 5 x U L NT B L ≥ 2 x baseli ne (e xce pt f or pa rtici pa nts wit h Gil bert’s 
s yn dr o me)
A b bre viati o ns : A L P = al kali ne p h os p hatase; A L T = ala ni ne a mi n otra nsferase; A S T = as partate a mi n otra nsferase; 
T B L = t otal bilir u bi n le vel; U L N = u p per li mit of n or mal.
If t he a b n or mality persists or w orse ns, cli nical a n d la b orat or y  mo ni t ori n g, a n d e val uati on f or 
p ossi ble ca uses of a b n or mal li ver tests s h o ul d be i nit iate d b y t he i n vesti gat or i n c o ns ultat i on wi t h 
t he Lill y-desi g nate d m e dical m o nit or . At a mi ni m u m, t his e val uat i on s h o ul d i ncl u de p h ysical 
e xa mi nat i on a n d a t h or o u g h me dical hist or y , i ncl u di n g s y m pt o ms, rece nt ill nesses (f or e xa m ple:
heart fail ure, s yste mic i nfect i on, h y p ote ns i on, or seiz ures), rece nt tra vel, hist or y  of c o nc o mit a nt 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
5 7me dicat i ons (i ncl u di n g o ver -t he- c o u nter), her bal a n d dietar y s u p ple me nts, a n d hist or y of alc o h ol 
dri n ki n g a n d ot her s u bsta nce a b use. 
I nitiall y, mo ni t ori n g of s y m pt o ms a n d he patic bi oc he mical tests s h o ul d be d o ne at a fre q ue nc y o f 
1 t o 3 ti mes wee kl y, base d o n t he partici pa nt’s cli nical c o n dit i on a n d he pat ic bi oc he mical tests. 
S u bse q ue ntl y, t he fre q ue nc y  of mo ni t orin g m a y be lo were d t o o nce e ver y  1 t o 2 wee ks if t he 
parti ci pa nt’s cli nical c o n dit i on a n d l a b orat or y res ults sta bilize. M o ni t ori n g of A L T, A S T, A L P, 
a n d T B L s h o ul d c o nti n ue u nt il le vels n or malize or ret ur n t o a p pr o xi mate baseli ne le vels.
C o m pre he nsi ve H e pat ic E val uat i on  
A c o m pre he nsi ve e val uat i on s h o ul d be perf or m e d t o searc h f or p ossi ble c a uses of li ver i nj ur y if 
1 or m ore of t hese c o n dit i ons occ ur:
If a p artici p a nt wit h b aseli ne res ults of... de vel o ps t he f oll o wi n g ele v ati o ns:
A L T or A S T < 1. 5 x U L N A L T or A S T ≥ 3 x U L N wit h he patic si g ns/s y m pt o ms *, or
A L T or A S T ≥ 5 x U L N
A L P < 1. 5 x U L N A L P ≥ 3 x U L N
T B L < 1. 5 x U L N T B L ≥ 2 x U L N (e xce pt f or partici pa nt s wit h Gil bert’s s y n dr o me)
A L T or A S T ≥ 1. 5 x U L N A L T or A S T ≥ 2 x baseli ne wit h he patic si g ns/s y m pt o ms *, or
A L T or A S T ≥ 3 x baseli ne
A L P ≥ 1. 5 x U L N A L P ≥ 2 x baseli ne
T B L ≥ 1. 5 x U L N T B L ≥ 1. 5 x baseli ne (e xce pt f or partici pants wit h Gil bert’s 
s yn dr o me) 
A b bre viati o ns : A L P = al kali ne p h os p hatase; A L T = ala ni ne a mi n otra nsferase; A S T = as partate a mi n otra nsferase; 
T B L = t otal bilir u bi n le vel; U L N = u p per li mit of n or mal.
* He patic si g ns/s y m pt o ms are se vere f ati g ue, na usea, v o miti n g, ri g ht u p per q ua dra nt a b d o mi nal pai n, fe ver, ras h, 
a n d/ or e osi n o p hilia > 5 %.
At  a mi ni m u m, t his e val uati on s h o ul d i ncl u de p h ysical e xa mi nat i on a n d a t h or o u g h me dical 
hist or y , as o utli ne d a b o ve, as well as tests f or Pr ot hr o m bi n ti me a n d I N R; tests f or viral 
he pat itis A, B, C, or E; tests f or a ut oi m m u ne he patit is; a n d a n a b d omi nal i ma gi n g st u d y (for 
e xa m ple, ultras o u n d or C T sca n). 
Base d o n t he partici pa nt ’s hist or y a n d i nitial r es ults, furt her testi n g s h o ul d be c o nsi dere d i n 
c o ns ultati o n wit h t he Lill y -desi g nate d m e dical mo ni t or, i ncl u di n g tests f or he patitis D vir us, 
c yt o me galo vir us, E pstei n -Barr vir us, aceta mi n o p he n le vels, aceta mi n o p he n pr otei n a d d ucts, 
uri ne t o xic o l og y  scree n, Wils on’s disease, bl o o d alc o h ol le vels, uri nar y et h yl gl uc ur o nide, a n d 
ser u m p h os p hati dylet ha n o l. Base d o n t he circ u msta nces a n d t he i n vest i gat or’s assess me nt of t he 
parti ci pa nt’s cli nical c o n dit i on, t he i n vest i gat or s h o ul d c o nsi der referri n g t he partici pa nt f or a 
he pat ol o gi st or gastr oe nter ol o gist c ons ultati o n, ma g net ic res o na nce c h olan gi o pa ncreat o gra p h y , 
e n d osc o pic retr o gra de c h ola n gi o pa ncreat o gra p h y, c ar diac ec h ocar dio gr a m , or a li ver bi o ps y. 
8. 2. 7. S uici d al I de ati o n a n d Be h a vi or Ris k M o nit ori n g
P arti cip a nts bei n g treate d wit h d o na ne ma b s h o uld b e m o ni t or ed a p pr o priatel y a n d o bser ve d 
clos el y  for s ui ci dal i deat i on a n d be ha vi or or a n y  ot her u n us ual c ha n ges i n be ha vi or, es peciall y at 
t he be gi n ni n g a n d e n d of t he c o urse of i nter ve nt i on or at t he ti me of d ose c ha n ges, eit her 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391795] u d y  A A C H usi n g t he C-S S R S. 
C- S S R S
T he C -S S R S is a scale t hat ca pt ures t he occ urre nce, se verity,  a n d fre q ue nc y of s uici dal i deati o n 
a n d be ha vi or d uri n g t he assess me nt peri o d via a q uesti o n naire . T he scale was de vel o pe d b y t he 
NI M H trial gr o u p f or t he p ur p ose of bei n g c o u nter part t o t he C ol u m bia Class ificati on Al g ori t h m 
of  S uici de Assess me nt ( C -C A S A) cate g orizati o n of s uici dal e ve nts.
8. 3. A d verse E ve nts a n d Seri o us A d verse E ve nts
A E s will be re p orte d b y t he partici pa nt ( or, w he n a p pr o priate, b y a care gi ver, st u d y part ner, 
s urr o gate, or t he partici pa nt's legall y a ut h ori ze d re prese ntati ve).
T he i n vest i gat or a n d a n y q ualifie d desi g nees are res p o nsi ble f or detecti n g, d oc u me nti n g, a n d 
rec or di n g e ve nts t hat meet t he defi niti on of a n A E or S A E, a n d re mai n res p o nsi ble f or f o ll owi n g 
u p o n A Es t hat are seri o us, c o nsi dere d rel ate d t o t he I P or st u d y pr oce d ures, or t hat ca use d t he 
parti ci pa nt t o disc o nti n ue t he I P (see Secti o n 7 ).
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y f or C ol lecti n g A E a n d S A E I nf or m ati o n
All S A Es will be c o llecte d fr om t he sig ni n g of t he I C F t hr o u g h t he ti me p oi nts s pecifie d i n t he 
S o A ( Secti o n 1. 3 ).
All A Es will be c o llecte d fr om t he sig ni n g of t he I C F t hr o u g h t he ti me p oi nts s pecifie d i n t he 
S o A .
Me dical occ urre nces t hat be gi n bef ore t he start of I P b ut after si g ni n g of t he I C F will b e rec or de d 
o n t he A E C R F.
Alt h o u g h all A Es after si g ni n g t he I C F are rec or de d b y t he site i n t he C R F/electr o nic data e ntr y, 
S A E re p orti n g t o s p o ns or be gi ns after t he partici pa nt has si g ne d t he I C F a n d has recei ve d I P or 
P E T tracer . H o we ver, if a n S A E occ ur s after si g ni n g t he I C F, b ut pri or t o recei vi n g I P or P E T 
tracer, it nee ds t o be re p orte d O N L Y if it is c o nsi dere d reas o na bl y p ossi bl y relate d t o st u d y 
pr oce d ures.
All S A Es will be rec or de d a n d re p orte d t o t he s p o ns or or desi g nee i m me diatel y a n d u n der n o 
c irc u msta nce s h o uld t hi s e xcee d [ADDRESS_391796] u d y , a n d he/s he c o nsi ders t he e ve nt t o be reas o na bl y 
r elate d t o t he I P or st u d y p artici pat i on, t he i n vest i gator m ust pr o m ptl y n otif y t he s p o ns or.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391797] i on 1 0. 3 .
Care will be ta ke n n ot t o i ntr o d uce bias w he n detecti n g A Es a n d/ or S A Es. O pe n -e n de d a n d 
n o nlea di n g ver bal q uesti o ni n g of t he partici pa nt is t he preferre d met h o d t o i n q uire a b o ut A E
occ urre nc es.
8. 3. 3. F oll o w - Up of A Es a n d S A Es
After t he i nit ial A E/ S A E re p ort, t he i n vesti gat or is re q uire d t o pr oacti vel y f oll ow eac h partici pa nt 
at s u bse q ue nt visits/c o ntacts. All S A Es, a n d A Es of s pecial i nterest (as defi ne d i n Sect i on 8. 3. 8 ), 
will be f o ll owe d u nt il res ol uti on, sta bilizat i on, t he e ve nt is ot her wise e x plai ne d, or t he partici pa nt 
is l ost t o f oll o w-u p (as defi ne d i n Sect i on 7. 3 ). F urt her i nf or mati on o n f o ll ow- u p pr oce d ures i s 
pr o vi de d i n Sect i on [ADDRESS_391798] y  wit h c o u ntr y-s pecific re g ulat or y r e q uire me nts relat i n g t o safety re p orti n g t o t he 
re g ulat or y a ut h orit y, I R Bs/I E Cs, a n d i n vesti gat ors.
A n i n vesti gat or w h o recei ves a n i n vesti gat or safet y re p ort descri bi n g a n S A E or ot her s pecific 
safet y i nf or mati on ( f or e xa m ple, s u m mar y or listi n g of S A Es) fr om t he s p o ns or will re vie w a n d 
t he n file it al o n g wit h t he I B, a n d will n otif y t he I R B/I E C if a p pr o priate acc or di n g t o l ocal 
re q uire me nts.
8. 3. 5. Pre g n a nc y
W O C B P are e xcl u de d fr o m St u d y  A A C H . T heref ore, pre g na nc y is n ot e x pecte d t o occ ur . 
H o we ver, if pre g na nc y d oes occ ur, f o ll ow t he i nstr ucti o ns bel o w.
Details o f all pre g na ncies i n fe male partici pa nts a n d, if i n dicate d, fe male part ners of male 
parti ci pa nts will be c o llecte d after t he start of I P a n d u ntil [ADDRESS_391799] d ose of I P 
recei ve d.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
6 0If a pre g na nc y is re p orte d, t he i n vesti gat or s h o ul d i nf or m t he s p o ns or wit hi n 2 4 h o urs of  lear ni n g 
of  t he pre g na nc y.
A b n or m al pre g na nc y o utc o mes ( f or e xa m ple, s p o nta ne o us a b orti o n, fetal deat h, still birt h, 
c o n genit al a n o malies, ect o pic pre g na nc y) are c o nsi dere d S A Es.
8. 3. 6. H y perse nsiti vit y, I ncl u di n g I nf usi o n -Rel ate d Re acti o ns
8. 3. 6. 1. M a n a ge me nt of I nf usi o n -Rel ate d Re acti o ns
Ma n y  dr u gs, b ut partic ularl y bi o l ogic a ge nts, carr y t he ris k of s yste mic h y perse nsit i vity 
reactio ns . If s uc h a reacti o n occ urs, a d dit i onal data descri bi n g eac h s y m pt o m s h o ul d be pr o vi de d 
t o t he s p o ns or i n t he C R F.
Si tes s h o uld ha ve a p pr o pri atel y trai ne d me dical staff a n d a p pr o priate me dical e q ui p me nt 
a vaila ble w he n st u d y p artici pa nts are recei vi n g I P. It is rec om me n de d t hat partici pa nts w h o 
e x perie nce a s yste mic h y perse nsit i vity reacti on be treate d per t he l ocal sta n dar d of care.
I n t he case of ge neralize d urticaria or s us pecte d a na p h yla xis, a d dit i on al  blo o d a n d uri ne sa m ples 
s h o uld be c ollecte d as descri be d i n Sect i on [ADDRESS_391800] i gat ors (see Secti o n 6. 5. 2 ). T he me dicati o ns use d s h o ul d be 
d oc u m e nte d.
T he parti ci pa nt ma y be pre me dicate d f or s u bse q ue nt i nf usi o ns . If i nf usi on react i ons are 
o bser ve d, b ut re vie w of t he data s u g gests t hat d osi n g ma y  c o nti n ue, a d mi nistr atio n of  me dici nes 
ma na gi n g t he reacti o n ma y  be a d mi nistere d bef ore starti n g s u bse q ue nt i nf usi o ns at t he discret i on 
of  t he i n vesti gat or, acc or di n g t o l ocal practice g ui deli nes.
D osi n g rec halle n ge is c o ntrai n dicate d i n partici pa nts t hat ha ve e x perie nce d a s us pecte d or 
p ossi ble a na p h ylact ic reacti o n (e. g., reactio n i n v o l vi n g 2 or m ore or ga n s y ste ms [f or e xa mple, 
m uc oc uta ne o us, res pi[INVESTIGATOR_1305] y , car dio vasc ular, or gastr oi nt est i nal s yste ms] occ urri n g i n cl o se 
pr o xi mit y t o d osi n g), i n a pri or d ose ( Sa m ps o n et al. 2 0 0 6). F or i nf usi o n -relate d reactio ns w hic h 
are n ot s us pi[INVESTIGATOR_37180] o us f or a na p h yla xis, after re vie w o f t he data, a n d at t he i n vest i gat or’s discreti o n, 
t he partici pa nt ma y be rec halle n ge d. If rec halle n ge is pla n ne d, t he partici pa nt ma y be 
pr e m e dicate d f or s u bse q ue nt d oses at t he i n vesti gat or’s discreti o n a n d acc or di n g t o l ocal pract ice 
g ui deli nes. 
Pri or t o i ni tiati n g pre me dicat i on, t he i n vest i gat or m ust c o ns ult wit h t he s p o ns or. 
A n y pre me dicat i on gi ve n will be d oc u me nte d as a c o nc o mita nt t hera p y ( Sect i on 6. 5. 2 ).
8. 3. 7. A m yl oi d - Rel ate d I m a gi n g A b n or m alities ( A RI A-E a n d A RI A -H)
W hile m ost cases of A RI A -E are as y m pt o mat ic, s erio us cases ha ve bee n re p orte d. A vaila ble data 
s u g gest seri o us cases are m ost li kel y t o occ ur earl y i n d osi n g, after t he first, sec o n d, or t hir d 
i nf usi on.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391801] c o m m o nl y: 
 hea dac he, 
 w orse ni n g of c o g nit i ve f u ncti on, 
 alt er atio n of  c o nsci o us ness, 
 seiz ures, 
 u nstea di ness, a n d 
 v o mit i n g. 
If a parti ci pa nt si m ulta ne o usl y de vel o ps m ore t ha n [ADDRESS_391802] i ve of A RI A-E, 
t he n a n u nsc he d ule d M RI s h o ul d be perf or me d . A si n gle s y m pt o m s u g gesti ve of A RI A-E of  
s ufficie nt se verity ma y als o warra nt a n M RI.
If t he a b o ve-me nt i one d s y m pt o ms are re p orte d, a n d: 
 A RI A- E i s s us pecte d, t he n t he a b n or malit y is best detecte d b y  F L AI R se q ue nces o n 
M RI, w hile
 A RI A- H is best detecte d wit h t he T 2 * gra die nt -recalle d ec h o o n M RI.
A n u nsc he d ule d M RI wit h t hese i ma gi n g se q ue nces s h o ul d be o btai ne d u p o n s us pi[INVESTIGATOR_37180] o n o f A RI A . 
If A RI A is prese nt, it is rec om me n de d t o re peat M RIs wit h t hese se q ue nces e ver y 4 t o 6 wee ks 
u nt il res ol uti on of A RI A -E or sta bilizat i on of A RI A -H is d oc u m e nte d. F or as y m pt o mat ic or mil d 
s y m pt o ms, t he parti ci pa nt ca n be o bser ve d . For m o derate s y m pt o m s ass ociat e d wit h A RI A-E, 
t he use of oral or I V ster oi ds ca n be c o nsi dere d . I n t he case of se vere s y m pt o ms ass ociate d wit h 
A RI A- E, i t is rec o m me n de d t o h os pi[INVESTIGATOR_18552] t he partici pa nt f or close o bser vat i on a n d c o nsi der t he 
use of I V ster oi ds s uc h as hi g h -d ose de xa met has o ne or a si milar a ge nt.
T he u nsc he d ule d M RI s h o ul d be perf or me d i n t he sa me ma n ner as t he c urre nt l y sc he d ule d M RIs 
i n t he pr ot oc ol, w hic h i ncl u des se n di n g t he i ma ges f or ce ntral re vie w ( Secti o n 8. 2. 5 ). 
F or pr oce d ure s t o f oll ow i n t he e ve nt of A RI A -E or A RI A -H, see Secti o n 7. 1. 1. [ADDRESS_391803] u d y incl u de, b ut are n ot li mite d t o, t he f o ll owi n g : 
 A RI A- E
 A RI A- H
 H y perse nsi tivi t y, i m me diate a n d n o n- i m me diate, i ncl u di n g i nf usi on- relate d reactio ns 
a n d a na p h yla xis
T he t o pi [INVESTIGATOR_318307] d a b o ve, as well as ot her t o pi[INVESTIGATOR_1102] w hic h ma y be s u bse q ue nt l y deter mi ne d b y t he 
s p o ns or, will be s u bject t o e n ha nce d s ur veilla nce acti vit ies. A d dit i onall y , t he t o pi[INVESTIGATOR_1102] a b o ve will be 
a nal yze d f or prese ntati o n i n t he c li nical st u d y re p ort i n acc or da nce wit h t he S A P.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391804] i gat or as s o o n as p ossi ble if he or s he has a 
c o mplai nt or pr o bl e m wit h t he I P s o t hat t he sit uati o n ca n be assesse d.
N O T E: A E s/ S A Es t hat are ass ociate d wit h a pr o d uct c o m plai nt will als o f o ll ow t he pr ocesses 
o utli ne d i n Sect i on 8. 3. [ADDRESS_391805] i gat or is res p o nsi ble f or e ns uri n g t hat f oll o w-u p i ncl u des a n y s u p ple me ntal 
i n vesti gati ons as i n dicate d t o el uci date t he nat ure a n d/ or ca usalit y of  t he pr o d uct c o m plai nt .
Ne w or u p date d i nf or mat i on will be rec or de d o n t he ori gi nall y c o m p lete d f or m with all c ha n ges 
sig ne d a n d date d b y t he i n vest i gat or a n d s u b mitte d t o t he s p o ns or.
8. 4. Tre at me nt of O ver d ose
I n t he e ve nt of a n o ver d ose, t he i n vesti gat or or treati n g p h ysicia n s h o uld:
1. C o nta ct  t he m e dical m o ni t or i m me diatel y.
2. Cl os el y  mo ni t or t he partici pa nt f or a n y A E/ S A E a n d la b orat or y a b n or malities.
3. O btai n a plas ma sa m ple f or P K a nal ysis o f I P if re q ueste d b y t he m e dical mo ni t or 
( deter mi ne d o n a case- b y-case basis).
Decisi o ns re gar di n g d ose i nterr u pti o ns or m o dificati o ns will be ma de b y t he i n vest i gat or i n 
c o ns ultati o n wit h t he m e dical m o ni t or base d o n t he cli nical e val uati o n of t he partici pa nt.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
6 38. 5. P h ar m ac o ki netics
At  t he visits a n d ti mes s pecifie d i n t he S o A ( Sectio n 1. 3 ), ve n o us bl o o d sa m ples will be c o llecte d 
t o deter mi ne t he ser u m c o nce ntrati o ns of d o na ne ma b . I nstr uctio ns f or t he c ollect i on a n d ha n dli n g 
of  blo o d s a m ples will  b e pr o vide d b y t he s p o ns or . T he act ual  date a n d ti me ( 2 4-h o ur cl oc k ti me) 
of  eac h sa m pli n g will be rec or de d.
A ma xi m u m of [ADDRESS_391806] orat or y a nal yses s uc h as meta b o lis m, pr otei n bi n di n g, 
or bi oa nal y tical met h o d de vel o p me nt/ va li dati o n w or k.
8. 6. P h ar m ac o d y n a mics
8. 6. 1. Cle ar a nce of A m yl oi d De p osits 
Fl or beta pi r F 1 8 P E T pr o vi des q ua nti tati ve assess me nt of a m yl oi d pla q ue de p ositi on i n t he brai n 
a n d ca n ser ve as a P D bi o mar ker of cleara nce of a m yl o i d de p osits.
Cl eara nce of a m yl o i d de p osits (as assesse d b y flor b et a pir F 1 8 P E T si g nal) will be a ssesse d at 
ti me p oi nts descri be d i n Part B a n d C of t he S o A ( Secti o n 1. 3 ).
8. 7. Ge netics
Ge net ics are n ot e val uate d i n t his st u d y.
8. 8. Bi o m ar kers
Bl o o d - Base d Bi o m ar kers
Bi o m ar ker researc h is perf or me d t o a d dress q uesti o ns of rele va nce t o dr u g dis p osit i on, tar get 
e n ga ge me nt, P D, mec ha nis m of act i on, varia bilit y of  parti ci pa nt res p o nse (i ncl u di n g safety) , a n d 
cli nical o utc o me . S a mple c ollecti o n is i nc or p orate d i nt o cli nical st u dies t o e na ble e xa mi nat i on of 
t hese q uest i ons t hr o u g h meas ure me nt of bi o m o lec ules i ncl u di n g R N A, pr otei ns, li pi [INVESTIGATOR_805], a n d ot her 
cell ular ele me nts.
S er u m, pl as ma, a n d w h o le bl o o d R N A sa m ples f or e x pl orat or y bi o mar ker researc h will be 
c ollecte d at t he ti mes s pecifie d i n t he S o A ( Secti o n 1. 3 ) w here l ocal re g ulat i ons all o w.
S a m ples will  be use d f or researc h o n t he dr u g tar get, disease pr ocess, varia ble res p o nse t o 
d o na ne ma b , pat h wa ys ass ociat e d wit h A D, mec ha nis m of act i on of d o na ne ma b , a n d/ or researc h 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
6 4met h o d or i n vali dat i n g dia g n ostic t o ols or assa y(s) relate d t o A D or ot her ne ur ol o gical 
c o n ditio ns.
All sa m ples will be c o de d wit h t he partici pa nt n u m ber . T hese sa m ples a n d a n y data ge nerate d 
ca n be li n ke d bac k t o t he parti ci pa nt o nl y  b y t he i n vestig at or si te pers o n nel.
S a m ples will  be retai ne d at a facilit y selecte d b y Lill y or its desi g nee f or a ma xi m u m of [ADDRESS_391807] i gati on of varia ble res p o nse t hat ma y n ot be o bser ve d u nt il later 
i n t he de vel o p me nt of d o na ne ma b or af t er d o na ne ma b bec o mes c o m merciall y a vaila ble.
Acc u m ul ati o n of T a u De p osits
Fl ort a u ci pir F 1 8 P E T pr o vi des q ua nti tati ve assess me nt of ta u de p ositi o n i n t he brai n a n d ca n 
ser ve as a P D bi omar ker of acc u m ulat i on of ta u de p osits as A D pr o gresses.
Acc u m ulat i on of  ta u de p osits (as assesse d b y fl orta uci pir F 1 8 P E T si g nal) will be assesse d at t he 
ti me p oi nt descri be d i n Part C of t he S o A ( Secti o n 1. 3 ).
V ol u metric M RI
Effects o n re gi o nal brai n v o l umes, as assesse d b y v o l umetric M RI , will be perf or med acc or di n g 
t o t he S o A ( Secti o n 1. 3 ). D o na ne ma b effects o n vol u metric M RI will be assesse d t o e val uate t he 
l oss of brai n v olu me t hat occ urs i n A D pat ient s.
8. 9. I m m u n o ge nicit y Assess me nts
W here l ocal re g ulat i ons a n d E R Bs all o w, at t he visits a n d ti mes s pecifie d i n t he S o A 
( Sectio n 1. 3 ), ve n o us bl o od sa m ples will be c ollecte d t o deter mi ne a nti b o d y  pr o d u ctio n a gai nst 
d o na ne ma b . T o i nter pret t he res ults of i m m u n o ge nicit y,  a ve n o us blo o d s a m ple will be c ollecte d, 
if warra nte d, at t he sa me ti me p oi nts t o deter mi ne t he ser u m c o nce ntrati o ns of d o na ne ma b . A ll 
sa m ples f or i m m u n o ge nicit y s h o ul d be ta ke n pre d ose w he n a p plica ble a n d p ossi ble.
I mm u n o ge nicit y will  be assesse d b y a vali date d assa y desi g ne d t o detect A D As i n t he prese nce 
of  d o na ne ma b at a la b orat or y a p pr o ve d b y t he s p o ns or. A nt i b o dies ma y be f urt her c haracterize d 
a n d/ or e val uate d f or t heir a bilit y t o ne utralize t he acti vity of  d o na ne ma b . 
T E A D As are defi ne d i n Sect i on 9. 4. 6. [ADDRESS_391808] partici pa nt visi t, or for a 
s h orter peri o d if l ocal re g ulat i ons a n d E R Bs all o w, at a facilit y selecte d b y  t he s p o ns or. T he 
d urati o n all o ws t he s p o ns or t o res p o n d t o f ut ure re g ulat or y  re q uests relate d t o d o na ne ma b . A n y 
sa m ples re mai ni n g after 1 5 years will be destr o ye d.
8. 1 0. Me dic al Res o urce Utiliz ati o n a n d He alt h Ec o n o mics
N ot a p plica ble.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391809] atistic al H y p ot heses
P art A :
T he I C C c o m pari n g V T C a d mi nistrati o n of t he A D A S -C o g 1 3, t he A D C S-A D L, t he M M S E , a n d 
t he C D R -S B will s h o w at a mi ni m u m ‘acce pta ble ’ a gree me nt wit h t he o n-site assess me nt of  t he 
sa me scales. Acce pta ble a gree me nt is defi ne d as a n I C C val ue of 0. 7 0 or greater ( K o o a n d Li 
2 0 1 6 ; C o o ns 2 0 09).
T he I C C will re mai n c o nsiste nt acr oss m u lti ple pairs of  V T C a n d o n-site assess me nts.
Di sease pr o gressi o n meas ure d b y V T C a d mi nistrati o n will be n o differe nt t ha n disease 
pr o gressi o n meas ure d b y  o n-site assess me nts.
P art B :
N o stati stical h y p ot heses f or Part B of t he st u d y .
9. 2. S a m ple Size Deter mi n ati o n
A p pr o xi matel y  2 0 0 parti ci pa nts will be e nr olle d a n d ra n d o mize d i n a 1: 1 rati o t o t he 2 gr o u ps 
(Gr o u p 1: C o g nit i ve/f u ncti onal scale assess me nt o n- sit e, fol l owe d b y V T C assess me nt; or 
Gr o u p 2: C o g nit i ve/f u ncti o nal scale assess me nt b y V T C, f oll owe d b y  assess me nt o n -sit e). It is 
e x pecte d t hat a p pr o xi matel y [ADDRESS_391810] i mates were deri ve d fr om S t udi es I 8 D-M C -A Z E S , I 8 D-M C -A Z E T , a n d 
H 8 A -M C -L Z A X , all reflecti n g a n earl y or mil d A D p o p ulati o n.
T his sa m ple size will pr o vi de a p pr o xi matel y 8 1 % p o w er t o de mo nstrate ‘acce pta ble’ relia bility , 
defi ne d as t he l o wer li mit of t he 9 5 % c o nfi de nce i nter val f or I C C a b o ve 0. [ADDRESS_391811] varia bilit y fr om o n -site t o V T C assess me nt. Ot her scales s h o uld 
t heref ore de m o nstrate e q ual or greater p o wer f or t hese c o m paris o ns.
Si m ulati o ns ( c arrie d o ut i n R) wi t h 1 0 0 0 it er atio ns , utilizi n g a b o ve descri be d ass u m pti o n, yiel ds 
a n a vera ge I C C of 0. 7 9 3 a n d a vera ge 9 5 % c o nfi de nce i nter val of  0. 73 2 t o 0. 8 4 1.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
6 69. 3. P o p ul ati o ns f or A n al yses
T he f oll owi n g p o p ul at i ons are defi ne d:
P o p ul ati o n Descri pti o n
E nr olle d Part A: All partici pa nts ra n d o mize d . Partici pa nts will be a nal yze d acc or di n g t o 
t he assess me nt or der act uall y c o m plete d .
Part B: All partici pa nts gi ve n I P d uri n g Part B.
Part C: All partici pa nts partici pati n g i n a Part C f oll o w-u p assess me nt .
Efficac y E v al ua ble
(scale-de pe n de nt)Part A: All partici pa nts wit h a t least 1 c o m plete pair of assess me nts f or t he 
c o nsi dere d scale.
Part B: All partici pa nts wit h a n y Part B efficac y assess me nt.
Part C: All partici pa nts wit h a n y Part C efficac y assess me nt.
Safet y All partici pa nts w h o recei ve at least [ADDRESS_391812] 1 e val ua ble P K sa m ple.
A b bre viati o ns: I P = i n vesti gati o nal pr o d uct; P K = p har mac o ki netics.
9. 4. St atistic al A n al yses
9. 4. 1. Ge ner al C o nsi der ati o ns
Stati stical a nal ysis of  t his st u d y will  be t he res p o nsi bilit y of  t he sp o ns or or i ts desig nee.
U nless ot her wise n ote d, stat istical tests will be c o n d ucte d at a 2-si de d al p ha le vel of  0. 0 5 a n d 
9 5 % c o nfi de nce i nter v als will be dis pla ye d as 2-si ded.
N o a dj ust me nt s for m ul tipl e c o m paris o ns are pla n ne d . 
All a nal yses i n v o l vi n g calc ulati on of I C Cs will be li mi te d t o t he Efficac y E val ua ble p o p ulati on, 
re q uirin g partici pa nts t o c o ntri b ute c o m plete pairs of o n -site a n d re mo te cli nical assess me nts t o 
be i ncl u de d. T he I C C will be calc ulate d as [ADDRESS_391813] ificati o n f or ma ki n g t he c ha n ge, will be descri be d 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391814] i on , t he n u m ber of 
missi n g i t e ms acr oss t he a d mi nistrati o n of eac h of t he cli nical scales will s u m marize d b y 
m o dali t y.
9. 4. 2. Pri m ar y E n d p oi nt (s)
P art A
T he pri mar y  o bjecti ve f or Part A of t his st u d y is t o e val uate t he relia bility of  V T C c o mpare d 
wi t h o n-site a d mi nistere d c o g niti ve a n d f u ncti o nal meas ures. T his will be assesse d b y est i mati n g 
t he I C C a n d t he ass ociate d 9 5 % c o nfi de nce i nter val f or t he first pair of o bser vati o ns fr o m 
parti ci pa nts a n d c o m pari n g t he l o wer b o u n d of t he c o nfi de nce i nter val t o 0. 7 0 , t he I C C c ut -off 
f or acce pta ble relia bility.
Usi n g t he g ui deli nes a n d n otati o n f or defi ni n g I C Cs p u blis he d b y Mc Gra w a n d W o n g ( 1 9 9 6), t he 
I C C of pri mar y int erest f or t his st u d y is a 2- w a y  mi xe d mo d el , i nteractio n a bse nt, wi t h si n gle 
meas ure me nts fr o m eac h mo dali t y o n p arti ci pa nts, l o o ki n g at a bs ol ute a gree me nt – I C C( A, 1). I n 
t he prese nt st u d y, t he ‘raters’ are t he [ADDRESS_391815], a ge, y ears of 
e d ucati o n, a n d prese nce/a bse nce of a nt i-d e m e nt ia dr u gs . T o esti mate t he I C C a n d t he ass ociate d 
c o nfi de nce i nter val, t he a p pr o priate mea n s q uares fr o m t his m o del will be use d f or t hese 
esti mates. Refer t o t he S A P f or more details .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391816] u d y , safety will be ass esse d b y s u m marizi n g s p o nta ne o usl y 
re p orte d A Es (i ncl u di n g i nf usi o n-relate d reactio ns), l a b orat or y a nal yt es, vit al sig ns a n d b o d y  
w ei g ht meas ure me nts, E C Gs, p h y sical a n d ne ur olo gi cal e xa mi nat i ons, M RI sca ns, a n d C -S S R S 
assess me nts.
9. 4. 3. Sec o n d ar y E n d p oi nt (s)
T o assess t he effect of d o na ne ma b o n cli nical pr o gressi o n i n partici pa nts wit h s y m pt o matic A D, 
M M R M s will be fit t o t he Part B data u p t o Wee k 7 2 f or A D A S-C o g 1 3, A D C S-A D L, i A D R S, 
M M S E, a n d C D R -S B . T he m o d el s will i ncl u de ter ms f or visit, a ge, years of e d ucat i on, a n d 
prese nce/a bse nce of a nt i-d e m e nt ia dr u gs. Vi sit will be c o nsi dere d a cate g orical varia ble. 
O bser ve d case a nal yses will als o be c o n d ucte d f or eac h scale. A d dit i onall y , if particip a nt 
n u m bers are a de q uate, A D pr o gressi o n fr o m t hese m o dels ca n be c o m p are d t o a ntici pate d 
pr o gressi o n ha d t he patie nt re mai ne d u ntreate d. Details of s uc h a c o m paris o n are c o ntai ne d i n t he 
S A P.
C ha n ge fr o m baseli ne i n brai n a m yl o i d de p ositio n at Wee k 3 6 a n d Wee k 7 2 of Part B will be 
assesse d usi n g a n M M R M . T he m o d el  will in cl u de ter ms f or vi sit, a ge, years of e d ucati on, a n d 
prese nce/a bse nce of a nt i-d e m e nt ia dr u gs. Vi sit will be c o nsi dere d a cate g orical varia ble. A n 
o bser ve d case a nal ysis will als o be c o n d ucte d.
C ha n ge fr o m baseli ne i n brai n re gi o n v o l umes at Wee k 7 2 f or Part B will be assesse d usi n g a n 
A N C O V A m o del . T he m o d el  will incl u de ter m s for a ge, y ears of e d ucat i on, a n d 
prese nce/a bse nce of a nt i-d e m e nt ia dr u gs. A n o bser ve d case a nal ysis will als o be c o n d ucte d . T he 
brai n re gi o ns o f i nterest will be defi ne d i n t he S A P.
P K a nal yses will be defi ne d b y t he P K scie nt ist a n d will be s pecifie d i n t he P K a nal ysis pla n.
Cate g orical dis pla ys o f A D A s a gai nst d o na ne ma b a n d ne utralizi n g a nt i b o dies will be prese nte d.
9. 4. 4. Terti ar y/ E x pl or at or y E n d p oi nt (s)
As a se nsit i vity a nal ysis f or t he pri m ar y e nd p oi nt of Part A, t o assess w het her t he V T C cli nical 
assess me nt i ncl u des a n y bias relat i ve t o t he o n-site cli nical assess me nt, a n I C C lo o ki n g at t he 
c o nsiste nc y of t he 2 meas ures will be calc ulate d – I C C( C, 1) per Mc Gra w a n d W o n g ( 1 9 9 6). B y 
defi nit i on, t he c o nsiste nc y I C C will be e q ual t o or lar ger t ha n t he I C C f or a bs ol ute a gree me nt . 
Lar ge differe nces bet wee n t he a bs o l ute a gree me nt a n d c o nsiste nc y I C Cs s u g gest a s hift ( u p war d 
or d o w n war d) i n t he V T C relati ve t o t he o n -site assess me nt. 
Usi n g t he sa me A N O V A m o del s pecifie d i n Secti o n 9. 4. 2 , t he I C Cs a n d 9 5 % c o nfi de nce 
i nter vals f or t he sec o n d pair a n d t hir d pair of o n -site a n d re mote cli nical asses s me nts will be 
esti mate d. C o m paris o ns bet wee n t he I C C s fr om t he first pair of assess me nts a n d t he sec o n d a n d 
t hir d p airs of assess me nts will be ma de t o meas ure c o nsiste nc y a cr oss meas ures. If fe wer t ha n 
[ADDRESS_391817] mo d a lity ( V T C a n d o n-sit e). 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391818] i on, a ge, y ears of 
e d ucati o n, a n d prese nce/a bse nce of a nt i-d e m e nt ia dr u gs . Visit will be c o nsi dere d a cate g orical 
varia ble . T he n ull h y p ot hesis is t hat t he c o ntrast bet wee n t he V T C m o dalit y vers us t he o n -sit e 
m o dali t y at eac h visit e q uals 0. A n u nstr uct ure d c o varia nce matri x will be use d t o m o del t he 
wi t hi n-s u bject varia nce-c o varia nce err ors. If t he u nstr uct ure d c o varia nce str uct ure matri x res ults 
i n a lac k of c o n ver ge nce, t he f oll o wi n g tests will be use d i n se q ue nce:
 heter o ge ne o us T oe plitz c o varia nce str uct ure
 heter o ge ne o us a ut ore gressi ve c o varia nce str uct ure
 heter o ge ne o us c o m p o u n d s y m metr y  c o varia nce str uct ure 
 c o mp o u n d s y m metr y  c o varia nce str uct ure
T he Ke n wa r d-R o ger a p pr o xi mat i on will  be use d t o esti mate t he de n o mi nat or de grees of 
free d om.
C ha n ges i n t he bl o o d -base d bi o mar kers of Nf L, P- ta u, a n d A β d uri n g Part B will be s u m marize d 
wi t h o bser ve d case a nal yses. 
F or partici pa nt s i n Part C of t he st u d y, t he i nterest is w het her t he c ha n ges i n brai n a m yl oi d 
de p osi tio n, brai n ta u de p osi tio n, a n d cli nical pr o gressi o n of A D f or partici pa nt s w h o recei ve d 
d o na ne ma b i n t he ori gi nat i n g st u d y ar e mai ntai ne d after d o na ne ma b treat me nt is re m o ve d . F or 
eac h of t hese e n d p oi nts, c ha n ge fr o m t he last o bser vat i on of t he ori gi nat i n g st u d y will be fit 
usi n g a n A N C O V A m o del i ncl u di n g ter ms f or a ge, years of e d ucat i on, a n d prese nce/a bse nce of 
a nt i-de me nt ia dr u gs. O bser ve d case a nal yses will als o be prese nte d.
9. 4. 5. Ot her S afet y A n al yse (s)
A d dit i onal safety s u m maries will be perf or me d if warra nte d u p o n re vie w of t he data.
9. 4. 6. Ot her A n al yse (s)
9. 4. 6. 1. E v al u ati o n of I m m u n o ge nicit y
T he fre q ue nc y a n d perce nta ge of s u bjects wit h pree xist i n g ( baseli ne) A D As, A D As at a n y ti me 
after baseli ne, a n d T E A D As t o d o na ne ma b will be ta b ulate d.  If n o A D As are detecte d at 
baseli ne, T E A D As are defi ne d as t h ose wit h a titer 2 -f ol d ( 1 dil uti on) greater t ha n t he mi ni mal 
re q uire d dil uti on of t he assa y.  F or sa m ples wit h A D As detecte d at baseli ne, T E A D As are
defi ne d as t h os e wi t h a 4-f ol d ( 2 dil uti ons) i ncrease i n titer c o m pare d t o baseli ne.  F or t he T E 
A D A s u bjects, t he distri b ut i on of ma xi m u m t iters will be descri be d.  T he fre q ue nc y of 
ne utralizi n g a nt i b o dies ma y als o be ta b ulate d.  T he relati ons hi p bet wee n t he prese nce of  
a nt i b o dies t o d o na ne ma b a n d P K, P D, safet y,  a n d/ or efficac y assess me nt ma y be assesse d.
Ot her a nal yses are descri be d i n t he S A P.
9. 5. I nteri m A n al yses 
N o i nt eri m a nal yses are pla n ne d f or t his st u d y. All data i s u n bli n de d f or sp o ns or use o n a 
c o nti n ual basis.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 09. 6. D at a M o nit ori n g C o m mittee ( D M C)
N ot a p plica ble . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 11 0. S u p p orti n g D oc u me nt ati o n a n d O per ati o n al C o nsi der ati o ns
1 0. 1. A p pe n di x 1: Re g ul at or y, Et hic al, a n d St u d y O versi g ht 
C o nsi der ati o ns
[ADDRESS_391819] u d y  will be c o n d ucte d i n acc or da nce wi t h t he pr ot oc ol a n d wit h t he f oll owi n g:
 C o nse ns us et hical pri nci ples deri ve d fr o m i nter nati o nal g ui deli nes i ncl u di n g t he 
Declarati o n of Helsi n ki a n d CI O M S I nter nat i onal Et hical G ui deli nes
 A p plica ble I C H G C P G ui deli nes
 A p plica ble la ws a n d re g ulati o ns
T he pr ot oc ol, pr ot oc ol a me n d me nts, I C F, I B, a n d ot her rele va nt d oc u me nts (e. g., a d vertise me nts) 
m ust be s u b mitte d t o a n I R B/I E C b y  t he i n vesti gat or a n d re vie we d a n d a p pr o ve d b y t he I R B/I E C
bef ore t he st u d y  is i nitiate d.
A n y a me n d me nts t o t he pr ot oc ol will re q uire I R B/I E C a p pr o val b efore i m ple me ntati o n of  
c ha n ges ma de t o t he st u d y desi g n, e xce pt f or c ha n ges necessar y t o eli mi nate a n i m me diate 
hazar d t o st u d y  p artici pa nts.
T he i n vest i gat or will be res p o nsi ble f or t he f oll owi n g:
 Pr o vi di n g wri tte n s u m maries of t he stat us of t he st u d y t o t he I R B/I E C a n n uall y or mor e 
fre q ue ntl y i n acc or da nce wit h t he re q uire me nts, p olicies, a n d pr oce d ures esta blis he d b y 
t he I R B/I E C.
 N otif yi n g t he I R B/I E C of S A Es or ot her si g nifica nt safet y fi n di n gs as re q uire d b y 
I R B/I E C pr oce d ures.
 Pr o vi di n g o versi g ht of t he c o n d uct of t he st u d y  at t he site a n d a d here nce t o re q uire me nts 
of  2 1 C F R, I C H g uideli nes, t he I R B/I E C, E ur o pea n re g ulat i on 5 3 6/ [ADDRESS_391820] u dies (if a p plica ble), a n d all ot her a p plica ble l ocal re g ulat i ons.
I n vesti gat or sites are c o mpe nsate d f or parti ci pat i on i n t he st u d y as detaile d i n t he C T A .
[ADDRESS_391821] i gat or or his/ her re prese ntati ve will e x plai n t he nat ure of t he st u d y, i ncl u di n g t he ris ks 
a n d be nefits, t o t he partici pa nt or his/ her l e gall y a ut h orize d re prese ntative a n d a ns wer all
q uesti o ns re gar di n g t he st u d y.
P arti cipa nts m ust be i nf or m e d t hat t heir p artici pat i o n is v ol unt ar y. Participa nts or t hei r le gall y 
a ut h orize d re prese ntati ve will be re q uire d t o si g n a state me nt of i nf or me d c o nse nt t hat meets t he 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 2re q uire me nts of 2 1 C F R 5 0, l ocal re g ulati o ns, I C H g ui deli nes, HI P A A re q uire me nts, w here 
a p plica ble, a n d t he I R B/I E C or st u d y ce nter.
As use d i n t his pr ot oc ol, t he ter m “i nf or me d c o nse nt” i ncl u des all c o nse nt a n d asse nt gi ve n b y 
t he partici pa nt or t heir le gal re prese ntati ves a n d b y st u d y  part ners.
T he m e dical rec or d must i ncl u de a state m e nt t hat writte n i nf or me d c o nse nt was o btai ne d bef ore 
t he partici pa nt was e nter e d i n t he st u d y a n d t he date t he writte n c o nse nt was o btai ne d. T he 
a ut h orize d pers o n o btai ni n g t he i nf or me d c o nse nt m ust als o si g n t he I C F.
P arti cip a nt s m ust be re-c o nse nte d t o t he m ost c urre nt versi o n of t he I C F(s) d uri n g t h eir 
parti ci pat i on i n t he st u d y.
A c o p y  of t he I C F(s) must be pr o vi de d t o t he partici pa nt or t he partici pa nt’s le gall y a ut h orize d 
re prese ntative a n d is ke pt o n file. 
P arti cipa nts w h o are rescree ne d are re q uire d t o si g n a ne w I C F.
1 0. 1. 4. D at a Pr otecti o n
P arti cipa nts will be assi g ne d a u ni q ue i de nt ifier b y t he s p o ns or. A n y partici pa nt rec or ds, datasets
or ti ss ue sa m ples t hat are tra nsferre d t o t he s p o ns or will c o ntai n t he i de ntifier o nl y; p artici pa nt 
na mes or a n y  inf or m at i on w hic h w o ul d ma ke t he partici pa nt i de nt ifia ble will n ot be tra nsferre d.
T he parti ci pa nt m ust be i nf or me d t hat his/ her pers o nal st u d y-r elate d data will be use d b y t he 
s p o ns or i n acc or da nce with l ocal data pr otectio n la w. T he le vel o f di s clos ur e m ust als o b e 
e x plai ne d t o t he partici pa nt w h o will be re q uire d t o gi ve c o nse nt f or t heir data t o be use d as 
descri be d i n t he i nf or me d c o nse nt .
T he parti ci pa nt m ust be i nf or me d t hat his/ h er me dical rec or ds ma y be e xa mi ne d b y Cli nical
Q ualit y Ass ura nce a u dit ors or ot her a ut h orize d pers o n nel a p p o i nte d b y t he s p o ns or, b y 
a p pr o priate I R B/I E C me m bers, a n d b y i ns pect ors fr o m re g ulat or y  a ut h orities.
T he sp o ns or has pr ocesses i n place t o e ns ure data pr otecti o n, i nf or mat i on sec urit y, a n d data 
i nte grit y. T hese pr ocesses i ncl u de a p pr o priate c o nti n ge nc y pla n(s) f or a p pr o priate a n d ti mel y 
res p o nse i n t he e ve nt of a data sec urity breac h.
[ADDRESS_391822] u die d has bee n a p pr o ve d i n t he U S a n d E U, a n d after pri mar y p u blicat i on 
acce pta nce, w hic he ver is later . N o e x pi[INVESTIGATOR_20325] i on date of data re q uests is c urre nt l y set o nce data are 
ma de a vaila ble.    
Access i s pr o vid e d af ter a pr o p osal has bee n a p pr o ve d b y a n i n de pe n de nt re vie w c o m mittee 
i de ntifie d f or t his p ur p ose a n d after recei pt of a si g ne d data s hari n g a gree me nt. Data a n d 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391823] u d y will be rec or de d o n pri nte d or electr o nic C R F u nless 
tra ns mitte d t o t he s p o ns or or desi g nee electr o nicall y (e. g., la b orat or y data). T he i n vesti gat or is 
res po nsi ble f or verif yi n g t hat data e ntries are acc urate a n d c orrect b y  p h ysicall y or electr o nicall y 
sig ni n g t he C R F.
T he i n vest i gat or m ust mai ntai n acc urate d oc u me ntati o n (s o urce data) t hat s u p p orts t he 
i nf or mat i on e ntere d i n t he C R F.
T he i n vest i gat or m ust per mit st u d y-r elat e d mo ni t ori n g, a u dits, I R B/I E C re vie w, a n d re g ulat or y 
a ge nc y ins pect i ons a n d pr o vi de direct a ccess t o s o urce data d oc u me nts.
M o ni t ori n g details descri bi n g strate g y ( e.g. , ris k-base d i nit iati ves i n o perati o ns a n d q uality s uc h 
as Ris k Ma na ge me nt a n d Mitigat i on Strate gies a n d A nal yt ical Ris k -Base d M o nit ori n g), met h o ds, 
res p o nsi bilities, a n d re q uire me nts, i ncl u di n g ha n dli n g of n o nc o m p lia nce iss ues a n d m o nit ori n g 
tec h ni q ues are pr o vi de d i n t he M o ni t ori n g Pla n.
T he s p o ns or or desi g nee is res p o nsi b le f or t he data ma na ge me nt of t his st u d y incl u di n g q ualit y 
c hec ki n g o f t he data.
T he s p o ns or ass u mes acc o u nta bilit y f or actio ns dele gate d t o ot her i n di vi d uals (e . g., co ntract 
researc h o r ga nizati ons).
St u d y  mo ni t ors will perf or m o n g oi n g s o urce data verificatio n t o c o nfir m  t hat data e ntere d i nt o 
t he C R F b y a ut h orize d site pers o n nel are acc urate, c o mplete, a n d verifia ble fr o m s o urce 
d oc u m e nts; t hat t he safet y a n d rig hts of  p artici pa nts are bei n g pr otecte d; a n d t hat t he st u d y  is 
bei n g c o n d ucte d i n acc or da nce wi t h t he c urre ntl y a p pr o ve d pr ot oc ol a n d a n y ot her st u d y 
a gree me nts, I C H G C P, a n d all a p plica ble re g u lator y  re q uire me nts.
Rec or ds a n d d oc u me nts, i ncl u di n g si g ne d I C Fs, pertai ni n g t o t he c o n d uct of t his st u d y  must be 
retai ne d b y t he i n vesti gat or f or t he ti me p eri o d o utli ne d i n t he C T A u nless l ocal re g ulat i ons or 
i nstituti o nal  p olicies re q uir e a lo n ger rete nti o n peri o d. N o rec or ds ma y be destr o y e d d uri n g t he 
rete ntio n peri o d wi t ho ut t he wri tte n a p pr o val of t he s p o ns or. N o rec or ds ma y be tra nsferre d t o 
a n ot her lo c ati o n or part y  wit ho ut wri tte n n otificati o n t o t he s p o ns or.
I n a d diti on, sp o ns or or i ts re prese ntati ves will peri o dicall y c hec k a sa m ple of t he parti ci pa nt data 
rec or de d a gai nst s o urce d oc u me nts at t he st u d y sit e. T he st u d y  ma y be a u dite d b y sp o ns or or i ts 
re prese ntati ves, a n d/ or re g ulat or y a ge ncies at a n y ti me. I n vesti gat ors will be gi ve n n otice bef ore 
a n a u dit occ urs.
D at a C a pt ure S yste m
T he i n vest i gat or is res p o nsi ble f or e ns uri n g t he acc urac y, c o m plete ness, le gi bility,  a n d ti meli ness 
of  t he data re p orte d t o t he s p o ns or. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391824] i gat or is res p o nsi ble f or t he i de ntificati on of a n y  d at a 
t o be c o nsi dere d s o urce a n d f or t he c o nfir mat i on t hat data re p orte d are acc urate a n d c o m plete b y  
si gni n g t he C R F .
A d dit i onall y , C O A data ( partici pa nt -f oc use d o utc o me i nstr u me nt) will be c o llecte d b y t he 
parti ci pa nt a n d/ or i n vesti gat or site pers o n nel via a pa per s o urce d oc u me nt a n d will be tra nscri be d 
b y t he i n vesti gat or site pers o n nel i nt o t he E D C s yst e m.
A d dit i onall y , e C O A data ( partici pa nt -f oc use d o utc o me i nstr u me nt) will be direct l y rec or de d b y 
t he i n vesti gat or site pers o n nel i nto a n i nstr u m e nt ( f or e xa m ple, ta blet). T he e C O A data will ser ve 
as t he s o urce d oc u me ntati o n a n d t he i n vest i gat or will n ot mai ntai n a se parate, writte n or 
ele ctr o nic, rec or d of t hese data . 
Data c ollecte d via t he s p o ns or- pr o vi de d data ca pt ure s yste m will be st ore d at a t hird- part y . T he 
i n vesti gat or will ha ve c o nti n u o us access t o t he data d uri n g t he st u d y a n d u ntil dec om missi o ni n g 
of  t he data ca pt ure s yst e m. Pri or t o dec o m missi o ni n g, t he i n vest i gat or will recei ve a n arc hi val 
c o p y of perti ne nt data f or rete nti o n.
Data m a na ge d b y a ce ntral ve n d or, s uc h as la b orat or y test data, will be st ore d electr o nicall y in 
t he ce ntral ve n d or’s data base s yste m a n d re p orts will be pr o vi de d t o t he i n vesti gat or f or re vie w 
a n d rete nti o n. Data will s u bse q ue nt l y be tra nsferre d fr o m t he ce ntral ve n d or t o t he s p o ns or data 
ware h o use.
Data fr o m c o m p lai nt f or ms s u b mitte d t o t he s p o ns or will be e nc o de d a n d st ore d i n t he gl o bal 
pr o d uct c o m plai nt ma na ge me nt s y st e m.
1 0. 1. 7. S o urce D oc u me nts
S o urce d oc u me nts pr o vi de e vi de nce f or t he e xiste nce of t he partici pa nt a n d s u bsta ntiate t he 
i nte grit y of t he data c ollecte d. S o urce d oc u me nts are file d at t he i n vesti gat or’s site.
Data re p orte d o n t he C R F or e ntere d i n t he e C R F t hat are tra nscri be d fr o m s o urce d oc u me nts 
m ust be c o nsiste nt wit h t he s o urce d oc u me nts or t he discre pa ncies m ust be e x plai ne d. T he 
i n vesti gat or ma y nee d t o re q uest pre vi o us me dical rec or ds or tra nsfer rec or d s, de pe n di n g o n t he 
st u d y. Als o, c urre nt me dical rec or ds m ust be a vaila ble.
[ADDRESS_391825] u d y-sit e clos ure at a n y  time, pr o vi de d t here i s reas o na ble ca use 
a n d s ufficie nt n oti ce is gi ve n i n a d va nce of t he i nte n de d ter mi nat i on.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391826] u d y  site b y t he s p o ns or or i n vesti gat or ma y incl u de b ut are 
n ot li mite d t o:
 Fail ure of t he i n vest i gat or t o c o m pl y with t he pr ot oc ol, t he re q uire me nts of t he I R B/I E C 
or l o c al  healt h a ut h orities, t he s p o ns or's pr oce d ures, or G C P g ui deli nes
 I na de q uate recr uitme nt  of p artici pa nts b y t he i n vestigat or
 Di sc o nti n uatio n of  furt her I P de vel o p me nt
If t he st u d y is pre mat urel y ter mi nate d or s us pe n de d, t he s p o ns or s hall pr o m ptl y i nf or m t he 
in vesti gat ors, t he I E Cs/I R Bs, t he re g ulat or y  a ut h orities, a n d a n y c o ntract researc h or ga nizati on(s) 
use d i n t he st u d y  of t he reas o n f or ter mi nati on or s us pe nsi o n, as s pecifie d b y t he a p plica ble 
re g ulat or y r e q uire me nts. T he in vesti gat or s hall pr o m pt l y i nf or m t he parti ci pa nt a n d ass ure s
a p pr o priate partici pa nt t hera p y a n d/ or f ollo w - u p.
1 0. 1. 9. P u blic ati o n P olic y
I n acc or da nce wit h t he s p o ns or’s p u blicati o n p olic y, t he res ults of t his st u d y will be s u b mitte d 
f or p u blicati on b y a peer -re vie we d j o ur nal.
[ADDRESS_391827] u d y.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 61 0. 2. A p pe n di x 2: Cli nic al L a b or at or y Tests
 T he tests detaile d i n t he ta ble bel o w will be perf or me d b y t he ce ntral la b orat or y  ( u nless 
s pecifie d ot her wise bel o w).
 Pr ot oc ol -s pecific re q uire me nts f or i ncl usi o n or e xcl usi o n of partici p a nts are detaile d i n 
Secti o n 5 of  t he pr ot oc ol.
 A d dit i onal tests ma y be perf or me d at a n y  time d uri n g t he st u d y  as deter mi ne d necessar y 
b y t he i n vesti gat or or as re q uire d b y l ocal re g ulati ons.
I n vesti gat ors m ust d oc u me nt t heir re vie w of eac h la b orat or y safet y re p ort.
La b orat or y  a nal yte res ults de n ote d belo w t hat c o uld u n bli n d t he st u d y  will not be re p orte d t o 
i n vesti gati ve sites or ot her bli n de d pers o n nel.
Cli nic al L a b or at or y Tests C o m me nts  
He m at ol o g y Assa y e d b y Lill y-desi g nate d la b orat or y
He m o gl o bi n
He mat ocrit
Er y t hr oc yte c o u nt ( R B Cs)
Mea n cell v ol u me 
Mea n cell he m o gl o bi n
Mea n cell he m o gl o bi n c o nce ntrati o n 
Le u k oc ytes ( W B Cs) 
Differe ntial
   Ne utr o p hils, se g me nte d
   L y m p h oc y tes
   M o n oc ytes
   E osi n o p hils
   Bas o p hils
Platelets
Cell m or p h ol o g y ( R B C a n d W B C)
Cli nic al C he mistr y Assa y e d b y Lill y-desi g nate d la b orat or y
S o di u m
P otassi u m
C hl ori de
Bicar b o nate
T otal bilir u bi n
Direct bilir u bi n
A L P
A L T
A S T
G G T
B U N
Creati ni ne 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 7Cli nic al L a b or at or y Tests C o m me nts  
C K
Ur ic aci d
Al b u mi n
Calci u m
Gl uc ose
C h olester ol 
P K S a m ples – D o na ne ma b C o n ce ntrati o n Assa y e d b y Lill y-desi g nate d la b orat or y . Res ults will n ot 
be pr o vi de d t o t he i n vesti gati ve sites.
Bi o m ar kers Assa y e d b y Lill y-desi g nate d la b orat or y . Res ults will n ot 
be pr o vi de d t o t he i n vesti gati ve sites.
Nf L
P-t a u
A 
St ore d S a m ples Assa y e d b y Lill y-desi g nate d la b orat or y . Res ults will n ot 
be pr o vi de d t o t he i n vesti gati ve sites.
E x pl o rat or y st ora ge sa m ples: 
Ser u m
Plas ma ( E D T A)
Pa x ge ne R N A t u be
I m m u n o ge nicit y S a m ples Assa y e d b y Lill y-desi g nate d la b orat or y . Res ults will n ot 
be pr o vi de d t o t he i n vesti gati ve sites.
   A n ti-d o na ne ma b a nti b o dies 
   A n ti-d o na ne ma b a nti b o dies ne utralizati o n
H y perse nsiti vit y Tests Selecte d test s m a y  be o btai ne d i n t he e ve nt of 
a na p h yla xis or  s yste mic aller gic/ h y perse nsiti vit y 
reacti o ns. T hese s h o ul d be c ollecte d as s o o n after t he 
e ve nt as p ossi ble. Assa ye d b y Lill y -desi g nate d 
la b orat or y. Res ults will n ot be pr o vi de d t o t he 
i n vesti gati ve sites.
A nti -d o na ne ma b a nti b o dies (I m m u n o ge nicit y)
D o na ne ma b co nce ntrati o ns ( P K)
Tr y ptase D o n ot c ollect i f > 1 2 h o urs ha ve passe d si nce t he 
h y perse nsiti vit y e ve nt.
N M H O btai n o nl y if tr y ptase sa m ple was c ollecte d > [ADDRESS_391828] Will be perf or me d if a vali date d assa y is a vaila ble.
C o m ple me nt ( C 3, C 3 a, a n d C5a)
C yt o ki ne Pa nel
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 8A b bre viati o ns : A  = a m yl oi d beta; A L P = al kali ne p h os p hatase; A L T = ala ni ne a mi n otra nsferase; A S T = as partate 
a mi n otra nsferase; B U N = bl o o d urea nitr o ge n; C K = creati ne ki nase; E D T A = Et h yle ne dia mi netetraacetic aci d ;
G G T = ga m ma -gl uta m yl tra nsferase; I g E = i m m u n o gl o b uli n E ; Nf L = ne ur ofila me nt li g ht c hai n; 
N M H = N met h y l hista mi ne; R B C = re d bl o o d cell; P K = p har mac o ki netics; P -ta u = p h os p h or ylate d ta u; 
R N A = ri b o n ucleic aci d; W B C = white b l o o d cell .
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
7 91 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or 
Rec or di n g, E v al u ati n g, F oll o w - Up, a n d Re p orti n g
1 0. 3. 1. Defi niti o n of A E
A E Defi niti o n
 A n A E i s a n y u nt o war d me dical occ urre nce i n a parti ci pa nt or cli nical st u d y  
parti ci pa nt, te mp orall y ass oci at e d wit h t he use of I P, w het her or n ot c o nsi dere d relate d 
t o t he I P.
 N O T E: A n A E ca n t heref ore be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n 
a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y 
ass ociat e d wit h t he use of I P. 
E ve nts Meeti n g t he A E Defi niti o n
 A n y a b n or mal la b orat or y  test res ults ( he mat olo g y , cli nical c he mistr y, or urinal ysis) or 
ot her safet y assess me nts (e . g., E C G, ra di ol ogical sca ns, vital si g ns meas ure me nts), 
i ncl u di n g t h ose t hat w orse n fr om baseli ne, c o nsi dere d cli nicall y si g nifica nt i n t he 
me dical a n d scie nt ific ju d g me nt of t he i n vesti gat or (i .e. , n ot relate d t o pr o gressi o n of 
u n derl yi n g disease).
 E xacer bat i on of a c hr o nic or i nter mitte nt pree xisti n g c o n dit i on i ncl u di n g eit her a n 
i ncrease i n fre q ue nc y a n d/ or i nte nsity of  t he c o n ditio n .
 Ne w c o n dit i ons detecte d or di a g n ose d after I P a d mi nistrati o n e ve n t h o u g h it ma y ha ve 
bee n prese nt bef ore t he start of t he st u d y .
 Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d dr u g -dr u g i nteracti o n.
 Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pecte d o ver d ose of eit her I P or a 
c o nc o mita nt me dicat i on. O ver d ose per se will n ot be re p orte d as a n A E/ S A E u nless it 
is a n i nte nti onal o ver d ose ta ke n wit h p ossi ble s uici dal/self- har mi n g i nte nt. S uc h 
o ver d ose s h o ul d be re p orte d re gar dless of se q uelae . 
 “Lac k of efficac y ” or “fail ure of e x pecte d p har mac ol o gical acti on” per se will n ot be 
re p orte d as a n A E or S A E. S uc h i nsta nces will be ca pt ure d i n t he efficac y assess me nts. 
H o we ver, t he si g ns, s y m pt o ms, a n d/ or cli nical se q uelae res ult i n g fr om lac k of efficac y 
will be re p orte d as A E or S A E if t he y f ulfil l t he defi nit i on of a n A E or S A E .
E ve nts N O T Meeti n g t he A E D efi niti o n
 A n y cli nicall y  sig nifica nt a b n or mal la b orat or y  fi n di n gs or ot her a b n or mal safety 
assess me nts, w hic h are ass ociate d wit h t he u n derl yi n g disease, u nless j u d ge d b y t he 
i n vesti gat or t o be m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n diti on.
 T he disease/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or s y m pt o m s of t he 
di sease/ dis or der bein g st u die d, u nless m ore se vere t ha n e x pecte d f or t he partici pa nt’s 
c o n ditio n.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 0 Me dical or s ur gical pr oce d ure (e . g., e n d osc o p y, a p pe n dect o m y): t he c o n diti on t hat 
lea ds t o t he pr oce d ure is t he A E.
 Si t u atio ns i n w hic h a n u nt o war d me dical occ urre nce di d n ot occ ur (s ocial a n d/ or 
c o n ve nie nce a d missi o n t o a h os pi[INVESTIGATOR_307]).
 A nt ici pate d da y-t o-da y fl uct uati o ns of pree xisti n g disease(s) or c o n ditio n(s) prese nt or 
detecte d at t he start of t he st u d y  t hat d o n ot w orse n. 
1 0. 3. 2. Defi niti o n of S A E
If a n e ve nt is n ot a n A E per defi nit i on a b o ve, t he n it ca n n ot be a n S A E e ve n if seri o us c o n dit i ons 
are met (e. g., h os pi[INVESTIGATOR_28689] f or sig ns/s y m pt o ms of t he disease u n der st u d y , deat h d ue t o 
pr o gressi o n of disease).
A n S A E is defi ne d as a n y u nt o w ar d me dic al occ urre nce t h at, at a n y d ose :
a. Res ults i n de at h
b. Is life-t hre ate ni n g
T he ter m  'life-t hreate ni n g' i n t he defi niti on of 'seri o us' refers t o a n e ve nt i n w hic h t he 
parti ci pa nt was at ris k of deat h at t he ti me of t he e ve nt. It d oes n ot refer t o a n e ve nt, w hic h 
h y p ot heti call y mi g ht ha ve ca use d deat h, if it were m ore se vere.
c. Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n
 I n ge neral, h os pi[INVESTIGATOR_318308] g nifies t hat t he partici pa nt has bee n a d mitte d t o h os pi t al
f or o bser vati on a n d/ or treat me nt t hat w o ul d n ot h a ve bee n a p pr o priate i n t he 
p h ysicia n’s office or o ut patie nt setti n g. C o m plicat i o ns t hat occ ur d uri n g h os pi[INVESTIGATOR_1314] o n 
are A Es. If a c o m plicat i on pr ol o n gs h os pi [INVESTIGATOR_5186] n or f ulfills a n y  ot her serio us cri t eria, 
t he e ve nt is seri o us. W he n i n d o u bt as t o w het her “ h os pi[INVESTIGATOR_1314] o n” occ urre d or was 
necessar y , t he A E s h o uld be c o nsi dere d seri o us.
 H os pi[INVESTIGATOR_1314] o n f or elect i ve treat me nt of a pree xisti n g c o n diti on t hat di d n ot w orse n 
fr om baseli ne is n ot c o nsi dere d a n A E.
d. Res ults i n persiste nt dis a bilit y/i nc a p acit y
 T he ter m disa bili t y mea ns a s u bsta nt ial disr u pt i on of a pers o n’s a bilit y t o c o n d uct 
n or m al lif e fu nct i ons.
 T his defi nit i on is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y mi n or me dical 
sig nifica nce s uc h as u nc o m p licate d hea dac he, na usea, v o miti n g, diarr hea, i nfl ue nza, 
a n d acci de ntal tra u ma (e . g., s prai ne d a n kle) w hic h ma y i nterfere wit h or pre ve nt 
e ver y da y life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pt i on .
e. Is a c o n ge nit al a n o m al y/ birt h defect
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 1f. Ot her sit u ati o ns:
 Me dical or scie nt ific j u d g me nt s h o ul d be e xercise d i n deci di n g w het her S A E re p orti n g 
is a p pr o priate i n ot her sit uati o ns s uc h as i m p orta nt me dical e ve nts t hat ma y n ot be 
i m me diatel y life-t hreate ni n g or res ult i n deat h or h os pi[INVESTIGATOR_1314] o n b ut ma y je o par dize t he 
parti ci pa nt or ma y re q uir e me dical or s ur gical i nter ve nt i on t o pre ve nt o ne of t he ot her 
o utc o m es liste d i n t he a b o ve defi nit i on. T hese e ve nts s h o ul d us uall y be c o nsi dere d 
serio us.
E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve treat me nt i n 
a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d yscrasias or 
c o n v ulsi o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_90730] i on, or de vel o p me nt of dr u g de pe n de nc y or 
dr u g a b use . 
1 0. 3. 3. Rec or di n g a n d F oll o w - Up of A E a n d/ or S A E
A E a n d S A E Rec or di n g
 W he n a n A E/ S A E occ urs, it  is t he res p o nsi bility of t he i n vesti gat or t o re vie w all 
d oc u m e nt atio n (e . g., h os pi[INVESTIGATOR_75512] o gress n otes, la b orat or y re p orts, a n d dia g n ostics 
re p orts) relate d t o t he e ve nt.
 T he i n vest i gat or will t he n rec or d all rele va nt A E/ S A E i nf or mati on i n t he C R F.
 It is n ot acce pta ble f or t he i n vest i gat or t o se n d p h ot oc o pi[INVESTIGATOR_1309] t he partici pa nt’s me dical 
rec or ds t o sp o ns or or desi g nee i n lie u of c om p leti o n of t he A E/ S A E C R F pa ge.
 T here m a y be i nsta nces w he n c o pi[INVESTIGATOR_75513] f or certai n cases are re q ueste d 
b y sp o ns or or desi g nee . I n t his case, all partici pa nt i de ntifiers, wit h t he e xce pti on of t he 
parti ci pa nt n u m ber, will be re dacte d o n t he c o pi[INVESTIGATOR_1309] t he me dical rec or ds bef ore 
s u b missi on t o sp o ns or or desi g nee .
 T he i n vest i gat or will atte m pt t o esta blis h a dia g n osis of  t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mati on. W he ne ver p ossi ble, t he dia g n osis ( n ot t he 
i n di vi d ual si g ns/s y m pt o ms) will be d oc u me nte d as t he A E/ S A E. 
Assess me nt of I nte nsit y
T he i n vest i gat or will ma ke a n assess me nt of i nte nsit y for eac h A E a n d S A E re p orte d d uri n g 
t he st u d y a n d assi g n it t o 1 of t he f o ll owi n g cate g ori es:
 Mil d: A n e ve nt t hat is easil y t olerate d b y t he partici pa nt, ca usi n g mi ni mal disc o mf o rt 
a n d n ot i nterferi n g wit h e ver y da y act i vities.
 M o derate: A n e ve nt t hat ca uses s ufficie nt disc o mf ort a n d i nterferes wit h n or m al 
e ver y da y act i vities.
 Se vere: A n e ve nt t hat pre ve nts n or mal e ver y da y acti vi ties. A n A E t hat is assesse d as 
se vere s h o ul d n ot be c o nf use d wit h an S A E. Se vere is a cate g or y  utilize d f or rati n g t he 
i nte nsit y of a n e ve nt; a n d b ot h A Es a n d S A Es ca n be assesse d as se vere.
A n e ve nt is defi ne d as ‘seri o us’ w he n it meets at least 1 of t he pre defi ne d o utc o mes as 
descri be d i n t he defi nit i on o f a n S A E, N O T w he n it is rate d as se vere . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 2Assess me nt of C a us alit y
 T he i n vest i gat or is o bli gate d t o assess t he relati o ns hi p bet wee n I P a n d eac h occ urre nce 
of  eac h A E/ S A E.
 A “reas o na ble p ossi bility” of  a r elat i ons hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca usal relat i ons hi p, rat he r t ha n a relati ons hi p ca n n ot be 
r ule d o ut.
 T he i n vest i gat or will use cli nical j u d g me nt t o deter mi ne t he relati ons hi p.
 Alt er nat i ve ca uses, s uc h as u n derl yi n g disease(s), c o nc o mita nt t hera p y, a n d ot her ris k 
fact ors, as well as t he te m p oral relati o ns hi p of t he e ve nt t o I P a d mi nistrati o n will be 
c o nsi dere d a n d i n vest i gate d.
 T he i n vest i gat or will als o c o ns ult t he I B a n d/ or Pr o d uct I nf or mati o n, f or mar kete d 
pr o d ucts, i n his/ her assess me nt.
 F or eac h A E/ S A E, t he i n vest i gat or m ust d oc u me nt i n t he me dical n otes t hat he/s he has 
re vie we d t he A E/ S A E a n d has pr o vi de d a n assess me nt of ca usality.
 T here m a y be sit u atio ns i n w hic h a n S A E has occ urre d a n d t he i n vest i gat or has 
mi ni mal i nf or mat i on t o i ncl u de i n t he i nit ial re p ort t o sp o ns or or desi g nee . H o we ver, it 
is ver y  i m p orta nt t hat t he i n vesti gat or al wa ys ma ke a n assess me nt of ca usality f or 
e ver y e ve nt bef ore t he i nit ial tra ns missi on of t he S A E data t o sp o ns or or desi g nee .
 T he i n vest i gat or ma y c ha n ge his/ her o pi [INVESTIGATOR_318309] y i n li g ht of  fol l ow- u p 
i nf or mat i on a n d se n d a n S A E f oll o w -u p re p ort wi t h t he u p date d ca usality assess me nt.
 T he ca usalit y assess me nt is o ne of t he crit eria use d w he n deter mi ni n g re g ulat or y 
re p orti n g re q uire me nts. 
F oll o w - Up of A Es a n d S A Es
 T he i n vest i gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uat i ons as me dicall y i n dicate d or as re q ueste d b y sp o ns or or 
desi g nee t o eluci date t he nat ure a n d/ or ca usalit y of  t he A E or S A E as f ull y as p ossi ble. 
T his m a y i ncl u de a d dit i on al  la b orat or y tests or i n vesti gati o ns, hist o pat h ol o gical 
e xa mi nat i ons, or c o ns ultati o n wit h ot her healt hcare pr ofessi o nals.
 If a partici pa nt dies d uri n g partici pati o n i n t he st u d y or d uri n g a rec o g nize d f oll ow- u p 
p eri o d, t he i n ve sti gat or will pr o vi de sp o ns or or desi g nee wi t h a c o p y of a n y 
p ost m ort e m  fi n din gs i ncl u di n g hist o pat h ol o g y .
 Ne w or u p date d i nf or mat i on will be rec or de d i n t he ori gi nall y c o m p lete d C R F.
 T he i n vest i gat or will s u b mit a n y u p date d S A E data t o sp o ns or or desi g nee wi t hi n 
2 4 h o urs of recei pt of t he i nf or mati o n . 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 31 0. 3. 4. Re p orti n g of S A Es
S A E Re p orti n g vi a a n Electr o nic D at a C ollecti o n T o ol
 T he pri mar y  mec ha nis m for re p orti n g a n S A E will be t he electr o nic data c ollect i on 
t o ol.
 If t he electr o nic s yste m is u na vaila ble, t he n t he site will use t he pa per S A E data 
c ollect i on t o ol  (see ne xt sectio n) i n or der t o re p ort t he e ve nt wit hi n 2 4 h o urs.
 T he site will e nter t he S A E data i nt o t he electr o nic s y st e m as s o o n as it b e c o mes 
a vaila ble.
 After t he st u d y  is c o mplete d at a gi ve n site, t he electr o nic data c ollect i on t o ol  will be 
ta ke n off-li ne t o pre ve nt t he e ntr y of ne w data or c ha n ges t o e xist i n g data.
 If a site recei ves a re p ort of a ne w S A E fr om a st u d y p artici pa nt or recei ves u p date d 
da ta o n a pre vio usl y  re p orte d S A E after t he electr o nic data c ollecti o n t o ol has bee n 
ta ke n off-li ne, t he n t he site ca n re p ort t his i nf or mati on o n a pa per S A E f or m (see ne xt 
secti on) or t o t he me d ical m o nit or b y tele p h o ne.
 C o ntacts f or S A E re p orti n g ca n be f o u n d i n e C R F. 
S A E Re p orti n g vi a P a per C R F
 Facsi mile tra ns missi o n of t he S A E pa per C R F is t he preferre d met h o d t o tra ns mit t his 
i nf or mat i on t o t he me dical m o nit or .
 I nitial notificati o n via tele p h o ne d oes n ot re place t he nee d f or t he i n vest i gat or t o 
c o mplete a n d si g n t he S A E C R F pa ges wit hi n t he desi g nate d re p orti n g ti me fra mes.
 C o ntacts f or S A E re p orti n g ca n be f o u n d i n e C R F. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 41 0. 4. A p pe n di x 4 : Li ver S afet y: S u g geste d Acti o ns a n d F oll o w-U p 
Assess me nts
He p atic E v al u ati o n Testi n g
T he Lill y -desi g nate d ce ntral la b orat or y m ust c o m plete t he a nal ysis of all selecte d testi n g e xce pt 
f or micr o bi ol o g y  testi n g.
L ocal  testi n g ma y be perf or me d i n a d diti on t o ce ntral testi n g w he n necessar y f or i m me diate 
parti ci pa nt ma na ge me nt.
Res ults will be re p orte d if a vali date d test or calc ulati o n is a vaila ble.
He m at ol o g y Cli nic al C he mistr y
He m o gl o bi n T otal bilir u bi n
He mat ocrit Direct bilir u bi n
Er y t hr oc ytes ( R B Cs - re d bl o o d cells) Al kali ne p h os p hatase ( A L P)
Le u k oc ytes ( W B Cs - w h ite bl o o d cells) Ala ni ne a mi n otra nsferase ( A L T)
Differe ntial: As partate a mi n otra nsferase ( A S T)
    Ne utr o p hils, se g me nte d Ga m ma -gl uta m yl tra nsferase ( G G T)
    L y m p h oc ytes Creati ne ki nase ( C K)
    M o n oc yt es Ot her C he mistr y
    Bas o p hils Aceta mi n o p he n
    E osi n o p hils Aceta mi n o p he n pr otei n a d d ucts
Platelets Al kali ne p h os p hatase is oe nz y mes
Cell m or p h ol o g y ( R B C a n d W B C) Cer ul o plas mi n
C o a g ul ati o n C o p per
Et h y l alc o h ol ( Et O H)
Pr ot hr o m bi n ti me, I N R ( P T -I N R) Ha pt o gl o bi n
Ser ol o g y I m m u n o gl o b uli n A ( I g A) ( q ua ntitati ve)
He patitis A vir us ( H A V) testi n g: I m m u n o gl o b uli n G ( I g G) ( q ua ntitati ve)
    H A V t otal a nti b o d y I m m u n o gl o b uli n M ( I g M) ( q ua ntitati ve)
    H A V I g M a nti b o d y P h os p hati d ylet ha n ol ( P Et h)
He pat itis B vir us ( H B V) testi n g: Uri ne C he mistr y
    He patitis B s urface a nti ge n ( H Bs A g) Dr u g scree n
    He patitis B s urface a nti b o d y (a nti -H Bs) Et h y l gl uc ur o ni de ( Et G)
    He patitis B c ore t otal a nti b o d y (a nti -H Bc) Ot her Ser ol o g y
    He patitis B c ore I g M a nti b o d y A nti- n uclear a nti b o d y ( A N A)
    He patitis B c ore I g G a nti b o d y A nti- s m o ot h m uscle a nti b o d y ( A S M A) a
    H B V D N A b A nti- acti n a nti b o d y c
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 5He patitis C vir us ( H C V) testi n g: E pstei n -Barr vir us ( E B V) testi n g:
    H C V a nti b o d y     E B V a nti b o d y
    H C V R N A b     E B V D N A b
He patitis D vir us ( H D V) testi n g: C y t o me gal o vir us ( C M V) testi n g:
    H D V a nti b o d y     C M V a nti b o d y
He patitis E vir us ( H E V) testi n g:     C M V D N A b
    H E V I g G a nti b o d y Her pes si m ple x vir us ( H S V) testi n g:
    H E V I g M a nti b o d y     H S V ( T y pe 1 a n d 2) a nti b o d y 
    H E V R N A b     H S V ( T y pe 1 a n d 2) D N A b
Micr o bi ol o g y d Li ver ki d ne y micr os o mal t y pe 1 ( L K M -1) a nti b o d y
C ult ure:
    Bl o o d
A b bre viati o ns: I N R = i nter nati o nal n or malize d rati o; R N A = ri b o n ucleic aci d.
aN ot re q uire d if a nti -acti n a nti b o d y is teste d.
bRefle x/c o nfir mati o n de pe n de nt o n re g ulat o r y re q uire me nts, testi n g a vaila bilit y, or b ot h.
cN ot re q uire d if A S M A is teste d.
dAssa y e d O N L Y b y i n vesti gat or -desi g nate d l ocal la b orat or y; n o ce ntral testi n g a vaila ble.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 61 0. 5. A p pe n di x 5 : Fl or bet a pir F [ADDRESS_391829] u d y as i n dicate d i n t he S o A 
( Sectio n 1. 3 ).
Si te i n vesti gat ors, partici pa nt s, a n d st u d y part ners will n ot be i nf or me d of sca n res ults o btai ne d . 
A n y si g nifica nt fi n di n gs t hat ma y be of p ote ntial me dical c o ncer n will be pr o vi de d f or 
a p pr o priate f o ll ow- u p.
P E T Sc a n -S pecific I nf or m ati o n
P E T Sc a n Pr oce d ures
S pecific i ma gi n g ac q uisit i on pr ot oc ols desi g ne d t o e ns ure c o nsiste nc y a cr oss sites will be 
pr o vi de d i n a P E T I ma gi n g Ma n ual. 
P E T Sc a n S afet y
T he pri mar y  ris k relate d t o flor b et a pir F 1 8 P E T i s r a diat i on e x p os ure . Details o n t he a m o u nt of 
e x p os ure esti mate d t o occ ur o n eac h i ma gi n g occasi o n a n d c u m ulati vel y are prese nte d i n t he 
ta bles bel o w a n d will be pr o vi de d i n t he I C F. Details o n t he cli nical i nf or mati o n t o date 
re gar di n g fl or beta pir F 1 8 e x p os ure will be pr o vi de d i n t he I C F . M ore detaile d i nf or mat i on a b o ut 
t he k n o w n a n d e x pecte d be nefits a n d ris ks of fl or beta pir F 1 8 ca n be f o u n d i n t he U S Pac ka ge 
I nsert f or fl or beta pir F 1 8 I njecti on ( A m y vi dT Mpac ka ge i nsert, 2 0 1 2).
P arti cipa nt s m ust mi ni mize m o ve me nt d uri n g eac h P E T pr oce d ure, w hic h ca n last [ADDRESS_391830] state -of -t he- art i ma gi n g s yste ms are d esig ne d t o re d uce hea d 
m o tio n a n d partici pa nt disc o mf ort.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 7P A R T B: T he ta ble bel o w s h o ws t he effecti ve ra diati o n d ose of t he St u d y A A C H’s P E T sca ns.
Effect i ve 
D ose 
( mS v) per 
Sca n *N u m ber 
of  Sca ns 
i n First 
Year * *Effect i ve 
D ose 
( mS v) f or 
Sca ns i n 
Fi rst Y e arN u m ber 
of  Sca ns 
i n 
Sec o n d 
YearEffect i ve 
D ose ( m S v ) 
f or Sca ns i n 
Sec o n d 
YearS u m  of 
Effect i ve 
D ose ( m S v ) 
f or Years 1 
a n d 2
Fl or beta pi r F 
1 8 Sca n 
( 1 0 m C i I V)7. 4 3 1 7. 4 3 0 0 7. 4 3
T ot al s 1 7. 4 3 0 0 7. 4 3
A b bre viati o ns: C T = c o m p ute d t o m o gra p h y; E D = earl y disc o nti n uati o n; I V = i ntra ve n o us; P E T = p ositr o n e missi o n 
t o m o gra p h y.
* D ose s h o w n i ncl u des ra diati o n e x p os ure fr o m t he ra di otracer a n d ass u mes a n o ncli nical C T sca n is o btai ne d 
(esti mate d at 0. 4 m S v) as part of t he P E T sca n atte n uati o n c orrecti o n process w he n t he sca n is d o ne o n a 
P E T/ C T sca n ner. A cli nical C T sca n is n ot nee de d d uri n g t he P E T sca n sessi o n a n d, beca use it will a d d 
a d diti o nal ra diati o n e x p os ure, it is n ot rec o m me n de d.
N ote : I n t he e ve nt a re peat sca n is re q uire d (f or e xa m ple., t he scan is n ot a nal yza ble), [ADDRESS_391831] 3 d oses of d o na ne m a b.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 8P A R T C: T he ta ble bel o w s h o ws t he effect i ve ra diati on d ose of t he St u d y  A A C H’s P E T sca ns.
Effect i ve D ose 
( mS v) per Sca n *N u m ber of Sca ns 
i n Part CEffect i ve D ose 
( mS v) f or Part C
Fl ort a u ci pir F 1 8 Sca n 
( 1 0 m C i I V)9. 1 0 1 9. 1 0
Fl or beta pi r F 1 8 Sca n 
( 1 0 m C i I V)7. 4 3 1 7. 4 3
T ot al s 2 1 6. 5 3
A b bre viati o ns: C T = c o m p ute d t o m o gra p h y; I V = i ntra ve n o us; P E T = p ositr o n e missi o n t o m o gra p h y.
* D ose s h o w n i ncl u des ra diati o n e x p os ure fr o m t he ra di otracer a n d ass u mes a n o n -cli nical C T sca n is o btai ne d 
(esti mate d at 0. 4 m S v) as part of t he P E T sca n atte n uati o n c orrecti o n pr ocess w he n t he sca n is d o ne o n a 
P E T/ C T sca n ner. A cli nical C T sca n is n ot nee de d d uri n g t he P E T sca n sessi o n a n d, beca use it will a d d 
a d diti o nal ra diati o n e x p os ure, it is n ot rec o m me n de d.
N ote : I n t he e ve nt a re peat sca n is re q uire d (f or e xa m ple, t he sca n is n ot a nal yza ble), 1 a d diti o nal fl or beta pir F 1 8 
sca n ma y be recei ve d. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
8 91 0. 6. A p pe n di x 6 : Fl ort a uci pir F [ADDRESS_391832] u d y  as i n dicate d i n t he S o A 
( Sectio n 1. 3 ).
Si te i n vesti gat ors, partici pa nt s, a n d st u d y part ners will not be i nf or me d of sca n res ults o btai ne d . 
A n y si g nifica nt fi n di n gs t hat ma y be of p ote ntial me dical c o ncer n will be pr o vi de d f or 
a p pr o priate f o ll ow- u p . 
P E T Sc a n -S pecific I nf or m ati o n
P E T Sc a n Pr oce d ures
S pecific i ma gi n g ac q uisit i on pr ot oc ols desi g ne d t o e ns ure c o nsiste nc y  acr oss sites will be 
pr o vi de d i n a P E T I ma gi n g Ma n ual. 
Sc a n S afet y
T he pri mar y  ris k relate d t o flort a u ci pi r F 1 8 P E T i s ra diat i on e x p os ure . Details o n t he a m o u nt of 
e x p os ure esti mate d t o occ ur o n eac h i ma gi n g occasi o n a n d c u m ulati vel y are s h o w n i n t he ta ble 
a b o ve (Secti o n 1 0. 5 ) a n d will be pr o vi de d i n t he I C F. Details o n t he cli nical i nf or mat i on t o date 
re gar di n g fl orta uci pir F [ADDRESS_391833] state -of -t he- art i ma gi n g s yste ms are desi g ne d t o re d uce hea d 
m o tio n a n d partici pa nt disc o mf ort.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9 01 0. 7. A p pe n di x 7 : A b bre vi ati o ns
T er m D efi niti o n
A β a m yl oi d beta
A D Alz hei mer’s disease
A D A anti dr u g a nti b o d y
A D A S -C o g 1 3 Alz hei mer’s Disease Assess me nt Scale – C o g niti ve s u bscale
A D C S -A D L Alz hei mer’s Disease C o o perati ve St u d y – Acti vities of Dail y Li vi n g I n ve nt or y
A D C S -i A D L Alz hei mer’s Disease C o o perati ve St u d y – i nstr u me ntal Acti vities of Dail y Li vi n g
A E a d verse e ve nt
A L P a l kali ne p h os p hatase
A L T ala ni ne a mi n otra nsferase
A N C O V A a nal ysis of c o varia nce
A N O V A anal y sis of varia nce
A RI A a m y l oi d-relate d i ma gi n g a b n or mality
A S T as partate a mi n otra nsferase
C DI S C Cli nical Data I nterc ha n ge Sta n dar ds C o ns orti u m
C D R -S B Cli nical De me ntia Rati n g Scale – S u m of B o xes
CI O M S C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces
c o m pl ai nt A c o m plai nt is a n y writte n, electr o nic, or oral c o m m u nicati o n t hat alle ges deficie ncies 
relate d t o t he i de ntit y, q ualit y, p urit y, d ura bilit y, relia bilit y, safet y or effecti ve ness, or 
perf or ma nce of a dr u g or dr u g deli ver y s yste m.
c o m pli a n c e A d here nce t o all st u d y -relate d, g o o d cli nical practice ( G C P), a n d a p plica ble re g ulat or y 
re q uire me nts.
C O N S O R T C o ns oli date d Sta n dar ds of Re p orti n g Trials
C R F case re p ort f or m
C K creati n e ki nase
C- S S R S C ol u m bia S uici de Se verit y Rati n g Scale
C T c o m p ute d t o m o gra p h y
C T A cli nical trial a gree me nt
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391834]
i A D R S i nte grate d Alz hei mer’s Disease Rati n g Scale
I B I n vesti gat or’s Br oc h ure
I C C intraclass c orrelati o n
I C F i nf or me d c o nse nt f or m
I C H I nter nati o nal C o u ncil f or Har m o nisati o n
I E C I n de pe n de nt Et hics C o m mittee
I nf or m e d c o n s e nt A pr ocess b y w hic h a partici pa nt v ol u ntaril y c o nfir ms his or her willi n g ness t o 
partici pate i n a partic ular st u d y, after ha vi n g bee n i nf or me d of all as pects of t he st u d y 
t hat are rele va nt t o t he partici pa nt’s decisi o n t o partici pate . I nf or me d c o nse nt is 
d oc u me nte d b y mea ns of a writte n, si g ne d, a n d date d i nf or me d c o nse nt f or m .
I N R i nter nati onal n o r malize d rati o
I P i n vesti gati o nal pr o d uct; a p har mace utical f or m of a n acti ve i n gre die nt or place b o bei n g 
teste d or use d as a refere nce i n a cli nical trial, i ncl u di n g pr o d ucts alrea d y o n t he mar ket 
w h e n use d or asse m ble d (f or m ulate d or pac ka ge d) i n a wa y differe nt fr o m t he 
a ut h orize d f or m, or mar kete d pr o d ucts use d f or a n u na ut h orize d i n dicati o n, or mar kete d 
pr o d ucts use d t o gai n f urt her i nf or mati o n a b o ut t he a ut h orize d f or m.
I R B I nstit uti onal Re vie w B oar d
I V i ntra ve n o us(l y)
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391835] m o del f or re peate d meas ure me nts
M M S E Mi ni Me ntal State E xa mi nati o n
M RI m a g netic res o na nce i ma gi n g 
Nf L ne ur ofila me nt li g ht c hai n
NI M H Nati o nal I nstit ute of Me ntal Healt h
P AI R A c o m plete cr oss o ver c o m prisi n g a n at h o me assess me nt a n d a n o n -site assess me nt. 
 Pair 1 c o m prises V isits 6 0 2 a n d 6 0 3
 Pair 2 c o m prises V isits 6 0 4 a n d 6 0 5
 Pair 3 c o m prises V isits 6 0 6 a n d 6 0 7
p arti ci p a nt E q ui vale nt t o C DI S C ter m “s u bject”: a n i n di vi d ual w h o partici pates i n a cli nical trial, 
eit her as reci pie nt of a n i n vesti gati o nal me dici nal pr o d uct or as a c o ntr ol
P D p har mac o d y na mics
P E T p ositr o n e missi o n t o m o gra p h y
PI [INVESTIGATOR_32449] i n vesti gat or
P K p har mac o ki netics
P R O/ e P R O patie nt -re p orte d o utc o mes/electr o nic patie nt-re p orte d o utc o mes
Q 2 W e ver y 2 wee ks
Q 4 W e ver y 4 wee ks
Q T c c orrecte d Q T i nter val
Q T c F Fri dericia’s f or m ula
R N A ri b o n ucleic aci d
S A E seri o us a d verse e ve nt
S A P statistical a nal ysis pla n
s cr e e n T he act of deter mi ni n g if a n i n di vi d ual meets mi ni m u m re q uire me nts t o bec o me part of 
a p o ol of p ote ntial ca n di dates f or partici pati o n i n a cli nical st u d y. 
S o A Sc he d ule of A cti vities
S U Vr Sta n dar dize d u pta ke val ue rati o
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9 3T B L t otal bilir u bi n le vel
T E treat me nt-e mer ge nt
U L N u p per li mit of n or mal
V T C v i de o telec o nfere nce
W O C B P w o me n of c hil d beari n g p ote ntial
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9 41 0. 8. A p pe n di x 8: Pr o visi o ns f or C h a n ges i n St u d y C o n d uct D u ri n g
E xce pti o n al Circ u mst a nces
E xce pt i onal circ u msta nces, s uc h as pa n de mics or nat ural  disasters, ma y ca use disr u pti o ns t o t he 
c o n d uct of t he st u d y. T hese disr u pti o ns ma y li mit t he a bilit y of  t he i n vesti gat ors, partici pa nts, or 
b ot h t o atte n d o n -site visits or t o c o n d uct pla n ne d st u d y pr oce d ures.
I n a n e xce pti onal circ u msta nce, after recei vi n g t he s p o ns or’s writte n a p pr o val, sites ma y  
i m ple me nt c ha n ges if per mitte d b y l ocal re g ulati ons. S uc h c ha n ges are i nte n de d t o mit i gate ris ks 
of  p artici pa nts missi n g visits, all o w parti ci pa nts t o c o nti n ue safel y i n t he st u d y, a n d mai ntai n t he 
data i nte grit y of  t he st u d y. G C P c o mplia nce a n d mi ni mizat i on of ri s k t o st u d y int e grit y are 
i m p orta nt c o nsi derati o ns. E ns uri n g t he safety of  st u d y p artici pa nts is t he pre vaili n g 
c o nsi derati o n.
T he c ha n ges t o pr oce d ures descri be d i n t his a p pe n di x are te mp orar y  meas ures i nte n de d t o be 
use d o nl y d uri n g s pecific ti me peri o ds as directe d b y t he s p o ns or i n part ners hi p with t he 
in vesti g at or . 
A d dit i onal wri tt e n g ui da nce , if nee de d, will be pr o vi de d b y  t he s p o ns or i n t he 
e ve nt wri tt e n a p pr o val is gra nte d f or c ha n ges i n st u d y c o n d uct. 
E R Bs , re g ulat or y bo dies , a n d a n y ot her rele va nt lo c al  a ut h orities, as re q uire d, will be n otifie d as 
earl y as p ossi ble t o c o m m u nicate i m ple me ntati o n of c ha n ges i n st u d y c o n d uct d ue 
t o e xce pt i onal circ u msta nces. T o pr otect t he safety of  st u d y p artici pa nts, ur ge nt c ha n ges ma y be 
i m ple me nte d bef ore s uc h c om m u nicat i ons are ma de, b ut all c ha n ges will be re p orte d as s o o n as 
p ossi ble f o ll owi n g i m ple me ntati o n. If a p pr o val of E R Bs, re g ulat or y  bo dies, or b ot h i s re q uire d 
per l o c al  re g ulatio ns, c o nfir mat i on of t his a p pr o val will be retai ne d i n t he st u d y rec or ds.
I nf or me d C o nse nt
A d dit i onal c o nse nt fr o m t he participa nt will  be o btai ne d, as a p plica ble, f or:
parti ci pat i on i n re m ote visits, as defi ne d i n t he Re m ote Visit secti on,
a c ha n ge of t he met h o d, l ocatio n, or b ot h, of  I P a d mi nistrati o n,
alter nate deli ver y of st u d y int er ve ntio n a n d a ncillar y  s u p plies, a n d
pr o vi sio n  of t h eir pers o nal or me dical inf or m atio n r e q ui r e d prior t o i m ple me ntati o n of 
t hese acti vit ies.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391836] u d y site w he n partici pa nts ca n n ot tra vel t o t he site d ue t o a n e xce pt i onal circ u msta nce 
if wri tte n a p pr o val is pr o vide d b y  t he s p o ns or. Pr oce d ures perf or me d at s uc h visits i ncl u de, b ut 
are n ot li mit e d t o : re vie w of c o nc o mit a nt me dicat i o ns, c ollect i on of bl o o d sa m ples, p h ysical 
assess me nts, a d mi nistrati o n o f P R Os, a d mi nistrati o n of I P, a n d c ollect i on of healt h i nf or mati on . 
Ot her alt er nate lo c ati o ns
Ot her pr oce d ures t hat ma y  be d o ne at a n alter nate l ocati o n i n e xce pti o nal 
circ u msta nces are inf usi o n, l a b orat or y dra ws, et c.
Re gar dless of t he t y p e of  r e mote visits i m ple me nte d, t he pr ot oc o l re q uire me nts re gar di n g t he 
re p orti n g of A Es, S A Es, a n d pr o d uct c o m plai nts re mai n u nc ha n ge d. F urt her m or e, e ver y eff ort 
s h o uld be ma de t o e na ble parti ci pa nts t o ret ur n t o o n-site visits as s o o n as reas o na bl y p ossi ble, 
w hile e ns uri n g t he safet y of b ot h t he partici pa nts a n d t he sit e staff.
I n vesti g ati o n al P r o d uct a n d A ncill ar y S u p plies
W he n a parti ci pa nt is u na ble t o g o t o t he site t o recei ve st u d y s u p plies d uri n g n or m al o n-sit e 
visit s, t he site s h o ul d w or k wit h t he s p o ns or t o deter mi ne a p pr o priate acti o ns. T hese 
actio ns ma y i ncl u de: 
 as ki n g t he partici pa nt t o g o t o t he sit e a n d recei ve st u d y s u p plies fr o m site staff with o ut 
c o mplet i on of a f ull st u d y visit ;
 as ki n g t he partici pa nt’s d esi g nee t o g o t o t he sit e a n d recei ve st u d y s u p plies o n 
a partici pa nt’s be half ;
 arra n gi n g deli ver y of  st u d y s u p plies; a n d
 w or ki n g wit h t he s p o ns or t o deter mi ne h o w I P is t o be a d mi nistere d t o t he partici pa nt.  
E xa m ples: A d mi n istr atio n of  I P t o t he participa nt d uri n g a m o bile healt hcare visit or at 
a n alter nate i nf usi on ce nter. T he first [ADDRESS_391837] be met bef ore acti o n is ta ke n:
 Alt er nate deli ver y  of I P s h o uld be perf or me d i n a ma n ner t hat d oes n ot c o m pr o mise 
pati e nt c o nfi de nt iality a n d e ns ures pr o d uct i nte grit y. T h e e xist i n g pr ot oc ol re q uire me nts 
f or pr o d uct acc o u n ta bility re mai n u nc ha n ge d, i ncl u di n g verificat i on of partici pa nt’s 
receipt of  st u d y s u p plies.
 W he n deli veri n g s u p plies t o a l ocat i on ot her t ha n t he st u d y  sit e (e. g. , partici pa nt’s 
h o me), i n vesti gat or, s p o ns or, or b ot h s h o uld e ns ure o versi g ht of t he s hi p pi n g 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391838] q ualit y (t hat is, st ora ge 
c o n ditio ns mai ntai ne d a n d i ntact pac ka gi n g u p o n recei pt).
 Instr ucti o ns s h o ul d be pr o vi de d t o t he partici pa nt o n h o w t o ret ur n a n y  u n use d or 
c o mplete d st u d y s u p plies.
I n a d diti on, if I P is t o be a d mi nistere d t o t he partici pa nt d uri n g a m o bile healt hcare visit or at a n 
alter nate lo c ati o n, t hese a d dit i onal re q uire me nts m ust be met : 
 O nl y a ut h orize d st u d y pers o n nel ma y s u p pl y, pre pare, or a d mi nister I P; a n d
 F o ll ow i nf usi o n i nstr ucti o ns descri be d i n Secti on 6. [ADDRESS_391839] i gat or’s discreti o n, partici pa nts 
s h o uld c o m p lete t he us ual S o A . T o ma xi mize t he p ossi bilit y t h at t hese visits ca n be c o n d ucte d 
as o n -site visits, t here b y mi ni mizi n g missi n g data a n d preser vi n g t he i nte n de d c o n d uct of t he 
st u d y, t he wi n d o ws f or visits ma y be a djuste d, u p o n f urt her s pecific g ui da nce fr om t he s p o ns or, 
b ut wit hi n t his ra n ge:
Visit N u m ber T oler a nce
Part B
Visits 2 t hr o u g h 1 5, a n d 
Visits 8 0 1 a n d 8 0 2I n e xte n uati n g circ u msta nces, t he visit wi n d o w f or visits i n Part B ma y be e xte n de d 
t o ± 1 0 da ys.
N ote : I P ca n n ot be a d mi nistere d t wice wit hi n 2 1 da ys ( Secti o n 6. 1 ).
A b bre viati o n: I P = i n vesti gati o nal pr o d uct. 
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
[ADDRESS_391840] will be d o c u m e nte d:
 Si tes will i de ntif y a n d d oc u me nt t he details of h o w partici pa nts, visits t ypes, 
a n d c o n d ucte d acti vit ies were affecte d b y e xce ptio nal circ u msta nces.
Di s pe nsi n g/s hi p me nt rec or ds of I P a n d rele va nt c o m m u nicat i ons, i ncl u di n g dele gat i on, 
s h o uld be file d wit h site st u d y rec or ds. Als o, i n vesti gat or s h o ul d d oc u me nt w he n st u d y  
c o n d uct ret ur ns t o n or mal.
 S o urce d oc u me nts ge nerate d at a l ocati o n ot her t ha n t he st u d y site s h o uld be part of t he 
i n vesti gat or’s s o urce d oc u me ntati o n a n d s h o ul d be tra nsferre d t o t he site i n a sec ure 
a n d ti mel y ma n ner. 
Missi n g D ata a n d O t her P r ot oc ol D e viat i ons
T he st u d y  site s h o uld d o c u m e nt s pecific e x pla nati o ns f or a n y missi n g data a n d ot her pr ot oc ol 
de viat i ons . T his i nf or mat i on will als o be ca pt ure d b y t he m o nit ors i n t he m o nit ori n g s yste m . 
Alt h o u g h pr ot oc ol  de viatio ns ma y  be u na v oida ble i n a n e xce pti o nal circ u msta nce, 
d oc u m e nt atio n of pr ot oc ol de viat i ons a n d missi n g data will be i m p orta nt f or data a nal ysis a n d 
re p orti n g.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9 81 0. 9. A p pe n di x 9: Pr ot oc ol A me n d me nt Hist or y
T he Pr ot o c ol  A me n d me nt S u m mar y of C ha n ges Ta ble f or t he c urre nt a me n d me nt is l ocate d 
di rectl y bef ore t he Ta ble of C o nte nts ( T O C)
A me n d me nt a ( 2 7 J a n 2 0 2 1)
O ver all R ati o n ale f or t he A me n d me nt
T his a me n d me nt a d ds a titrati o n peri o d t o Part B i n res p o nse t o [ADDRESS_391841] u d y.
Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale
1. [ADDRESS_391842] i vities ( S o A)A d de d t olera nce f or M RI at Visit 4.
C orrecte d f o ot n ote a. “ V 6 0 2 ca n n ot 
occ ur ≤ 3 0 d a y s...”  T o all o w M RI re vie w pri or t o 
pl a n ne d d ose escalat i on.  
C orrecti o n.
2. 2. 3. [ADDRESS_391843] u d y  I nter ve nti o n 
C o m plia nceA d de d i nstr ucti o ns f or w he n a 
parti ci pa nt d oes n ot c o m plete t he 
titr atio n p hase.S af et y.
6. 6 D ose M o dificat i on A d de d i nstr ucti o ns f or w he n a 
parti ci pa nt de vel o ps A RI A. S af et y.  
8. 1. 2 Or der of 
Assess me nts a n d 
Rater R olesCl arifie d n ote f or A D A S -C o g 1 3a n d 
M M S E.Cl arificat i on.
1 0. 6 A p pe n di x 6: 
Fl ort a u ci pir F 1 8 Ta u 
P E T I m a gi n gRe m o ve d se nte nce relate d t o 
flort a u ci p ir F 1 8 bei n g i n cli nical 
e val uat i on.  U S F D A a p pr o val o f 
flort a u ci pir F 1 8 tracer 
esta blis he d a k n o w n safet y 
pr ofile. 
T hr o u g h o ut E di t orial c ha n ges Mi n or e di t orial c ha n ges, 
t heref ore, n ot descri be d.
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
9 91 1. Refere nces
A m y vi dT M[ pac ka ge i nsert]. I n dia na p olis, I N: Eli Lill y a n d C om pa n y; 2 0 1 2.
Braa k H, Braa k E. E v ol ut i on of t he ne ur o pat h ol o g y o f Alz hei mer's disease. Act a Ne ur ol Sc a n d 
S u p pl . 1 9 9 6; 1 6 5: 3-1 2. htt ps:// d oi . or g/1 0. 1 1 1 1/j. [ADDRESS_391844] ad mi nistrati o n b y 
v i de oc o nfere nce: a syste m at ic re vie w a n d m et a- anal ysis. Ne ur o psyc h ol Rev . 
2 0 1 7; 2 7( 2): 1 7 4 - 18 6. htt ps:// d oi. or g/ 1 0. 1 0 0 7/s 1 1 0 6 5 - 0 1 7- 9 3 4 9- 1
Car ote n ut o A, Rea R, Trai ni E, et al. C o g ni tive assess me nt of p atie nts w ith a lzhei mer's d isease 
b y tele me dici ne: p il ot st u d y. J MI R Me nt He alt h . 2 0 1 8; 5( 2):e 3 1. 
ht t ps:// d oi. or g/1 0. 2 1 9 6/ me ntal. 8 0 9 7
Casta n h o T C, S o usa N, Sa nt os N C. W he n n e w tec h n o l og y  is a n a ns wer f or o l d p r o ble ms: the u se 
of  v i de oc o nfere nci n g i n co g ni tive agi n g assess me nt. J Alz hei mers Dis Re p . 2 0 1 7; 1( 1): 1 5-2 1. 
ht t ps:// d oi. or g/1 0. 3 2 3 3/ A D R - 1 7 0 0 0 7
Ce dar ba u m J M, Jar os M, Her na n dez C, et al. Rati o nale f or use of t he Cli nical De me nt ia Rati n g 
S u m  of B o xes as a pri mar y o utc o me meas ur e for Alz hei mer's disease cli nical trials. 
Alz hei mers De me nt . 2 0 1 3; 9( [ADDRESS_391845]): S 4 5-S 5 5. ht t ps:// d oi. or g/ 1 0. 1 0 1 6/j.jalz. 2 0 1 1. 1 1. 0 0 2
Ci e mi ns E L, H oll o wa y B, C o o n PJ, et  al. T ele me dici ne a n d t he mi ni-me ntal  state e xa mi nati on: 
assess me nt fr o m a dista nce. Tele me d J E He alt h . 2 0 0 9; 1 5( 5): 4 7 6- 4 7 8. 
ht t ps:// d oi. or g/1 0. 1 0 8 9/t mj. 2 0 0 8. 0 1 4 4
C ol e y N, A n drie u S, Jar os M, et al. S ui ta bilit y of t he Cli nical De me ntia Rati n g-S u m  of B o xes as 
a si n gle pri mar y e nd p oi nt f or Alz hei mer's disease trials. Alz hei mers De me nt . 
2 0 1 1; 7( 6): 6 0 2 -6 1 0.e 2. htt ps:// d oi. or g/ 1 0. 1 0 1 6/j.jalz. 2 0 1 1. 0 1. 0 0 5
C o o ns SJ, G wal t ne y CJ, Ha ys R D, et al. Rec o m me n dat i ons o n E vi de nce Nee de d t o S u p p ort
Meas ure me nt E q ui vale nce bet wee n Electr o nic a n d Pa per -Base d Patie nt -Re p orte d O utc o me 
( P R O) Meas ures: I S P O R e P R O G o o d Researc h Practices Tas k F orce Re p ort . V al ue He alt h . 
2 0 0 9; 1 2( 4): 4 1 9- 4 2 9.
C ull u m C M , H y na n L S, Gr osc h M, et al. T el e ne ur o ps yc h olo g y : e vi de nce f or vi de o 
t elec o nfere nce -base d ne ur o ps y c h o l ogi cal assess me nt. J I nt Ne ur o psyc h ol S oc . 
2 0 1 4; 2 0( 1 0): 1 0 2 8 - 1 0 3 3. htt ps:// d oi. or g/ 1 0. 1 0 1 7/ S 1 3 5 5 6 1 7 7 1 4 0 0 0 8 7 3
D o o d y  R S, T h o mas R G, Farlo w M, et al . P hase 3 trials of s o lanez u ma b f or mil d -t o-m o derate 
Alz hei mer's disease. N E n gl J Me d . 2 0 1 4; 3 7 0( 4): 3 1 1-3 2 1. 
ht t ps:// d oi. or g/1 0. 1 0 5 6/ N EJ M oa 1 3 1 2 8 8 9
Fleis her A S, C he n K, Q uir oz Y T, et al. Ass ociat i ons bet wee n bi o mar kers a n d a ge i n t he 
prese nili n 1 E 2 8 0 A a ut os o mal d o mi na nt Alz hei mer disease ki n dre d: a cr oss- secti o nal st u d y. 
J A M A Ne ur ol . 2 0 1 5; 7 2( 3): 3 1 6-3 2 4. htt ps:// d oi. or g/ 1 0. 1 0 0 1/ja ma ne ur ol. [ADDRESS_391846] ei n S E, McH u g h P R. “ Mi ni -me ntal  state”. A practical met h o d for gra di n g t he 
c o g nitive state of patie nts f or t he cli nicia n. J Psyc hi atr Res. 1 9 7 5; 1 2( 3): 1 8 9-1 9 8.
ht t ps:// d oi. or g/ 1 0. 1 0 1 6/ 0 0 2 2-3 9 5 6( 7 5) 9 0 0 2 6 - 6
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 0 0G al as k o D, Be n nett D, Sa n o M, et al. A n i n ve nt or y t o assess activit ies of dail y li vi n g f or cli nical 
trials i n Alz hei mer’s disease. T he Alz hei mer’s Disease C o o perati ve St u d y . Alz hei mer Dis 
Ass oc Dis or d . 1 9 9 7; 1 1( S u p pl 2): S [ADDRESS_391847] i vities 
of  dail y li vi n g i n patient s wit h Alz hei mer’s disease. J A m Geri atr S oc. 2 0 0 4; 5 2( 7): 1 0 7 0- 1 0 7 6.
ht t ps:// d oi. or g/ 1 0. 1 1 1 1/j. 1 5 3 2-5 4 1 5. 2 0 0 4. 5 2 3 0 3. x
H u g hes C P, Ber g L, Da nzi ger W L, et al. A ne w cli nical scale f or t he sta gi n g of de me ntia. Br J 
Psyc hi atry . 1 9 8 2; 1 4 0: 5 6 6- 5 7 2. htt ps:// d oi. or g/ 1 0. 1 1 9 2/ bj p. 1 4 0. 6. 5 6 6
I g nat o wicz A, At hert o n H, Ber nstei n CJ, et al. I nter net vi de oc o nfere nci n g f or patie nt – cli nicia n 
c o ns ultati o ns i n l o n g -t er m c o n ditio ns: a re vie w of re vie ws a n d a p plicati ons i n li ne wit h 
g ui deli nes a n d rec o m me n dat i ons . Di git He alt h . 2 0 1 9; 5: 1-2 7. 
ht t ps:// d oi. or g/1 0. 1 1 7 7/ 2 0 5 5 2 0 7 6 1 9 8 4 5 8 3 1
K o o T K, Li  M Y. A g uideli ne of  selecti n g a n d re p orti n g i ntraclass c orrelati on c oefficie nts f or 
relia bility researc h. J C hir o pr Me d. 2 0 1 6 ; 1 5( 2): 1 5 5-1 6 3. 
ht t ps:// d oi. or g/ 1 0. 1 0 1 6/j.jc m. 2 0 1 6. 0 2. 0 1 2
Mc Gra w K O , W o n g S P. F or mi n g i nfere nces a b o ut s o me i ntraclass c orrelati o n c oefficie nts. 
Psy c h ol o gic al Met h o ds. 1 9 9 6; 1( 1): 3 0 -4 6. ht t ps:// d oi. or g/1 0. 1 0 3 7/ [ADDRESS_391848] u gs: a d diti ons t o t h e Alz hei mer’s Disease Assess me nt Sca le 
t hat br oa de n its sc o pe. T he Alz hei mer’s Disease C o o perati ve St u d y . Alz hei mer Dis Ass oc 
Dis or d . 1 9 9 7; 1 1( S u p pl 2): S 1 3-S 2 1.
M orri s J C. T he Cli nical De me ntia Rati n g ( C D R): c urre nt versi o n a n d sc ori n g r ules. Ne ur ol o gy . 
1 9 9 3; 4 3( 1 1): 2 4 1 2 - 2 4 1 4. htt ps:// d oi. or g/ 1 0. 1 2 1 2/ w nl. 4 3. 1 1. 2 4 1 2 -a
R ose n W G, M o hs R C, Da vis K L. A ne w rat i n g scale f or Alz hei mer’s disease. A m J Psyc hi atry . 
1 9 8 4; 1 4 1( 1 1): 1 3 5 6 -1 3 6 4. htt ps:// d oi . or g/ 1 0. 1 1 7 6/aj p. 1 4 1. 1 1. 1 3 5 6
S a m ps o n H A, M u ñ o z -F url o n g A, Ca m p bell R L, et al. Sec o n d s y m p osi u m o n t he defi nit i on a n d 
ma na ge me nt of a na p h yla xis: s u m mar y re p ort — Sec o n d Nati o nal I nst itute of Aller g y  a n d 
I nfecti o us Disease/ F o o d Aller g y a n d A na p h yla xis Net w or k s y m p osi u m. J Aller gy Cli n 
I m m u n ol. 2 0 0 6; 1 1 7( 2): 3 9 1 -3 9 7. htt ps:// d oi. or g/ 1 0. 1 0 1 6/j.jaci. 2 0 0 5. 1 2. 1 3 0 3
Si e mers E R, S u n dell K L, Carls o n C, et al. P hase 3 s ola nez u ma b trials: sec o n dar y  o ut c o mes i n 
mil d Alz hei mer's disease pat ient s. Alz hei mers De me nt . 2 0 1 6; 1 2( 2): 1 1 0-1 2 0. 
ht t ps:// d oi. or g/1 0. 1 0 1 6/j.jalz. 2 0 1 5. 0 6. 1 8 9 3
Wessels A M, Sie mers E R, Y u P, et al. A c o m bi ne d meas ure of c o g nit i on a n d f u ncti o n f or 
cli nical trials: t he i nte grate d Alz hei mer’s Disease Rati n g Scale (i A D R S). J Prev Alz hei mers 
Dis . 2 0 1 5; 2( 4): 2 2 7-2 4 1. htt ps: //d oi . or g/1 0. 1 4 2 8 3/j pa d. [ADDRESS_391849] ora n dt M, R oe C M, M orris J C. Pr o gressi o n of Alz hei mer's disease as meas ure d 
b y Cli nical De me ntia Rati n g S u m o f B o xes sc ores. Alz hei mers De me nt . 2 0 1 3; 9( [ADDRESS_391850] ): S 3 9-S 4 4. htt ps:// d oi . or g/1 0. 1 0 1 6/j.jalz. 2 0 1 2. 0 1. 0 0 5
C O N FI D E N TI A L Pr ot oc ol  n u m ber I 5 T-M C -A A C H ( b)
1 0 1Y os hi da K, Ya ma o ka Y, E g uc hi Y, et al . Re m ote ne ur o ps y c h o l ogi c al assess me nt of elderl y  
Ja pa nese p o p ulati on usi n g t he Alz hei mer's Disease Assess me nt Scale: a vali dati o n st u d y . 
J Tele me d Telec are . 2 02 0; 2 6( 7 -8): 4 8 2 - 4 87. htt ps:// d oi. or g/ 1 0. 1 1 7 7/ 1 3 5 7 6 3 3 X 1 9 8 4 5 2 7 8
L e o  D o c u m e n t  I D  =  3 5 e 2 5 f 8 6 - e 9 c 4 - 4 2 e 2 - b b 9 b - 6 7 d 0 9 c 7 3 0 1 6 1
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 1 - O c t - 2 0 2 1  1 4 : 5 7 : 2 4  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e d
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 1 - O c t - 2 0 2 1  1 5 : 1 7 : 4 4  G M T
S i g n a t u r e  m e a n i n g :  A p p r o v e dP P D
P P D